BioMedLib Search Engine
[ goto HOMEPAGE ]
Search the biomedical literature, for the most relevant articles.
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
adenoma alpha cell 2005:2010[pubdate] *count=100
377 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
adenoma alpha cell
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 377
1.
National Toxicology Program:
Toxicology and carcinogenesis studies of alpha-methylstyrene (Cas No. 98-83-9) in F344/N rats and B6C3F1 mice (inhalation studies).
Natl Toxicol Program Tech Rep Ser
; 2007 Nov;(543):1-210
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Toxicology and carcinogenesis studies of
alpha
-methylstyrene (Cas No. 98-83-9) in F344/N rats and B6C3F1 mice (inhalation studies).
alpha
-Methylstyrene is used in the production of acrylonitrile-butadiene-styrene resins and copolymers, which improve the impact and heat-resistant properties of polymers, specialty grades of plastics, rubber, and protective coatings.
alpha
-Methylstyrene also moderates polymerization rates and improves product clarity in coatings and resins.
Low molecular weight liquid polymers are used as plasticizers in paints, waxes, adhesives, and plastics.
alpha
-Methylstyrene was nominated by the U.S.
Male and female F344/N rats and B6C3F1 mice were exposed to
alpha
-methylstyrene (99.5% pure) by inhalation for 3 months or 2 years.
Genetic toxicology studies were conducted in Salmonella typhimurium, cultured Chinese hamster ovary
cells
, and mouse peripheral blood erythrocytes.
3-MONTH STUDY IN RATS: Groups of 10 male and 10 female rats were exposed by whole-body inhalation to
alpha
-methylstyrene at concentrations of 0, 75, 150, 300, 600, or 1,000 ppm for 6 hours per day, 5 days per week for 14 weeks.
Consistent with the hyaline droplet accumulation, an exposure-related increase in alpha2μ-globulin was detected in the kidneys of males exposed to
alpha
-methylstyrene.
Morphologic
changes were not detected in the liver.
3-MONTH STUDY IN MICE: Groups of 10 male and 10 female mice were exposed by whole-body inhalation to
alpha
-methylstyrene at concentrations of 0, 75, 150, 300, 600, or 1,000 ppm for 6 hours per day, 5 days per week for 14 weeks.
Minimal to mild centrilobular hypertrophy was present in the livers of male and female mice exposed to 600 or 1,000 ppm
alpha
-methylstyrene.
2-YEAR STUDY IN RATS: Groups of 50 male and 50 female rats were exposed by whole body inhalation to
alpha
-methylstyrene at concentrations of 0, 100, 300, or 1,000 ppm for 6 hours per day, 5 days per week, except holidays, for 105 weeks.
Two 1,000 ppm males and one 300 ppm male had renal tubule carcinomas, and one 300 ppm male had a renal tubule
adenoma
.
Because of the neoplasms observed in 300 and 1,000 ppm males at the end of the 2-year study and
the finding
of alpha2μ-globulin accumulation in the kidneys at 3 months, which is often associated with kidney neoplasms, additional step sections of kidney were prepared; additional males with focal hyperplasia or
adenoma
were identified.
The incidences of renal tubule
adenoma
and carcinoma (combined) in the 1,000 ppm males were significantly greater than those in the chamber controls when the single and step sections were combined.
The incidence of mononuclear
cell
leukemia in 1,000 ppm males was significantly increased compared to the chamber controls.
In the nose, the incidences of basal
cell
hyperplasia were significantly increased in all exposed groups of males and females, and the incidences of degeneration of the olfactory epithelium were increased in 1,000 ppm males and females and 300 ppm females.
2-YEAR STUDY IN MICE: Groups of 50 male and 50 female mice were exposed by whole body inhalation to
alpha
-methylstyrene at concentrations of 0, 100, 300, or 600 ppm for 6 hours per day, 5 days per week, except holidays, for 105 weeks.
The incidences of hepatocellular
adenoma
or carcinoma (combined) were significantly increased in the 100 and 600 ppm males and in all exposed groups of females.
The incidences of hepatocellular
adenoma
were significantly increased in all exposed groups of females, and the incidences in all exposed groups of males and females exceeded the historical range for chamber controls.
GENETIC TOXICOLOGY:
alpha
-Methylstyrene was not mutagenic in four strains of Salmonella typhimurium, with or without rat or hamster liver metabolic activation enzymes (S9).
alpha
-Methylstyrene did not induce chromosomal aberrations in cultured Chinese hamster ovary
cells
, with or without S9 activation, but did significantly increase the frequency of sister chromatid exchanges in cultures exposed in the presence of S9.
CONCLUSIONS: Under the conditions of this 2-year inhalation study, there was some evidence of carcinogenic activity of
alpha
-methylstyrene in male F344/N rats based on increased incidences of renal tubule
adenomas
and carcinomas (combined).
The increased incidence of mononuclear
cell
leukemia in 1,000 ppm male F344/N rats may have been related to
alpha
-methylstyrene exposure.
There was no evidence of carcinogenic activity of
alpha
-methylstyrene in female F344/N rats exposed to 100, 300, or 1,000 ppm.
There was equivocal evidence of carcinogenic activity of
alpha
-methylstyrene in male B6C3F1 mice based on marginally increased incidences of hepatocellular
adenoma
or carcinoma (combined).
There was clear evidence of carcinogenic activity of
alpha
-methylstyrene in female B6C3F1 mice based on increased incidences of hepatocellular
adenomas
and carcinomas.
Exposure of rats to
alpha
-methylstyrene resulted in kidney toxicity, which in males exhibited some features of alpha2μ-globulin nephropathy.
Exposure to
alpha
-methylstyrene resulted in nonneoplastic lesions of the nose in male and female rats and mice and of the liver and kidney in female mice.
[MeSH-minor]
Animals. Body Weight / drug effects. CHO
Cells
. Cricetinae. Cricetulus. DNA Damage. Female. Inhalation Exposure. Kidney / drug effects. Kidney / pathology. Kidney Neoplasms / chemically induced. Kidney Neoplasms / pathology. Leukemia, Myeloid / chemically induced. Leukemia, Myeloid / pathology. Liver Neoplasms / chemically induced. Liver Neoplasms / pathology. Male. Mice. Mice, Inbred Strains. Micronuclei, Chromosome-Defective / chemically induced. Nose Diseases / chemically induced. Rats. Rats, Inbred F344
Hazardous Substances Data Bank.
ALPHA-METHYL STYRENE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18685715.001).
[ISSN]
0888-8051
[Journal-full-title]
National Toxicology Program technical report series
[ISO-abbreviation]
Natl Toxicol Program Tech Rep Ser
[Language]
eng
[Publication-type]
Journal Article; Technical Report
[Publication-country]
United States
[Chemical-registry-number]
0 / Air Pollutants, Occupational; 0 / Carcinogens; 0 / Mutagens; 0 / Styrenes; 98-83-9 / alpha-methylstyrol
2.
Lewis RB, Lattin GE Jr, Paal E:
Pancreatic endocrine tumors: radiologic-clinicopathologic correlation.
Radiographics
; 2010 Oct;30(6):1445-64
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pancreatic
endocrine
tumors
: radiologic-clinicopathologic correlation.
Pancreatic
endocrine
tumors
(PETs) are primarily well-differentiated
tumors
composed
of cells
that resemble normal
islet cells
but that arise from
pancreatic
ductal
cells
.
They are classified as functioning or nonfunctioning according to their associated clinical symptoms; insulinoma, gastrinoma, and
glucagonoma
are the most common functioning PETs.
Most are sporadic, but some are associated with familial
syndromes
such as multiple endocrine neoplasia type 1, von Hippel-Lindau
syndrome
, and neurofibromatosis type 1.
At imaging, PETs typically appear as well-defined hypervascular masses,
a finding
indicative of their rich capillary network.
Cystic change, calcification, and necrosis are common in large
tumors
, which are associated with a poorer prognosis and a higher prevalence of local and vascular invasion and metastases than are smaller
tumors
.
Poorly differentiated PETs are rare and have an infiltrative appearance; patients with such
tumors
have a poor prognosis.
Knowledge of the characteristic clinical, pathologic, and radiologic features of PETs is important in the evaluation and management of patients with a suspected clinical
syndrome
or
a pancreatic
mass.
[MeSH-major]
Diagnostic Imaging.
Pancreatic
Neoplasms /
diagnosis
[MeSH-minor]
Adenoma
,
Islet
Cell
/
diagnosis
.
Adenoma
,
Islet
Cell
/ epidemiology.
Adenoma
,
Islet
Cell
/ pathology. Carcinoma,
Islet
Cell
/
diagnosis
. Carcinoma,
Islet
Cell
/ epidemiology. Carcinoma,
Islet
Cell
/ pathology.
Diagnosis
, Differential. Humans. Multiple Endocrine Neoplasia Type 1 / pathology. Neurofibromatosis 1 / pathology. Prevalence. von Hippel-Lindau
Disease
/ pathology
MedlinePlus Health Information.
consumer health - Diagnostic Imaging
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
© RSNA, 2010.
(PMID = 21071369.001).
[ISSN]
1527-1323
[Journal-full-title]
Radiographics : a review publication of the Radiological Society of North America, Inc
[ISO-abbreviation]
Radiographics
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
3.
Gupta N, Jadhav K, Ahmed MB, Amberkar VS:
Basal cell adenoma in a relatively rare site.
J Oral Maxillofac Pathol
; 2009 Jul;13(2):101-4
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Basal
cell adenoma
in a relatively rare
site
.
Basal
cell adenoma
(BCA) of the salivary glands is an uncommon type of monomorphic
adenoma
.
Histologically, it is seen as nests of isomorphic
cells
and interlaced trabeculae with a prominent basal membrane.
There is also slack, hyaline stroma with absence
of a
myxoid or chondroid component.
We describe a case of BCA of palatal minor salivary glands, a rare
site
for its occurrence.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Hum Pathol. 1982 May;13(5):497-500
[
7076228.001
]
[Cites]
Semin Diagn Pathol. 1987 May;4(2):117-35
[
3313598.001
]
[Cites]
Br J Radiol. 2005 Jul;78(931):642-5
[
15961849.001
]
[Cites]
Radiat Med. 2004 Jul-Aug;22(4):260-4
[
15468947.001
]
[Cites]
Med Oral Patol Oral Cir Bucal. 2006 Mar;11(2):E206-9
[
16505803.001
]
[Cites]
Ann Diagn Pathol. 2003 Oct;7(5):292-5
[
14571431.001
]
[Cites]
J Laryngol Otol. 2000 Jan;114(1):83-5
[
10789423.001
]
[Cites]
J Laryngol Otol. 1997 Feb;111(2):182-5
[
9102452.001
]
[Cites]
Eur J Dent. 2008 Jul;2(3):213-6
[
19212550.001
]
(PMID = 21887012.001).
[ISSN]
0973-029X
[Journal-full-title]
Journal of oral and maxillofacial pathology : JOMFP
[ISO-abbreviation]
J Oral Maxillofac Pathol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
India
[Other-IDs]
NLM/ PMC3162860
[Keywords]
NOTNLM ; Basal cell adenoma / alpha smooth muscle actin / monomorphic adenoma / pancytokeratin / squamous morules
Advertisement
4.
Couvelard A, O'Toole D, Turley H, Leek R, Sauvanet A, Degott C, Ruszniewski P, Belghiti J, Harris AL, Gatter K, Pezzella F:
Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression.
Br J Cancer
; 2005 Jan 17;92(1):94-101
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Microvascular density and hypoxia-inducible factor pathway in
pancreatic
endocrine tumours: negative correlation of microvascular density and VEGF expression with
tumour
progression.
Tumour
-associated angiogenesis is partly regulated by the hypoxia-inducible factor (HIF) pathway.
The aim of this study is to evaluate angiogenesis and expression of HIF-related molecules in a series of patients with
pancreatic
endocrine tumours (PETs).
The expression of vascular endothelial growth factor (VEGF), HIF-1alpha, HIF-2alpha and carbonic anhydrase 9 (CA9) was examined by immunohistochemistry in 45 patients with PETs and compared to microvascular density (MVD), endothelial proliferation,
tumour
stage and survival.
The regulation of HIF signalling appears to be specific in
pancreatic
endocrine tumours.
[MeSH-major]
Adenoma
,
Islet
Cell
/ blood supply.
Adenoma
,
Islet
Cell
/ metabolism. Neovascularization, Pathologic.
Pancreatic
Neoplasms / blood supply.
Pancreatic
Neoplasms / metabolism. Vascular Endothelial Growth Factors / metabolism
[MeSH-minor]
Adult. Basic Helix-Loop-Helix Transcription Factors. Carbonic Anhydrases / metabolism.
Disease
Progression. Female. Humans. Hypoxia-Inducible Factor 1,
alpha
Subunit. Male. Microcirculation. Transcription Factors / metabolism
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Eur J Cancer. 1998 Apr;34(5):609-18
[
9713263.001
]
[Cites]
Neuroendocrinology. 1986;43(2):159-65
[
3523276.001
]
[Cites]
Gut. 1998 Sep;43(3):422-7
[
9863490.001
]
[Cites]
Clin Cancer Res. 1997 Aug;3(8):1309-16
[
9815813.001
]
[Cites]
J Pathol. 1998 Nov;186(3):313-8
[
10211122.001
]
[Cites]
Oncogene. 1999 Sep 20;18(38):5356-62
[
10498889.001
]
[Cites]
J Clin Invest. 1997 Jul 15;100(2):404-10
[
9218518.001
]
[Cites]
Cancer Res. 1999 Nov 15;59(22):5830-5
[
10582706.001
]
[Cites]
J Clin Endocrinol Metab. 2000 Mar;85(3):1159-62
[
10720055.001
]
[Cites]
Cancer Res. 2000 Mar 1;60(5):1388-93
[
10728704.001
]
[Cites]
Br J Cancer. 2000 Apr;82(8):1441-5
[
10780524.001
]
[Cites]
J Endocrinol. 2000 May;165(2):475-81
[
10810311.001
]
[Cites]
Cancer. 2000 May 15;88(10):2239-45
[
10820344.001
]
[Cites]
Cancer. 2000 Jun 1;88(11):2606-18
[
10861440.001
]
[Cites]
Am J Pathol. 2000 Aug;157(2):411-21
[
10934146.001
]
[Cites]
Cancer Res. 2000 Sep 1;60(17):4693-6
[
10987269.001
]
[Cites]
Cancer Res. 2000 Dec 15;60(24):7075-83
[
11156414.001
]
[Cites]
Curr Opin Cell Biol. 2001 Apr;13(2):167-71
[
11248550.001
]
[Cites]
Cancer Res. 2001 Sep 1;61(17):6394-9
[
11522632.001
]
[Cites]
Nature. 2001 Aug 30;412(6850):877-84
[
11528470.001
]
[Cites]
Genes Chromosomes Cancer. 2001 Oct;32(2):177-81
[
11550286.001
]
[Cites]
Br J Cancer. 2001 Sep 14;85(6):881-90
[
11556841.001
]
[Cites]
Novartis Found Symp. 2001;240:212-25; discussion 225-31
[
11727931.001
]
[Cites]
Int J Cancer. 2002 Feb 20;97(6):719-25
[
11857345.001
]
[Cites]
Nat Rev Cancer. 2002 Jan;2(1):38-47
[
11902584.001
]
[Cites]
Br J Cancer. 2002 Apr 22;86(8):1276-82
[
11953885.001
]
[Cites]
Semin Cell Dev Biol. 2002 Feb;13(1):29-37
[
11969369.001
]
[Cites]
J Clin Oncol. 2002 Jun 1;20(11):2633-42
[
12039924.001
]
[Cites]
Pancreas. 2002 Aug;25(2):122-9
[
12142733.001
]
[Cites]
Clin Cancer Res. 2002 Aug;8(8):2595-604
[
12171890.001
]
[Cites]
J Surg Oncol. 2002 Sep;81(1):45-53; discussion 54
[
12210027.001
]
[Cites]
Nat Rev Cancer. 2002 Sep;2(9):673-82
[
12209156.001
]
[Cites]
J Clin Endocrinol Metab. 2002 Nov;87(11):4961-5
[
12414859.001
]
[Cites]
Microsc Res Tech. 2003 Feb 1;60(2):181-5
[
12539172.001
]
[Cites]
Hum Pathol. 2003 Jan;34(1):18-27
[
12605362.001
]
[Cites]
Histopathology. 2003 May;42(5):482-91
[
12713626.001
]
[Cites]
Virology. 1992 Apr;187(2):620-6
[
1312272.001
]
[Cites]
J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87
[
1281237.001
]
[Cites]
Am J Pathol. 1995 Jul;147(1):9-19
[
7541613.001
]
[Cites]
Br J Cancer. 1995 Aug;72(2):319-23
[
7543771.001
]
[Cites]
Hum Pathol. 1995 Nov;26(11):1196-200
[
7590692.001
]
[Cites]
Mol Endocrinol. 1995 Dec;9(12):1760-70
[
8614412.001
]
[Cites]
Genomics. 1996 May 1;33(3):480-7
[
8661007.001
]
[Cites]
Histopathology. 1997 Mar;30(3):294-301
[
9088964.001
]
[Cites]
Am J Pathol. 1997 Nov;151(5):1417-23
[
9358768.001
]
[Cites]
Am J Clin Pathol. 1998 Mar;109(3):286-93
[
9495200.001
]
[Cites]
Histopathology. 1998 Feb;32(2):133-8
[
9543669.001
]
[Cites]
Mod Pathol. 1998 Apr;11(4):329-33
[
9578082.001
]
[Cites]
J Pathol. 1998 Feb;184(2):119-22
[
9602700.001
]
[Cites]
Nat Med. 2003 Jun;9(6):653-60
[
12778163.001
]
[Cites]
Nat Med. 2003 Jun;9(6):677-84
[
12778166.001
]
[Cites]
Nat Rev Cancer. 2003 Jun;3(6):401-10
[
12778130.001
]
[Cites]
Cancer Cell. 2003 Aug;4(2):133-46
[
12957288.001
]
[Cites]
Gastroenterology. 2003 Oct;125(4):1094-104
[
14517793.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12596-601
[
9770531.001
]
(PMID = 15558070.001).
[ISSN]
0007-0920
[Journal-full-title]
British journal of cancer
[ISO-abbreviation]
Br. J. Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Basic Helix-Loop-Helix Transcription Factors; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Transcription Factors; 0 / Vascular Endothelial Growth Factors; 0 / endothelial PAS domain-containing protein 1; EC 4.2.1.1 / Carbonic Anhydrases
[Other-IDs]
NLM/ PMC2361752
5.
Dourakis SP, Alexopoulou A, Georgousi KK, Delladetsima JK, Tolis G, Archimandritis AJ:
Glucagonoma syndrome: survival 21 years with concurrent liver metastases.
Am J Med Sci
; 2007 Sep;334(3):225-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Glucagonoma syndrome
: survival 21 years with concurrent liver metastases.
A patient who survived for 21 years since initial discovery
of glucagonoma
with concurrent liver metastases is described.
Psychiatric symptoms, weight loss, necrolytic migratory erythema, diarrhea, and diabetes mellitus developed gradually after
diagnosis of the tumor
.
The longevity of this patient may be related to the slow
tumor
growth expressed histologically by ischemic necrosis of the malignant
cells
and in imaging by extensive
tumor
calcifications, a very rare
finding
in this type of the
tumor
.
[MeSH-major]
Glucagonoma
/ pathology. Liver Neoplasms / secondary.
Pancreatic
Neoplasms / pathology
Genetic Alliance.
consumer health - Glucagonoma
.
Genetic Alliance.
consumer health - Glucagonoma Syndrome
.
MedlinePlus Health Information.
consumer health - Liver Cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17873541.001).
[ISSN]
0002-9629
[Journal-full-title]
The American journal of the medical sciences
[ISO-abbreviation]
Am. J. Med. Sci.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
6.
Couvelard A, Deschamps L, Rebours V, Sauvanet A, Gatter K, Pezzella F, Ruszniewski P, Bedossa P:
Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH Is associated with tumor aggressiveness in pancreatic endocrine tumors.
Clin Cancer Res
; 2008 Oct 15;14(20):6634-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH Is associated with
tumor
aggressiveness in
pancreatic
endocrine
tumors
.
PURPOSE:
Tumor
hypoxia is associated with poor prognosis and resistance to treatment.
Our aim was to assess the expression of proteins that act as cellular oxygen sensors, directly regulating the hypoxia inducible factor (HIF) pathway, i.e., prolyl hydroxylase domain proteins (PHD)-1, PHD-2, PHD-3, and FIH in
pancreatic
endocrine
tumors
(PET).
The results were correlated with histoprognostic factors including Ki-67 index, presence
of a
fibrotic focus, and microvascular density (MVD).
FIH stromal expression was found in 23% of PETs and correlated with higher FIH nuclear expression (P = 0.0004) and poorer
disease
-free survival (P = 0.0018).
CONCLUSION: HIF regulatory proteins are highly expressed in PET and their expression is correlated with
tumor
metastases,
tumor
recurrence, and prognosis.
[MeSH-major]
Cell
Hypoxia. Dioxygenases / metabolism.
Pancreatic
Neoplasms / metabolism. Procollagen-Proline Dioxygenase / metabolism. Repressor Proteins / metabolism
[MeSH-minor]
Adenocarcinoma / metabolism. Adenocarcinoma / secondary.
Adenoma
,
Islet
Cell
/ metabolism.
Adenoma
,
Islet
Cell
/ pathology. Adult. Carcinoma,
Pancreatic
Ductal / metabolism. Carcinoma,
Pancreatic
Ductal / secondary.
Cell
Differentiation.
Cell
Proliferation. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic. Humans. Hypoxia-Inducible Factor 1,
alpha
Subunit / metabolism. Hypoxia-Inducible Factor-Proline Dioxygenases. Immunoenzyme Techniques. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Microcirculation. Mixed Function Oxygenases. Neoplasm Recurrence, Local /
diagnosis
. Neoplasm Recurrence, Local / metabolism. Neovascularization, Pathologic. Tissue Array Analysis
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18927305.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Repressor Proteins; EC 1.- / Mixed Function Oxygenases; EC 1.13.11.- / Dioxygenases; EC 1.14.11.- / HIF1AN protein, human; EC 1.14.11.2 / EGLN1 protein, human; EC 1.14.11.2 / Procollagen-Proline Dioxygenase; EC 1.14.11.29 / EGLN3 protein, human; EC 1.14.11.29 / Hypoxia-Inducible Factor-Proline Dioxygenases
7.
Nicol MR, Papacleovoulou G, Evans DB, Penning TM, Strachan MW, Advani A, Johnson SJ, Quinton R, Mason JI:
Estrogen biosynthesis in human H295 adrenocortical carcinoma cells.
Mol Cell Endocrinol
; 2009 Mar 5;300(1-2):115-20
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Estrogen biosynthesis in human H295 adrenocortical carcinoma
cells
.
The direct secretion of estradiol by adrenocortical
tumors
requires, in addition to the expression of aromatase (CYP19), the expression of one or more of the reductive 17beta-hydroxysteroid dehydrogenases.
The expression of CYP19 transcripts and protein were markedly induced in the H295 adrenocortical carcinoma
cell
line after treatment with either forskolin or vasoactive intestinal peptide (VIP).
The reductive type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) was also constitutively expressed in the H295
cells
but neither its mRNA transcript nor protein levels were altered after forskolin or VIP treatment.
Western immunoblotting of an estrogen-secreting adrenal carcinoma revealed notable levels of both aromatase and AKR1C3 expression while an aldosterone-
producing
adrenal
adenoma
lacked aromatase expression and showed a reduced level of AKR1C3 expression.
Immunohistochemistry of the carcinoma-bearing adrenal revealed localization of AKR1C3 not only in
the tumor
but also principally in the zona reticularis of the normal adrenal tissue.
Genetic Alliance.
consumer health - Adrenocortical Carcinoma
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Endocrinol Metab. 2001 Feb;86(2):649-52
[
11158024.001
]
[Cites]
J Clin Endocrinol Metab. 1996 Sep;81(9):3173-6
[
8784064.001
]
[Cites]
J Steroid Biochem Mol Biol. 2003 Mar;84(4):485-92
[
12732294.001
]
[Cites]
J Endocrinol. 2004 Jan;180(1):125-33
[
14709151.001
]
[Cites]
J Mol Endocrinol. 2004 Jun;32(3):869-77
[
15171718.001
]
[Cites]
Anal Biochem. 1976 May 7;72:248-54
[
942051.001
]
[Cites]
J Clin Invest. 1977 Aug;60(2):455-64
[
874104.001
]
[Cites]
Proc Natl Acad Sci U S A. 1988 Dec;85(23):8948-52
[
2848247.001
]
[Cites]
Lab Invest. 1990 Jul;63(1):132-6
[
2374399.001
]
[Cites]
Cancer Res. 1990 Sep 1;50(17):5488-96
[
2386954.001
]
[Cites]
Mol Endocrinol. 1993 Mar;7(3):423-33
[
8387159.001
]
[Cites]
J Clin Endocrinol Metab. 1993 Sep;77(3):731-7
[
8396576.001
]
[Cites]
Mol Cell Endocrinol. 1994 Apr;100(1-2):45-50
[
8056157.001
]
[Cites]
J Urol. 1995 Mar;153(3 Pt 2):1039-40
[
7853554.001
]
[Cites]
Medicine (Baltimore). 1965 Jan;44:37-79
[
14264352.001
]
[Cites]
Mol Cell Endocrinol. 2004 Dec 30;228(1-2):23-38
[
15541570.001
]
[Cites]
Steroids. 2004 Dec;69(13-14):795-801
[
15582534.001
]
[Cites]
J Steroid Biochem Mol Biol. 2005 May;95(1-5):35-9
[
16024247.001
]
[Cites]
Pharmacol Rev. 2005 Sep;57(3):359-83
[
16109840.001
]
[Cites]
J Endocrinol. 2006 Jan;188(1):59-68
[
16394175.001
]
[Cites]
J Clin Endocrinol Metab. 2006 Jun;91(6):2027-37
[
16551738.001
]
[Cites]
J Steroid Biochem Mol Biol. 2006 Nov;101(4-5):254-62
[
16979335.001
]
[Cites]
Arch Biochem Biophys. 2007 Aug 15;464(2):241-50
[
17537398.001
]
[Cites]
J Endocrinol. 2007 Oct;195(1):39-48
[
17911395.001
]
[Cites]
Hum Reprod. 2007 Nov;22(11):2981-91
[
17848403.001
]
[Cites]
Eur J Endocrinol. 2003 Apr;148(4):457-61
[
12656667.001
]
(PMID = 19026713.001).
[ISSN]
0303-7207
[Journal-full-title]
Molecular and cellular endocrinology
[ISO-abbreviation]
Mol. Cell. Endocrinol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA090744-07; United States / NCI NIH HHS / CA / R01 CA090744; United States / NCI NIH HHS / CA / R01 CA090744-07; United States / NCI NIH HHS / CA / R01-CA90744
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
Ireland
[Chemical-registry-number]
0 / Estrogens; 1F7A44V6OU / Colforsin; 37221-79-7 / Vasoactive Intestinal Peptide; EC 1.1.- / 17-Hydroxysteroid Dehydrogenases; EC 1.1.- / 3-Hydroxysteroid Dehydrogenases; EC 1.1.1.- / AKR1C3 protein, human; EC 1.1.1.- / Hydroxyprostaglandin Dehydrogenases; EC 1.1.1.145 / 3 beta-hydroxysteroid dehydrogenase type II; EC 1.1.1.145 / Progesterone Reductase; EC 1.14.14.1 / Aromatase; EC 1.14.15.4 / Cytochrome P-450 CYP11B2; EC 1.14.15.4 / Steroid 11-beta-Hydroxylase; EC 1.14.99.9 / Steroid 17-alpha-Hydroxylase
[Other-IDs]
NLM/ NIHMS99072; NLM/ PMC2673546
8.
Wezensky SJ, Hanks TS, Wilkison MJ, Ammons MC, Siemsen DW, Gauss KA:
Modulation of PLAGL2 transactivation by positive cofactor 2 (PC2), a component of the ARC/Mediator complex.
Gene
; 2010 Feb 15;452(1):22-34
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The pleomorphic
adenoma
gene (PLAG) family of transcription factors regulates a wide range of physiological processes, including
cell
proliferation, tissue-specific gene regulation, and embryonic development, although little is known regarding the mechanisms that regulate PLAG protein activity.
We show that PC2 cooperates with PLAGL2 and PU.1 to enhance the activity
of a
known PLAGL2 target promoter (NCF2).
The PLAGL2-binding element in the NCF2 promoter consisted of the core sequence of the bipartite PLAG1 consensus
site
, but lacked the G-cluster motif, and was recognized by PLAGL2 zinc fingers 5 and 6.
Co-immunoprecipitation and promoter-reporter studies reveal that the effect of PC2 on PLAGL2 target promoter activity was conferred via
the C
-terminus of PLAGL2, the region that is required for PC2 binding and contains the PLAGL2 activation domain.
Importantly, chromatin immunoprecipitation analysis and PC2 knockdown studies confirmed that endogenous PC2 protein associated with the NCF2 promoter in MM1
cells
in the region occupied by PLAGL2, and was required for PLAGL2 target promoter activity in TNF-
alpha
-treated MM1
cells
, respectively.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Published by Elsevier B.V.
[Cites]
Cancer Res. 2000 Jan 1;60(1):106-13
[
10646861.001
]
[Cites]
Blood. 2005 Apr 1;105(7):2900-7
[
15585652.001
]
[Cites]
Cancer Res. 2000 Sep 1;60(17):4869-72
[
10987300.001
]
[Cites]
J Biol Chem. 2001 Oct 19;276(42):39368-78
[
11483614.001
]
[Cites]
J Leukoc Biol. 2002 Jan;71(1):163-72
[
11781392.001
]
[Cites]
Cancer Res. 2002 Mar 1;62(5):1510-7
[
11888928.001
]
[Cites]
J Biol Chem. 2002 May 3;277(18):15851-8
[
11832486.001
]
[Cites]
J Biol Chem. 2002 May 31;277(22):19673-8
[
11882654.001
]
[Cites]
Nucleic Acids Res. 2002 Jul 1;30(13):2930-9
[
12087179.001
]
[Cites]
Nature. 2002 Aug 8;418(6898):641-6
[
12167862.001
]
[Cites]
J Biol Chem. 2003 Feb 21;278(8):6041-9
[
12473647.001
]
[Cites]
Comb Chem High Throughput Screen. 2003 Jun;6(4):381-7
[
12769682.001
]
[Cites]
Genes Chromosomes Cancer. 2004 Feb;39(2):126-37
[
14695992.001
]
[Cites]
Ann N Y Acad Sci. 2003 Dec;1010:264-5
[
15033731.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4924-9
[
15044690.001
]
[Cites]
Assay Drug Dev Technol. 2002 Nov;1(1 Pt 1):97-104
[
15090161.001
]
[Cites]
J Biol Chem. 2004 Aug 20;279(34):36121-31
[
15208321.001
]
[Cites]
Eur J Biochem. 1995 Oct 1;233(1):73-82
[
7588776.001
]
[Cites]
Nat Genet. 1997 Feb;15(2):170-4
[
9020842.001
]
[Cites]
Cancer Res. 1997 May 15;57(10):2029-34
[
9158001.001
]
[Cites]
Int J Cancer. 2005 Jul 10;115(5):690-700
[
15751035.001
]
[Cites]
Curr Opin Genet Dev. 2005 Oct;15(5):490-5
[
16098738.001
]
[Cites]
J Biol Chem. 2005 Dec 9;280(49):40773-81
[
16207715.001
]
[Cites]
Nature. 2006 Aug 10;442(7103):700-4
[
16799563.001
]
[Cites]
FEBS Lett. 2006 Sep 4;580(20):4784-92
[
16904669.001
]
[Cites]
Genomics. 2006 Nov;88(5):650-8
[
16928428.001
]
[Cites]
J Cell Physiol. 2007 Jan;210(1):16-25
[
17063461.001
]
[Cites]
Int J Oncol. 2007 Apr;30(4):765-74
[
17332914.001
]
[Cites]
J Biol Chem. 2007 Jun 15;282(24):17941-52
[
17462995.001
]
[Cites]
Biochimie. 2007 Dec;89(12):1439-46
[
17870225.001
]
[Cites]
J Cell Biochem. 2008 Feb 15;103(3):730-9
[
17551969.001
]
[Cites]
EMBO J. 1997 May 15;16(10):2814-25
[
9184226.001
]
[Cites]
J Biol Chem. 1998 Sep 4;273(36):23026-32
[
9722527.001
]
[Cites]
Dev Growth Differ. 2004 Oct;46(5):459-70
[
15606491.001
]
[Cites]
Int J Oncol. 2000 Jun;16(6):1107-10
[
10811981.001
]
(PMID = 20025940.001).
[ISSN]
1879-0038
[Journal-full-title]
Gene
[ISO-abbreviation]
Gene
[Language]
ENG
[Grant]
United States / NCRR NIH HHS / RR / RR-016455; United States / NCRR NIH HHS / RR / P20 RR16455-08; United States / NCRR NIH HHS / RR / RR-020185; United States / NCRR NIH HHS / RR / P20 RR024237-026650; United States / NCRR NIH HHS / RR / RR-024237; United States / NCRR NIH HHS / RR / RR024237-026650; United States / NCRR NIH HHS / RR / P20 RR024237; United States / NCRR NIH HHS / RR / P20 RR016455; United States / NCRR NIH HHS / RR / P20 RR020185
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / DNA-Binding Proteins; 0 / MED15 protein, human; 0 / Mediator Complex; 0 / Multiprotein Complexes; 0 / PLAGL2 protein, human; 0 / Proto-Oncogene Proteins; 0 / RNA-Binding Proteins; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Necrosis Factor-alpha; 0 / proto-oncogene protein Spi-1; 67763-97-7 / Insulin-Like Growth Factor II; EC 1.6.3.1 / NADPH Oxidase; EC 1.6.3.1 / NCF2 protein, human
[Other-IDs]
NLM/ NIHMS166082; NLM/ PMC2815083
9.
Iino K, Oki Y, Yamashita M, Matsushita F, Hayashi C, Yogo K, Nishizawa S, Yamada S, Maekawa M, Sasano H, Nakamura H:
Possible relevance between prohormone convertase 2 expression and tumor growth in human adrenocorticotropin-producing pituitary adenoma.
J Clin Endocrinol Metab
; 2010 Aug;95(8):4003-11
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Possible relevance between prohormone convertase 2 expression and
tumor
growth in human adrenocorticotropin-
producing
pituitary
adenoma
.
CONTEXT: Methods for preoperative
diagnosis of
prohormone convertase 2 (PC2)-positive ACTH-
producing
pituitary
adenomas
(APPAs) have not been established.
OBJECTIVE: This study was designed to understand the meaning of plasma alphaMSH levels and the role of
cell
proliferation-signaling molecules in PC2-positive APPAs.
RESULTS: Nine
adenomas
(47.4%) were immunopositive for PC2 and were large and invasive in nature.
Eight
adenomas
(42.1%) were immunopositive for both PC2 and p-Akt, and seven others (36.8%) were immunonegative for both, suggesting significant coexpression of PC2 and p-Akt in
tumors
.
CONCLUSIONS: Our study suggests that PC2 expression and Akt phosphorylation are related at the molecular level, resulting in a change in
cell
cycle and an increase in pituitary
adenoma
size.
An elevation of plasma alphaMSH could conjecture the activation of the phosphatidylinositol 3/Akt cascade in PC2-positive APPAs and may become a valuable clinical marker
of tumor
growth in Cushing'
s disease
.
[MeSH-major]
ACTH-Secreting Pituitary
Adenoma
/ metabolism.
Adenoma
/ metabolism. Proprotein Convertase 2 / metabolism.
alpha
-MSH / blood
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20501680.001).
[ISSN]
1945-7197
[Journal-full-title]
The Journal of clinical endocrinology and metabolism
[ISO-abbreviation]
J. Clin. Endocrinol. Metab.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / RNA, Messenger; 581-05-5 / alpha-MSH; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.4.21.94 / Proprotein Convertase 2
10.
Li W, Gomez E, Zhang Z:
Immunohistochemical expression of stromal cell-derived factor-1 (SDF-1) and CXCR4 ligand receptor system in hepatocellular carcinoma.
J Exp Clin Cancer Res
; 2007 Dec;26(4):527-33
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Immunohistochemical expression of stromal
cell
-derived factor-1 (SDF-1) and CXCR4 ligand receptor system in hepatocellular carcinoma.
The
alpha
-chemokine stromal
cell
-derived factor-1 (SDF-1) and its receptor CXCR4 have been recognized for their roles in regulating neoangiogenesis.
Formalin-fixed paraffin-embedded tissue sections of 28 HCC, 7 hepatocellular
adenoma
(HA), 26 cirrotic nodules (CN) and 16 normal liver tissues (NLT) were immunostained for SDF-1 and CXCR4.
SDF-1 and CXCR4 are detected in sinusoidal endothelial
cells
in HCC tissue, and their expressions are significantly higher than in non-HCC tissues.
Overexpressions of SDF-1 and CXCR4 in sinusoidal endothelial
cells
in HCC suggest that the SDF-1/CXCR4 pathway plays a possible role in HCC progression through neoangiogenesis.
[MeSH-minor]
Endothelial
Cells
/ metabolism. Humans. Immunohistochemistry. Neovascularization, Pathologic. Signal Transduction
MedlinePlus Health Information.
consumer health - Liver Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18365549.001).
[ISSN]
0392-9078
[Journal-full-title]
Journal of experimental & clinical cancer research : CR
[ISO-abbreviation]
J. Exp. Clin. Cancer Res.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Italy
[Chemical-registry-number]
0 / Chemokine CXCL12; 0 / Receptors, CXCR4
11.
Chaw L, Krop TM, Hood AF:
What is your diagnosis? Necrolytic migratory erythema associated with a glucagonoma.
Cutis
; 2008 Jan;81(1):25, 30-2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
What is your
diagnosis
? Necrolytic migratory erythema associated with
a glucagonoma
.
[MeSH-major]
Erythema / etiology.
Glucagonoma
/ complications.
Pancreatic
Neoplasms / complications. Paraneoplastic
Syndromes
/ pathology. Skin / pathology. Skin Diseases / etiology
[MeSH-minor]
Female.
Glucagon
/ blood. Humans. Middle Aged
Genetic Alliance.
consumer health - Glucagonoma
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
MedlinePlus Health Information.
consumer health - Skin Conditions
.
Hazardous Substances Data Bank.
GLUCAGON
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18306843.001).
[ISSN]
0011-4162
[Journal-full-title]
Cutis
[ISO-abbreviation]
Cutis
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
9007-92-5 / Glucagon
12.
Rao VP, Poutahidis T, Ge Z, Nambiar PR, Boussahmain C, Wang YY, Horwitz BH, Fox JG, Erdman SE:
Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice.
Cancer Res
; 2006 Aug 1;66(15):7395-400
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Here we report that infecting Rag2-deficient C57BL/6 Apc(Min/+) mice with an intestinal bacterial pathogen, Helicobacter hepaticus, significantly promotes mammary carcinoma in females and enhances intestinal
adenoma
multiplicity by
a tumor
necrosis factor
alpha
(TNFalpha)-dependent mechanism.
The mammary and intestinal
tumor
development as well as the increase in proinflammatory mediators is suppressed by adoptive transfer of interleukin 10-competent CD4+CD45RB(lo)CD25+ regulatory (T(R))
cells
.
Furthermore, prior exposure of donor mice to H. hepaticus significantly enhances antitumor potency of their T(R)
cells
.
Interestingly, these microbially experienced T(R)
cells
suppress tumorigenesis more effectively in recipient mice irrespective of their
tumor
etiology.
These data suggest that infections with enteric pathogens enhance T(R)-
cell
potency and protect against epithelial cancers later in life, potentially explaining paradoxical increases in cancer risk in developed countries having more stringent hygiene practices.
MedlinePlus Health Information.
consumer health - Helicobacter Pylori Infections
.
COS Scholar Universe.
author profiles
.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16885333.001).
[ISSN]
0008-5472
[Journal-full-title]
Cancer research
[ISO-abbreviation]
Cancer Res.
[Language]
ENG
[Grant]
United States / NCRR NIH HHS / RR / T32 RR 07036; United States / NIDDK NIH HHS / DK / R01 DK 52413; United States / NIAID NIH HHS / AI / R01 AI 52267-01; United States / NIEHS NIH HHS / ES / P30 ES002109; United States / NCI NIH HHS / CA / R01 CA 67529; United States / NIEHS NIH HHS / ES / P30 ES 02109; United States / NCI NIH HHS / CA / P01 CA 26731; United States / NCI NIH HHS / CA / R01 CA 108854
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / DNA-Binding Proteins; 0 / Immunoglobulins; 0 / Rag2 protein, mouse; 0 / Receptors, Interleukin-2; 0 / Recombinant Fusion Proteins; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10
13.
Jeannot E, Poussin K, Chiche L, Bacq Y, Sturm N, Scoazec JY, Buffet C, Van Nhieu JT, Bellanné-Chantelot C, de Toma C, Laurent-Puig P, Bioulac-Sage P, Zucman-Rossi J:
Association of CYP1B1 germ line mutations with hepatocyte nuclear factor 1alpha-mutated hepatocellular adenoma.
Cancer Res
; 2007 Mar 15;67(6):2611-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Association of CYP1B1 germ line mutations with hepatocyte nuclear factor 1alpha-mutated hepatocellular
adenoma
.
Biallelic somatic mutations of TCF1 coding for hepatocyte nuclear factor 1alpha (HNF1alpha) are found in 50% of the hepatocellular
adenoma
(HCA) cases usually associated with oral contraception.
For 10 genes (CYP1A1, CYP1A2, CYP3A4, CYP3A5, COMT, UGT2B7, NQO1, GSTM1, GSTP1, and GSTT1), we did not find mutations nor differences in the allele distribution among 32 women presenting HNF1alpha-mutated
adenomas
compared with 58 controls.
In contrast, we identified a CYP1B1 germ line heterozygous mutation in 4 of 32 women presenting HNF1alpha-mutated
adenomas
compared with none in 58 controls.
[MeSH-major]
Adenoma
, Liver
Cell
/ genetics. Cytochrome P-450 Enzyme System / genetics. Germ-Line Mutation. Hepatocyte Nuclear Factor 1-
alpha
/ genetics. Liver Neoplasms / genetics
[MeSH-minor]
Adolescent. Adult. Alleles. Aryl Hydrocarbon Hydroxylases. Child. Cytochrome P-450 CYP1B1. Female. Genetic Predisposition to
Disease
. Genotype. Humans. Middle Aged. Mutagenesis,
Site
-Directed. Pedigree
MedlinePlus Health Information.
consumer health - Liver Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17363580.001).
[ISSN]
0008-5472
[Journal-full-title]
Cancer research
[ISO-abbreviation]
Cancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Hepatocyte Nuclear Factor 1-alpha; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / CYP1B1 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP1B1
14.
Yoshida D, Kim K, Noha M, Teramoto A:
Anti-apoptotic action by hypoxia inducible factor 1-alpha in human pituitary adenoma cell line, HP-75 in hypoxic condition.
J Neurooncol
; 2006 Jul;78(3):217-25
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Anti-apoptotic action by hypoxia inducible factor 1-
alpha
in human pituitary
adenoma cell
line, HP-75 in hypoxic condition.
Hypoxia-inducible factor-1 (HIF-1)
alpha
is the major transcription factor involved in the adaptive response to hypoxia.
The purpose of this study was to investigate whether HIF 1-
alpha
protects HP75
cells
, pituitary
adenoma cell
line from hypoxia induced apoptosis.
HP75 was transfected with siRNA targeting HIF 1-
alpha
mRNA sequences or scrambled RNA duplexes, followed by subjected to hypoxia (1% oxygen) for 24 h, compared with normoxia (21%).
Membrane cDNA microarray was examined to detect gene profiling among the
cell
in normoxia, hypoxia, or hypoxia following the RNAi.
A significantly greater proportion of HP75
cells
transfected with specific siRNA duplexes and subsequently exposed to hypoxia demonstrated apoptosis to a large extent when compared with non-transfected
cells
.
Transfection with specific siRNA duplexes knocked down HIF 1-
alpha
mRNA and protein expression in hypoxia-exposed
cells
by approximately 80%, whereas transfection with scrambled siRNA duplexes had no noticeable effect on HIF 1-
alpha
expression.
Microarray analysis indicated that HIF1-
alpha
down-regulated caspase-10.
These findings strongly suggest that HIF 1-
alpha
exerts an antiapoptotic role in HP75 in hypoxia.
[MeSH-major]
Adenoma
/ metabolism. Apoptosis / physiology. Hypoxia / metabolism. Hypoxia-Inducible Factor 1,
alpha
Subunit / metabolism. Pituitary Neoplasms / metabolism
[MeSH-minor]
Adaptation, Physiological.
Cell
Line,
Tumor
.
Cell
Survival / genetics.
Cell
Survival / physiology. DNA Fingerprinting. Gene Expression Regulation, Neoplastic. Gene Silencing. Humans. RNA, Messenger / analysis. RNA, Small Interfering. Transfection
MedlinePlus Health Information.
consumer health - Pituitary Tumors
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Oncogene. 2004 Jun 24;23(29):4975-83
[
15107830.001
]
[Cites]
Oncogene. 2003 May 29;22(22):3431-40
[
12776195.001
]
[Cites]
Clin Neuropathol. 2004 Jan-Feb;23(1):8-15
[
14986928.001
]
[Cites]
Lab Invest. 2004 May;84(5):553-61
[
15064771.001
]
[Cites]
Oncogene. 2003 Jul 24;22(30):4734-44
[
12879018.001
]
[Cites]
Cell Cycle. 2004 Sep;3(9):1107-10
[
15326390.001
]
[Cites]
Int J Mol Med. 2000 Mar;5(3):253-9
[
10677565.001
]
[Cites]
J Biol Chem. 2004 Oct 1;279(40):41275-9
[
15310764.001
]
[Cites]
FASEB J. 2002 May;16(7):745-7
[
11923216.001
]
[Cites]
Cancer Res. 2001 Sep 1;61(17):6548-54
[
11522653.001
]
[Cites]
Respir Physiol Neurobiol. 2004 Nov 30;144(1):71-80
[
15522704.001
]
[Cites]
Pharmacol Ther. 2004 Nov;104(2):101-15
[
15518882.001
]
[Cites]
J Clin Pathol. 2004 Oct;57(10):1009-14
[
15452150.001
]
[Cites]
Drug Resist Updat. 2003 Dec;6(6):355-61
[
14744499.001
]
[Cites]
Pathol Biol (Paris). 2004 Jun;52(5):280-4
[
15217714.001
]
[Cites]
J Clin Pathol. 2003 Mar;56(3):209-13
[
12610101.001
]
[Cites]
Nat Rev Cancer. 2002 Jan;2(1):38-47
[
11902584.001
]
[Cites]
Cancer Cell. 2004 May;5(5):429-41
[
15144951.001
]
[Cites]
Apoptosis. 2000 Apr;5(2):99-105
[
11232248.001
]
[Cites]
Genes Cells. 2002 Feb;7(2):143-9
[
11895478.001
]
[Cites]
Diabetes. 2004 Aug;53(8):2034-41
[
15277383.001
]
[Cites]
Oncogene. 2000 Sep 21;19(40):4621-31
[
11030151.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):1027-36
[
12605983.001
]
[Cites]
Exp Cell Res. 2004 Mar 10;294(1):281-9
[
14980521.001
]
[Cites]
EMBO J. 2004 May 5;23 (9):1949-56
[
15071503.001
]
[Cites]
Dev Biol. 1999 May 15;209(2):254-67
[
10328919.001
]
[Cites]
Antioxid Redox Signal. 2003 Aug;5(4):467-73
[
13678535.001
]
[Cites]
J Biol Chem. 2002 May 3;277(18):15851-8
[
11832486.001
]
[Cites]
Histol Histopathol. 2003 Jul;18(3):679-86
[
12792878.001
]
[Cites]
Cancer Treat Rev. 2003 Aug;29(4):297-307
[
12927570.001
]
[Cites]
Pharmacology. 2003 Oct;69(2):74-8
[
12928580.001
]
[Cites]
Int J Cancer. 2004 Oct 10;111(6):849-57
[
15300796.001
]
[Cites]
Ann N Y Acad Sci. 2003 Dec;1010:520-4
[
15033783.001
]
[Cites]
Neurosurgery. 2003 Oct;53(4):880-5; discussion 885-6
[
14519220.001
]
[Cites]
Front Horm Res. 2004;32:217-34
[
15281349.001
]
(PMID = 16779673.001).
[ISSN]
0167-594X
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; 0 / RNA, Small Interfering
15.
Liu L, Qian J, Singh H, Meiers I, Zhou X, Bostwick DG:
Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis.
Arch Pathol Lab Med
; 2007 Aug;131(8):1290-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Immunohistochemical analysis of chromophobe renal
cell
carcinoma, renal oncocytoma, and clear
cell
carcinoma: an optimal and practical panel for differential
diagnosis
.
CONTEXT: The separation of chromophobe renal
cell
carcinoma, oncocytoma, and clear
cell
renal
cell
carcinoma using light microscopy remains problematic in some cases.
OBJECTIVE: To determine a practical immunohistochemical panel for the differential
diagnosis of
chromophobe carcinoma.
DESIGN: Vimentin, glutathione S-transferase
alpha
(GST-
alpha
), CD10, CD117, cytokeratin (CK) 7, and epithelial
cell
adhesion molecule (EpCAM) were investigated in 22 cases of chromophobe carcinoma, 17 cases of oncocytoma, and 45 cases of clear
cell
carcinoma.
RESULTS: Vimentin and GST-
alpha
expression were exclusively observed in clear
cell
carcinoma.
CD10 staining was more frequently detected in clear
cell
carcinoma (91%) than in chromophobe carcinoma (45%) and oncocytoma (29%).
CD117 was strongly expressed in chromophobe carcinoma (82%) and oncocytoma (100%), whereas none of the cases of clear
cell
carcinomas were immunoreactive.
EpCAM protein was expressed in all 22 cases of chromophobe carcinoma in more than 90%
of cells
, whereas all EpCAM-positive oncocytomas (5/17; 29%) displayed positivity in single
cells
or small
cell
clusters.
CONCLUSIONS: Using the combination of 3 markers (vimentin, GST-
alpha
, and EpCAM), we achieved 100% sensitivity and 100% specificity for the differential
diagnosis of
chromophobe carcinoma, oncocytoma, and clear
cell
carcinoma.
The pattern of "vimentin(-)/GST-
alpha
(-)" effectively excluded clear
cell
carcinoma, and homogeneous EpCAM expression confirmed
the diagnosis
of chromophobe carcinoma rather than oncocytoma.
CD117 and CK7 were also useful markers and could be used as second-line markers for the differential
diagnosis
, with high specificity (100%) and high sensitivity (90% and 86%, respectively).
[MeSH-major]
Adenocarcinoma, Clear
Cell
/
diagnosis
.
Adenoma
, Oxyphilic /
diagnosis
. Biomarkers,
Tumor
/ analysis. Carcinoma, Renal
Cell
/
diagnosis
. Immunoenzyme Techniques / methods. Kidney Neoplasms /
diagnosis
. Neoplasm Proteins / analysis
[MeSH-minor]
Diagnosis
, Differential. Fluorescent Antibody Technique, Indirect. Humans. Predictive Value of Tests
Genetic Alliance.
consumer health - Chromophobe Renal Cell Carcinoma
.
Genetic Alliance.
consumer health - Clear Cell Renal Cell Carcinoma
.
Genetic Alliance.
consumer health - Oncocytoma renal
.
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17683191.001).
[ISSN]
1543-2165
[Journal-full-title]
Archives of pathology & laboratory medicine
[ISO-abbreviation]
Arch. Pathol. Lab. Med.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
16.
Sun W, Iijima T, Kano J, Kobayashi H, Li D, Morishita Y, Okubo C, Anami Y, Noguchi M:
Frequent aberrant methylation of the promoter region of sterile alpha motif domain 14 in pulmonary adenocarcinoma.
Cancer Sci
; 2008 Nov;99(11):2177-84
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Frequent aberrant methylation of the promoter region of sterile
alpha
motif domain 14 in pulmonary adenocarcinoma.
Aberrant methylation of promoter CpG islands is known to be a major inactivation mechanism
of tumor
-suppressor and
tumor
-related genes.
In order to identify novel hypermethylated genes in early stage lung adenocarcinoma, we carried out methylated CpG island amplification, modified suppression subtractive hybridization, and methylation-specific polymerase chain reaction to identify aberrant methylation of CpG islands in
the A
/J mouse lung
adenoma
model, which histologically mimics the early stage of human pulmonary adenocarcinoma.
Of these two genes, we selected sterile
alpha
motif domain 14 (SAMD14) and further analyzed its methylation status and expression level by methylation-specific polymerase chain reaction and quantitative real-time polymerase chain reaction.
Most of the lung adenocarcinoma
cell
lines showed suppressed expression of SAMD14 together with hypermethylation at the promoter region, although an immortalized bronchial epithelium
cell
line (PL16B) did not show hypermethylation and did express SAMD14.
Hypermethylation at the CpG
site of
the SAMD14 promoter region was detected frequently in early invasive adenocarcinoma (8/24, 33.3%) but not in in situ adenocarcinoma (0/7, 0%) or normal lung tissue (0/31, 0%).
[MeSH-major]
Adenocarcinoma / genetics. DNA Methylation. Lung Neoplasms / genetics. Promoter Regions, Genetic / genetics.
Tumor
Suppressor Proteins / genetics
[MeSH-minor]
Animals. CpG Islands. DNA, Neoplasm / metabolism. Female. Humans. Kinesin / genetics. Kinesin / metabolism. Male. Mice. Mice, Inbred Strains. Middle Aged.
Tumor Cells
, Cultured
MedlinePlus Health Information.
consumer health - Lung Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18823374.001).
[ISSN]
1349-7006
[Journal-full-title]
Cancer science
[ISO-abbreviation]
Cancer Sci.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / DNA, Neoplasm; 0 / KIF21A protein, human; 0 / Kif21a protein, mouse; 0 / Tumor Suppressor Proteins; EC 3.6.1.- / Kinesin
17.
Oberg K:
Pancreatic endocrine tumors.
Semin Oncol
; 2010 Dec;37(6):594-618
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pancreatic
endocrine
tumors
.
Pancreatic
endocrine
tumors
have been steadily growing in incidence and prevalence during the last two decades, showing an incidence of 4-5/1,000,000 population.
They represent a heterogeneous group with very varying
tumor
biology and prognosis.
About half of the patients present clinical symptoms and
syndromes
related to substances released from
the tumors
(Zollinger-Ellison
syndrome
, insulinoma,
glucagonoma
, etc) and the other half are so-called nonfunctioning
tumors
mainly presenting with symptoms such as obstruction, jaundice, bleeding, and abdominal mass.
Ten percent to 15% of the
pancreatic
endocrine
tumors
are part of an inherited
syndrome
such as multiple endocrine neoplasia type 1 (MEN-1), von Hippel-Lindau (VHL), neurofibromatosis, or tuberousclerosis.
The diagnosis
is based on histopathology demonstrating
neuroendocrine
features such as positive staining for chromogranin A and specific hormones such as gastrin, proinsulin, and
glucagon
.
Moreover, the biochemical
diagnosis
includes measurement of chromogranins A and B or specific hormones such as gastrin, insulin,
glucagon
, and vasoactive intestinal polypeptide (VIP) in the circulation.
Surgery is still one of the cornerstones in the management
of pancreatic
endocrine
tumors
, but curative surgery is rarely obtained in most cases because of metastatic
disease
.
Cytotoxic drugs, biological agents, such as somatostatin analogs,
alpha
interferons, mammalian target of rapamycin (mTOR) inhibitors and tyrosine kinase inhibitors are routinely used.
Tumor
-targeted radioactive treatment is available in many centres in Europe and is effective in patients with
tumors
that express high content of somatostatin receptors type 2 and 5.
In the future, treatment will be based on
tumor
biology and molecular genetics with the aim of so-called personalized medicine.
[MeSH-major]
Pancreatic
Neoplasms
[MeSH-minor]
Antineoplastic Agents / therapeutic use. Biological Therapy / methods. Biomarkers,
Tumor
. Humans. Neoplastic
Syndromes
, Hereditary /
diagnosis
. Neoplastic
Syndromes
, Hereditary / therapy. Pancreatectomy. Paraneoplastic Endocrine
Syndromes
/
diagnosis
. Paraneoplastic Endocrine
Syndromes
/ therapy
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright © 2010 Elsevier Inc. All rights reserved.
(PMID = 21167379.001).
[ISSN]
1532-8708
[Journal-full-title]
Seminars in oncology
[ISO-abbreviation]
Semin. Oncol.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
18.
Gasparre G, Hervouet E, de Laplanche E, Demont J, Pennisi LF, Colombel M, Mège-Lechevallier F, Scoazec JY, Bonora E, Smeets R, Smeitink J, Lazar V, Lespinasse J, Giraud S, Godinot C, Romeo G, Simonnet H:
Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma.
Hum Mol Genet
; 2008 Apr 1;17(7):986-95
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Clonal expansion of mutated mitochondrial DNA is associated with
tumor
formation and complex I deficiency in the benign renal oncocytoma.
Here we show a benign
tumor
type in which mtDNA mutations that lead to complex I (CI) enzyme deficiency are found in all
tumors
and are the only genetic alteration detected.
Actually renal oncocytomas are homogeneous
tumors
characterized by dense accumulation of mitochondria and we had found that they are deficient in electron transport chain complex I (CI, NADH-ubiquinone oxidoreductase).
In this work total sequencing of mtDNA showed that 9/9
tumors
harbored point mutations in mtDNA, seven in CI genes, one in complex III, and one in the control region.
All
tumors
were somatically deficient for CI.
The clonal amplification of mutated mtDNA in 8/9
tumors
demonstrates that these alterations are selected and therefore favor or trigger growth.
We hypothesize that functional deficiency of the oxidative phosphorylation CI could create a loop of amplification of mitochondria during
cell
division, impair substrates oxidation and increase intermediary metabolites availability.
[MeSH-major]
Adenoma
, Oxyphilic / genetics. DNA, Mitochondrial / genetics. Electron Transport Complex I / genetics. Kidney Neoplasms / genetics
[MeSH-minor]
Cell
Culture Techniques.
Cell
Nucleus / genetics.
Cell
Proliferation. Citrate (si)-Synthase / metabolism. DNA Mutational Analysis. DNA-Directed DNA Polymerase / genetics. Electron Transport Chain Complex Proteins / genetics. Electron Transport Chain Complex Proteins / metabolism. Gene Amplification. Glucose / metabolism. Humans. Hypoxia-Inducible Factor 1,
alpha
Subunit / genetics. Hypoxia-Inducible Factor 1,
alpha
Subunit / metabolism. NADH Dehydrogenase / metabolism. Nucleic Acid Hybridization. Oxidative Phosphorylation. RNA, Messenger / genetics. RNA, Messenger / metabolism. Sequence Analysis, DNA
Genetic Alliance.
consumer health - Oncocytoma renal
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
Hazardous Substances Data Bank.
GLUCOSE
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18156159.001).
[ISSN]
1460-2083
[Journal-full-title]
Human molecular genetics
[ISO-abbreviation]
Hum. Mol. Genet.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / DNA, Mitochondrial; 0 / Electron Transport Chain Complex Proteins; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; EC 1.6.5.3 / Electron Transport Complex I; EC 1.6.99.3 / NADH Dehydrogenase; EC 2.3.3.1 / Citrate (si)-Synthase; EC 2.7.7.- / POLG protein, human; EC 2.7.7.7 / DNA-Directed DNA Polymerase; IY9XDZ35W2 / Glucose
19.
Pawlikowski M, Winczyk K:
Immunohistochemical detection of prothymosin alpha in pituitary adenomas--a new marker of tumor recurrence?
Folia Histochem Cytobiol
; 2009;47(4):559-62
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Immunohistochemical detection of prothymosin
alpha
in pituitary
adenomas
--a new marker
of tumor
recurrence?
Forty pituitary
adenomas
were immunostained with an antibody raised against
the C
-terminal fragment (101-109) of human prothymosin
alpha
(PT
alpha
).
The strong positive immunostaining was found in the subpopulation of
cell
nuclei and intratumoral vessel walls, while the cytoplasm of
adenoma
cells
was slightly immunopositive.
The significantly higher percentage of PT
alpha
-positive
cell
nuclei was found in recurrent pituitary
adenomas
as compared with primary
tumors
.
However, there was no correlation between the percentage of PT
alpha
-positive
cell
nuclei and Ki-67 indices.
Gonadotropinomas were characterized by higher nuclear PT
alpha
expression in comparison to other pituitary
adenomas
, which is probably linked with the high recurrence rate of these
tumors
.
It is suggested that PT
alpha
immunostaining may be helpful in predicting the pituitary
tumor
recurrence.
Moreover, PT
alpha
may be also useful as an immunohistochemical marker of the intratumoral microvasculature.
MedlinePlus Health Information.
consumer health - Pituitary Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20430720.001).
[ISSN]
1897-5631
[Journal-full-title]
Folia histochemica et cytobiologica
[ISO-abbreviation]
Folia Histochem. Cytobiol.
[Language]
ENG
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Poland
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Protein Precursors; 0 / prothymosin alpha; 61512-21-8 / Thymosin
20.
Di Leo A, Barone M, Maiorano E, Tanzi S, Piscitelli D, Marangi S, Lofano K, Ierardi E, Principi M, Francavilla A:
ER-beta expression in large bowel adenomas: implications in colon carcinogenesis.
Dig Liver Dis
; 2008 Apr;40(4):260-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
ER-beta expression in large bowel
adenomas
: implications in colon carcinogenesis.
AIM: In the present study, we evaluated oestrogen receptor-beta expression and its possible correlation with proliferative activity and apoptosis in colorectal
adenomas
and normal colon tissue.
RESULTS: In adenomatous tissue, a significant reduction of oestrogen receptor-beta was observed compared to normal mucosa (10.1+/-5.5% vs. 44.2+/-13.7; p<0.03), while the expression of oestrogen receptor-
alpha
remained unvaried.
Cell
proliferative activity significantly increased in adenomatous tissue compared to normal mucosa (59.3+/-7.1 vs. 18.5+/-8.8; p<0.0001), doubling the PCNA/apoptosis ratio.
An inverse correlation was found between oestrogen receptor-beta and PCNA expression in
adenomas
(r=-0.81), a datum confirmed by confocal microscopy evaluation.
[MeSH-major]
Adenoma
/ metabolism. Estrogen Receptor beta / metabolism. Intestinal Neoplasms / metabolism
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18093886.001).
[ISSN]
1590-8658
[Journal-full-title]
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
[ISO-abbreviation]
Dig Liver Dis
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Estrogen Receptor beta
21.
Levy A:
Molecular and trophic mechanisms of tumorigenesis.
Endocrinol Metab Clin North Am
; 2008 Mar;37(1):23-50, vii
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Classical proto-oncogene activation and
tumor
suppressor mutation are rarely responsible, and no histologic or molecular markers reliably predict behavior.
GNAS1 activation and the mutations associated with multiple endocrine neoplasia type 1 and Carney complex, aryl hydrocarbon receptor interacting protein gene mutations, and a narrowing region of chromosome 11q13 in familial isolated acromegaly together account for such a small proportion of pituitary
adenomas
that the pituitary
adenoma
pathogenic epiphany is surely yet to come.
[MeSH-major]
Cell
Transformation, Neoplastic / pathology. Pituitary Neoplasms / pathology
[MeSH-minor]
Animals. GTP-Binding Protein
alpha
Subunits, Gs / genetics. GTP-Binding Protein
alpha
Subunits, Gs / physiology. Humans. Phenotype
MedlinePlus Health Information.
consumer health - Pituitary Tumors
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18226729.001).
[ISSN]
0889-8529
[Journal-full-title]
Endocrinology and metabolism clinics of North America
[ISO-abbreviation]
Endocrinol. Metab. Clin. North Am.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
EC 3.6.1.- / GNAS protein, human; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs
[Number-of-references]
125
22.
Wang Y, Hua Q:
[Clinical significance of HIF-1 alpha,VEGF and VEGF-C expression in papillary thyroid carcinoma].
Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
; 2007 Mar;21(5):204-6, 208
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Clinical significance of HIF-1
alpha
,VEGF and VEGF-C expression in papillary thyroid carcinoma].
OBJECTIVE: To evaluate clinical significance of HIF-1
alpha
,VEGF and VEGF-C expression in papillary thyroid carcinoma.
METHOD: HIF-1a,VEGF and VEGF-C expression were detected by immunohistochemical method in 73 patients of papillary thyroid carcinoma(group I ), 32 patients of thyroid
adenoma
(group II) and 35 patients of nodular goiter(group II ) respectively.
RESULT: The expression of HIF-1
alpha
in group I (75.
VEGF and VEGF-C expression had a positive correlation with HIF-1
alpha
( P <0. 05).
CONCLUSION: In papillary thyroid carcinoma, HIF-1
alpha
, VEGF and VEGF-C expression are significantly increased.
Furthermore,VEGF and VEGF-C expression may be regulated by HIF-1
alpha
, involving in the process of cancer
cell
spreading to lymph nodes.
[MeSH-major]
Carcinoma, Papillary / metabolism. Hypoxia-Inducible Factor 1,
alpha
Subunit / metabolism. Thyroid Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor C / metabolism
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17536453.001).
[ISSN]
1001-1781
[Journal-full-title]
Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
[ISO-abbreviation]
Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
[Language]
chi
[Publication-type]
Controlled Clinical Trial; English Abstract; Journal Article
[Publication-country]
China
[Chemical-registry-number]
0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / VEGFA protein, human; 0 / VEGFC protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C
23.
Wagner S, Kiupel M, Peterson RA 2nd, Heikinheimo M, Wilson DB:
Cytochrome b5 expression in gonadectomy-induced adrenocortical neoplasms of the domestic ferret (Mustela putorius furo).
Vet Pathol
; 2008 Jul;45(4):439-42
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We screened ferret adrenocortical
tumor
specimens for expression of cytochrome b(5) (cyt b(5)), an allosteric regulator that selectively enhances the 17,20-lyase activity of P450c17.
Cyt b(5) immunoreactivity was evident in 24 of 25 (96%) adrenocortical
adenomas
/carcinomas from ferrets with signs of ectopic sex steroid production.
Normal adrenocortical
cells
lacked cyt b(5), which may account for the low production of adrenal androgens in healthy ferrets.
Other markers characteristic of gonadal somatic
cells
, such as luteinizing hormone receptor, aromatase, and GATA4, were coexpressed with cyt b(5) in some of the
tumors
.
We concluded that cyt b(5) is upregulated during gonadectomy-induced adrenocortical neoplasia and is a marker of androgen synthetic potential in these
tumors
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Vet Pathol. 2003 Mar;40(2):136-42
[
12637752.001
]
[Cites]
J Endocrinol. 1983 Dec;99(3):361-8
[
6417256.001
]
[Cites]
J Clin Endocrinol Metab. 1993 May;76(5):1286-90
[
8496319.001
]
[Cites]
Mol Cell Endocrinol. 2007 Feb;265-266:93-101
[
17222503.001
]
[Cites]
J Clin Endocrinol Metab. 1994 Jan;78(1):36-40
[
8288710.001
]
[Cites]
J Am Vet Med Assoc. 1996 Sep 15;209(6):1097-102
[
8800255.001
]
[Cites]
Semin Reprod Med. 2004 Nov;22(4):281-8
[
15635496.001
]
[Cites]
J Endocrinol. 2005 Nov;187(2):267-74
[
16293774.001
]
[Cites]
Vet Pathol. 2006 Mar;43(2):97-117
[
16537928.001
]
[Cites]
Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10619-23
[
7479852.001
]
(PMID = 18587089.001).
[ISSN]
0300-9858
[Journal-full-title]
Veterinary pathology
[ISO-abbreviation]
Vet. Pathol.
[Language]
ENG
[Grant]
United States / NIDDK NIH HHS / DK / DK075618-02; United States / NIDDK NIH HHS / DK / P30 DK052574-09; United States / NIDDK NIH HHS / DK / R01 DK075618-02; United States / NIDDK NIH HHS / DK / DK52574; United States / NIDDK NIH HHS / DK / DK075618; United States / NIDDK NIH HHS / DK / P30 DK052574; United States / NIDDK NIH HHS / DK / R01 DK075618
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / GATA4 Transcription Factor; 0 / Receptors, LH; 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins; 9035-39-6 / Cytochromes b5
[Other-IDs]
NLM/ NIHMS45245; NLM/ PMC2497446
24.
Antoniades D, Epivatianos A, Markopoulos A, Kolokotronis A, Zaraboukas T:
Coexistence of mucous retention cyst and basal cell adenoma arising from the lining epithelium of the cyst. Report of two cases.
Med Princ Pract
; 2009;18(3):248-52
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Coexistence of mucous retention cyst and basal
cell adenoma
arising from the lining epithelium of the cyst. Report of two cases.
OBJECTIVE: To report 2 cases of coexisting mucous retention cyst and basal
cell adenoma
arising from the lining epithelium of the cyst.
CLINICAL PRESENTATION AND INTERVENTION: Two cases of painless swellings, well-demarcated, soft to palpation, and located in the submucosa of the upper lip were clinically examined with the provisional
diagnosis of
mucocele or salivary gland
tumor
.
Histological examination showed the presence
of a
large unilocular cystic cavity in many parts surrounded by single or bilayered lining epithelium composed of flattened to cuboidal
cells
, and in other parts surrounded by projections
of cells
arranged in a trabecular pattern far into the cystic cavity.
The trabeculae were composed of basal and low columnar
cells
that sometimes formed small duct-like structures.
Immunohistochemistry showed that the lining epithelium of the cystic cavity and
the cells
of the projections expressed cytokeratin 7 and high-molecular-weight cytokeratins.
The cells
of the projections were weakly positive for S-100 protein and negative for vimentin and
alpha
-smooth muscle actin.
Based on the results,
a diagnosis
of coexisting mucous retention cysts and basal
cell
adenomas
arising from the lining epithelium of cysts was made.
CONCLUSION: The coexistence of mucous retention cysts and basal
cell
adenomas
arising from the lining epithelium of the cyst is reported.
[MeSH-major]
Adenoma
/ complications.
Adenoma
/ pathology. Mucocele / complications. Mucocele / pathology. Salivary Gland Diseases / complications. Salivary Gland Diseases / pathology
MedlinePlus Health Information.
consumer health - Salivary Gland Disorders
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2009 S. Karger AG, Basel.
(PMID = 19349732.001).
[ISSN]
1423-0151
[Journal-full-title]
Medical principles and practice : international journal of the Kuwait University, Health Science Centre
[ISO-abbreviation]
Med Princ Pract
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Switzerland
25.
Kumanov P, Nandipati KC, Tomova A, Robeva R, Agarwal A:
Significance of inhibin in reproductive pathophysiology and current clinical applications.
Reprod Biomed Online
; 2005 Jun;10(6):786-812
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
It is a glycoprotein hormone secreted by the Sertoli
cells of
the testis and granulosa and theca
cells of
the ovary.
Current understanding of inhibin physiology and pathology in the human suggests that inhibin B may be of importance as a marker of Sertoli
cell
function in men with infertility and as a prognostic indicator in women undergoing ovulation induction therapy.
Inhibin concentrations are elevated in patients with granulosa
cell
tumours and in post-menopausal women with mucinous ovarian cancers.
Immunoreactivity against the inhibin
alpha
-subunit was identified in all cases of adrenal cortical
adenoma
and carcinoma, and levels are suppressed in the malignant prostate
disease
.
[MeSH-minor]
Activins / chemistry. Activins / metabolism. Adult. Age Factors. Chromosomes, Human, Y. Exocrine Glands / metabolism. Female. Fertilization in Vitro / methods. Follistatin / chemistry. Follistatin / metabolism. Humans. Infant, Newborn. Male. Menstrual Cycle / physiology. Ovarian Neoplasms / blood. Polycystic Ovary
Syndrome
/ physiopathology. Pregnancy. Sequence Deletion.
alpha
-Macroglobulins / chemistry.
alpha
-Macroglobulins / metabolism
MedlinePlus Health Information.
consumer health - Male Infertility
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15970011.001).
[ISSN]
1472-6483
[Journal-full-title]
Reproductive biomedicine online
[ISO-abbreviation]
Reprod. Biomed. Online
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Follistatin; 0 / alpha-Macroglobulins; 104625-48-1 / Activins; 57285-09-3 / Inhibins
[Number-of-references]
114
26.
Waalkes MP, Liu J, Ward JM, Powell DA, Diwan BA:
Urogenital carcinogenesis in female CD1 mice induced by in utero arsenic exposure is exacerbated by postnatal diethylstilbestrol treatment.
Cancer Res
; 2006 Feb 1;66(3):1337-45
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Arsenic alone induced some urogenital system
tumors
, including mostly benign
tumors of
the ovary and uterus, and adrenal
adenoma
.
Diethylstilbestrol alone induced some
tumors
(primarily cervical) but when given after in utero arsenic, it greatly enhanced urogenital
tumor
incidence, multiplicity, and progression.
For instance, compared with the incidence of urogenital malignancies in the control (0%), arsenic alone (9%), and diethylstilbestrol alone (21%) groups, arsenic plus diethylstilbestrol acted synergistically, inducing a 48% incidence of malignant urogenital
tumors
.
Of the urogenital
tumors
induced by arsenic plus diethylstilbestrol, 80% were malignant, and 55% were multiple
site
.
Arsenic plus diethylstilbestrol increased ovarian, uterine, and vaginal
tumors
, and urinary bladder proliferative lesions, including three transitional
cell
carcinomas.
Tamoxifen alone did not increase urogenital
tumors
or affect arsenic-induced neoplasia but did increase arsenic-induced uroepithelial proliferative lesions.
Uterine and bladder carcinoma induced by arsenic plus diethylstilbestrol greatly overexpressed estrogen receptor-
alpha
(ER-
alpha
) and pS2, an estrogen-regulated gene.
In neonatal uteri, prenatal arsenic increased ER-
alpha
expression and enhanced estrogen-related gene expression induced by postnatal diethylstilbestrol.
[MeSH-minor]
Animals. Body Weight / drug effects. Drinking / drug effects. Drug Synergism. Estrogen Receptor
alpha
/ biosynthesis. Estrogen Receptor
alpha
/ genetics. Female. Gene Expression / drug effects. Maternal-Fetal Exchange. Mice. Pregnancy. Tamoxifen / toxicity. Uterus / drug effects. Uterus / metabolism. Uterus / physiology
MedlinePlus Health Information.
consumer health - Arsenic
.
MedlinePlus Health Information.
consumer health - Bladder Cancer
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
TAMOXIFEN
.
Hazardous Substances Data Bank.
DIETHYLSTILBESTROL
.
Hazardous Substances Data Bank.
ARSENIC, ELEMENTAL
.
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16452187.001).
[ISSN]
0008-5472
[Journal-full-title]
Cancer research
[ISO-abbreviation]
Cancer Res.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CO / N01 CO 12400; United States / Intramural NIH HHS / /
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Estrogen Receptor alpha; 094ZI81Y45 / Tamoxifen; 731DCA35BT / Diethylstilbestrol; N712M78A8G / Arsenic
27.
Zamora V, Cabanne A, Salanova R, Bestani C, Domenichini E, Marmissolle F, Giacomi N, O'Connor J, Méndez G, Roca E, Buenos Aires and La Plata Argentina Argentum Working Group:
Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours.
Dig Liver Dis
; 2010 Mar;42(3):220-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The somatostatin receptors types 1-5 expression in a series including 100 gastro-entero-
pancreatic
endocrine tumours were analysed.
METHODS: From a prospectively built database of patients with gastro-entero-
pancreatic
endocrine tumours referred from three institutions, 100 cases with clinical and pathological data were selected.
Somatostatin receptors expression by immunohistochemistry with somatostatin receptor types 1-5 antibodies in tissue paraffin sections were studied and correlated with the histological
diagnosis
according to the WHO classification, location and functional status.
RESULTS: Of the 100 cases, 67 were gastrointestinal tumours, 25
pancreatic
and 8 liver metastasis of unknown origin.
Thirty-one of them were functioning tumours: 2 insulinomas, 5 gastrinomas, 1
glucagonoma
and 23 carcinoids.
Somatostatin receptors expression was less frequent in
pancreatic
than in gastrointestinal tumours.
CONCLUSIONS: Immunohistochemistry revealed that somatostatin receptors were highly expressed in both primary and metastatic gastro-entero-
pancreatic
endocrine tumours with heterogeneous staining distribution.
It proved to be a reliable technique even in small
tumour
samples.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
2009 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
[CommentIn]
Dig Liver Dis. 2010 Mar;42(3):173-4
[
20117969.001
]
(PMID = 19819769.001).
[ISSN]
1878-3562
[Journal-full-title]
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
[ISO-abbreviation]
Dig Liver Dis
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Receptors, Somatostatin
28.
Laumonier H, Rullier A, Saric J, Balabaud C, Bioulac-Sage P:
Unexpected discovery of 2 cases of hepatocyte nuclear factor 1alpha-mutated infracentimetic adenomatosis.
World J Gastroenterol
; 2008 Aug 14;14(30):4830-3
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We present 2 cases of hepatocyte nuclear factor 1alpha (HNF1alpha)-mutated adenomatosis, discovered for reasons unrelated to this
disease
, and identified using immunohistochemical methods.
These new tools may further our understanding of the link between
adenomas
/adenomatosis subtypes and their complications, and their association with other abnormalities.
MedlinePlus Health Information.
consumer health - Liver Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Surg Pathol. 2001 Oct;25(10):1322-5
[
11688469.001
]
[Cites]
J Hepatol. 2008 Jan;48(1):163-70
[
17997499.001
]
[Cites]
Liver Int. 2003 Feb;23(1):35-7
[
12640725.001
]
[Cites]
J Hepatol. 2003 Jul;39(1):77-85
[
12821047.001
]
[Cites]
Gastroenterology. 2003 Nov;125(5):1470-5
[
14598263.001
]
[Cites]
J Clin Endocrinol Metab. 2004 Mar;89(3):1476-80
[
15001650.001
]
[Cites]
Gastroenterology. 2004 May;126(5):1323-9
[
15131793.001
]
[Cites]
N Engl J Med. 1978 Aug 3;299(5):239-41
[
207987.001
]
[Cites]
Gastroenterology. 1985 Nov;89(5):1132-8
[
2412930.001
]
[Cites]
Mod Pathol. 1989 Sep;2(5):456-62
[
2813344.001
]
[Cites]
Liver Transpl Surg. 1998 Sep;4(5):388-98
[
9724476.001
]
[Cites]
Gastroenterology. 2005 May;128(5):1211-8
[
15887105.001
]
[Cites]
Semin Liver Dis. 2005;25(2):230-6
[
15918151.001
]
[Cites]
Hepatology. 2006 Mar;43(3):515-24
[
16496320.001
]
[Cites]
Nat Clin Pract Gastroenterol Hepatol. 2006 Sep;3(9):526-31; quiz (following 531)
[
16951669.001
]
[Cites]
J Hepatol. 2007 Mar;46(3):521-7
[
17239484.001
]
[Cites]
Hepatology. 2007 Jul;46(1):140-6
[
17596890.001
]
[Cites]
Hepatology. 2007 Sep;46(3):740-8
[
17663417.001
]
[Cites]
Nat Genet. 2002 Oct;32(2):312-5
[
12355088.001
]
(PMID = 18720549.001).
[ISSN]
1007-9327
[Journal-full-title]
World journal of gastroenterology
[ISO-abbreviation]
World J. Gastroenterol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P50 CA095817
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Hepatocyte Nuclear Factor 1-alpha
[Other-IDs]
NLM/ PMC2739350
29.
Mizuno T, Hiraoka H, Yoshioka C, Takeda Y, Matsukane Y, Shimoyama N, Morimoto M, Hayashi T, Okuda M:
Superficial necrolytic dermatitis associated with extrapancreatic glucagonoma in a dog.
Vet Dermatol
; 2009 Feb;20(1):72-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Superficial necrolytic dermatitis associated with extrapancreatic
glucagonoma
in a dog.
Based on histopathological findings, blood examinations and necropsy findings, the condition was diagnosed as superficial necrolytic dermatitis associated with
a glucagon
-secreting extrapancreatic
neuroendocrine tumour
.
Gross necropsy revealed
tumour
invasion into the spleen, liver, adrenal glands and mesenteric lymph nodes.
Immunohistochemical analysis of the neoplastic
cells
revealed that
the tumour
was
a glucagonoma
, consistent with earlier findings of persistent glucagonaemia and hypoaminoacidaemia.
[MeSH-major]
Dermatitis / veterinary. Dog Diseases / pathology.
Glucagonoma
/ veterinary
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19152590.001).
[ISSN]
1365-3164
[Journal-full-title]
Veterinary dermatology
[ISO-abbreviation]
Vet. Dermatol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
England
30.
Yoshida A, Sen C, Asa SL, Rosenblum MK:
Composite pituitary adenoma and craniopharyngioma?: an unusual sellar neoplasm with divergent differentiation.
Am J Surg Pathol
; 2008 Nov;32(11):1736-41
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Composite pituitary
adenoma
and craniopharyngioma?: an unusual sellar neoplasm with divergent differentiation.
The patient was treated with thyroid radioablation and hormone replacement and followed for 7 years, during which time
the tumor
grew to 4.6 cm.
At transsphenoidal surgery,
a tumor
consisting
of a
pituitary
adenoma
and adamantinomatous craniopharyngiomalike components was resected.
Both components were closely intermingled, but there was no evidence of an intermediate
morphologic
phenotype.
Immunohistochemically, the
adenoma
was not only positive for beta-thyroid stimulating hormone,
alpha
subunit, and pituitary transcription factor 1, but also stained for beta-follicle stimulating hormone, steroidogenic factor-1, adrenocorticotropic hormone, and pituitary-restricted transcription factor (Tpit), exhibiting an unusual plurihormonal profile.
This lesion may represent an unusual composite
tumor
attributable to divergent differentiation
of a
common precursor.
Alternatively, it may be viewed as a pituitary
adenoma
showing metaplastic change analogous to the development of squamous
cell
nests of the pars tuberalis from adenohypophyseal endocrine
cells
.
[MeSH-major]
Adenoma
/ pathology. Craniopharyngioma / pathology. Neoplasms, Multiple Primary / pathology. Pituitary Neoplasms / pathology
Genetic Alliance.
consumer health - Craniopharyngioma
.
MedlinePlus Health Information.
consumer health - Pituitary Tumors
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18769335.001).
[ISSN]
1532-0979
[Journal-full-title]
The American journal of surgical pathology
[ISO-abbreviation]
Am. J. Surg. Pathol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
9002-71-5 / Thyrotropin
31.
Krause W:
Skin diseases in consequence of endocrine alterations.
Aging Male
; 2006 Jun;9(2):81-95
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
There, knowledge of skin alterations is important not only for dermatologists, but also for endocrinologists and other physicians, because a clinical
diagnosis of
the underlying
disease
is often possible.
These include acanthosis nigricans, diseases due to alterations of androgen metabolism, carcinoid
syndrome
, diseases due to alterations of corticosteroid metabolism, diseases in association with diabetes mellitus, diseases due to alterations of estrogen metabolism, genetic
syndromes
including dermatological and endocrine symptoms,
the glucagonoma syndrome
, diseases due to dysfunctions of growth hormone secretion, diseases in association with Merkel
cells of
the skin, diseases due to dysfunctions of the thyroid gland, diseases to alteration of vitamin D metabolism, and vitiligo and disorders of pigmentation.
[MeSH-minor]
Androgens / deficiency. Androgens / secretion. Estrogens / deficiency. Estrogens / secretion.
Glucagonoma
/ etiology. Malignant Carcinoid
Syndrome
/ etiology. Thyroid Hormones / deficiency. Thyroid Hormones / secretion. Vitamin D / secretion. Vitiligo / etiology
MedlinePlus Health Information.
consumer health - Skin Conditions
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16916743.001).
[ISSN]
1368-5538
[Journal-full-title]
The aging male : the official journal of the International Society for the Study of the Aging Male
[ISO-abbreviation]
Aging Male
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Androgens; 0 / Estrogens; 0 / Thyroid Hormones; 1406-16-2 / Vitamin D
[Number-of-references]
71
32.
Davies K, Conlon KC:
Neuroendocrine tumors of the pancreas.
Curr Gastroenterol Rep
; 2009 Apr;11(2):119-27
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Neuroendocrine tumors
of the
pancreas
.
Pancreatic
endocrine
tumors
are rare neoplasms accounting for less than 5%
of pancreatic
malignancies.
They are broadly classified into either functioning
tumors
(insulinomas, gastrinomas,
glucagonomas
, VIPomas, and somatostatinomas) or nonfunctioning
tumors
.
The diagnosis
of these
tumors
is difficult and requires a careful history and examination combined with laboratory tests and radiologic imaging.
Signs and symptoms are usually related to hormone hypersecretion in the case of functioning
tumors
and to
tumor
size or metastases with nonfunctioning
tumors
.
Surgical resection remains the treatment of choice even in the face of metastatic
disease
.
Further development of novel diagnostic and treatment modalities offers potential to greatly improve quality of life and prolong
disease
-free survival for patients with
pancreatic
endocrine
tumors
.
[MeSH-major]
Adenoma
,
Islet
Cell
. Carcinoma,
Islet
Cell
.
Pancreatic
Neoplasms
[MeSH-minor]
Algorithms. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Catheter Ablation. Chemoembolization, Therapeutic / methods. Evidence-Based Medicine. Gastrins / secretion.
Glucagon
/ secretion. Humans. Insulin / secretion. Quality of Life. Somatostatin / secretion. Survival Analysis. Treatment Outcome
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
Hazardous Substances Data Bank.
GLUCAGON
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 2002 Jun 1;20(11):2633-42
[
12039924.001
]
[Cites]
Cancer. 1991 Sep 15;68(6):1329-34
[
1678681.001
]
[Cites]
World J Surg. 2008 May;32(5):904-17
[
18264824.001
]
[Cites]
World J Surg. 2002 Aug;26(8):985-90
[
12016479.001
]
[Cites]
Ann Surg. 2007 Feb;245(2):273-81
[
17245182.001
]
[Cites]
Ann Oncol. 1999;10 Suppl 4:182-4
[
10436817.001
]
[Cites]
J Gastroenterol. 2007 Jun;42(6):497-500
[
17671766.001
]
[Cites]
J Gastrointest Surg. 2006 Jan;10(1):138-45
[
16368504.001
]
[Cites]
Gastroenterology. 1968 Dec;55(6):677-86
[
4302500.001
]
[Cites]
Ann Surg. 2006 Sep;244(3):410-9
[
16926567.001
]
[Cites]
Arch Surg. 1984 May;119(5):508-14
[
6143548.001
]
[Cites]
Endocr Relat Cancer. 2008 Jun;15(2):409-27
[
18508996.001
]
[Cites]
Eur J Surg Oncol. 2008 Mar;34(3):324-32
[
17967523.001
]
[Cites]
Am J Med. 1999 Mar;106(3):307-10
[
10190379.001
]
[Cites]
Ann Surg Oncol. 2008 Dec;15(12):3532-7
[
18825460.001
]
[Cites]
AJR Am J Roentgenol. 2003 Oct;181(4):987-92
[
14500214.001
]
[Cites]
Dig Dis Sci. 1991 Jul;36(7):933-42
[
2070707.001
]
[Cites]
N Engl J Med. 1992 Jun 25;326(26):1721-6
[
1317506.001
]
[Cites]
World J Surg. 1993 Jul-Aug;17 (4):427-32
[
8362525.001
]
[Cites]
Transplantation. 1998 Nov 27;66(10):1307-12
[
9846513.001
]
[Cites]
Medicine (Baltimore). 1996 Mar;75(2):53-63
[
8606627.001
]
[Cites]
Curr Probl Surg. 1990 Jun;27(6):301-86
[
1973365.001
]
[Cites]
N Engl J Med. 1977 Apr 28;296(17):963-7
[
321960.001
]
[Cites]
Mayo Clin Proc. 1991 Jul;66(7):711-9
[
1677058.001
]
[Cites]
Ann Surg. 2008 Jan;247(1):165-72
[
18156937.001
]
[Cites]
Arch Surg. 2002 Feb;137(2):164-8
[
11822953.001
]
[Cites]
Ann Surg. 1955 Oct;142(4):709-23; discussion, 724-8
[
13259432.001
]
[Cites]
N Engl J Med. 1986 May 1;314(18):1145-51
[
3007986.001
]
[Cites]
Ann Surg Oncol. 2001 Apr;8(3):249-53
[
11314942.001
]
[Cites]
Am J Med. 1958 Sep;25(3):374-80
[
13571250.001
]
[Cites]
Surg Clin North Am. 1987 Apr;67(2):379-93
[
3031836.001
]
[Cites]
Curr Opin Oncol. 1999 Jan;11(1):32-7
[
9914875.001
]
[Cites]
Pathol Res Pract. 1988 Apr;183(2):155-68
[
2898775.001
]
[Cites]
J Clin Endocrinol Metab. 1997 Aug;82(8):2622-8
[
9253344.001
]
[Cites]
J Gastrointest Surg. 1998 Sep-Oct;2(5):473-82
[
18335273.001
]
[Cites]
Arch Surg. 2006 Aug;141(8):765-9; discussion 769-70
[
16924083.001
]
[Cites]
J Med Res. 1902 Nov;8(2):385-95
[
19971505.001
]
[Cites]
J Clin Oncol. 2007 Dec 10;25(35):5609-15
[
18065733.001
]
[Cites]
Radiology. 1993 Mar;186(3):799-802
[
8381551.001
]
[Cites]
Am J Surg. 1990 Feb;159(2):258-64
[
2154144.001
]
(PMID = 19281699.001).
[ISSN]
1534-312X
[Journal-full-title]
Current gastroenterology reports
[ISO-abbreviation]
Curr Gastroenterol Rep
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Gastrins; 0 / Insulin; 51110-01-1 / Somatostatin; 9007-92-5 / Glucagon
[Number-of-references]
44
33.
Hong J, Abudula R, Chen J, Jeppesen PB, Dyrskog SE, Xiao J, Colombo M, Hermansen K:
The short-term effect of fatty acids on glucagon secretion is influenced by their chain length, spatial configuration, and degree of unsaturation: studies in vitro.
Metabolism
; 2005 Oct;54(10):1329-36
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The short-term effect of fatty acids on
glucagon
secretion is influenced by their chain length, spatial configuration, and degree of unsaturation: studies in vitro.
The influence of fatty acids on beta
cell
function has been well established whereas little is known about the role of fatty acids on
alpha cell
function.
The aim of our study was to investigate the short-term effects of chain length, spatial configuration, and degree of unsaturation of fatty acids on
glucagon
secretion from isolated mouse islets and
alpha
tumor
cell
1 clone 6
cells
(
alpha
TC1-6
cells
).
Glucagon
release was measured with different saturated and unsaturated fatty acids as well as cis and trans isomers of fatty acids at low and high glucose.
Palmitate (0.1-0.5 mmol/L) immediately stimulated
glucagon
release in a dose-dependent manner from both isolated islets and
alpha
TC 1-6
cells
.
The longer chain length of saturated fatty acids, the higher
glucagon
responses were obtained.
The average fold increase in
glucagon
to saturated fatty acids (0.3 mmol/L) compared to control was octanoate 1.5, laurate 2.0, myristate 2.9, palmitate 5.4, and stearate 6.2, respectively.
Saturated fatty acids were more effective than unsaturated fatty acids in stimulating
glucagon
secretion.
Fatty acids immediately stimulate
glucagon
secretion from isolated mouse islets
pancreatic
alpha
cells
.
[MeSH-major]
Fatty Acids / pharmacology.
Glucagon
/ secretion
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
GLUCAGON
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16154432.001).
[ISSN]
0026-0495
[Journal-full-title]
Metabolism: clinical and experimental
[ISO-abbreviation]
Metab. Clin. Exp.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Fatty Acids; 0 / Insulin; 9007-92-5 / Glucagon
34.
Katori H, Nozawa A, Tsukuda M:
Expression of epidermal growth factor receptor, transforming growth factor-alpha and Ki-67 in relationship to malignant transformation of pleomorphic adenoma.
Acta Otolaryngol
; 2007 Nov;127(11):1207-13
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of epidermal growth factor receptor, transforming growth factor-
alpha
and Ki-67 in relationship to malignant transformation of pleomorphic
adenoma
.
The data support the hypothesis that increased epidermal growth factor receptor (EGFR) and transforming growth factor (TGF)-
alpha
expression is associated with early events in malignant transformation of pleomorphic
adenoma
(PA).
OBJECTIVE: In the present study, we attempted to identify EGFR and TGF-
alpha
expression and Ki-67 index in carcinoma ex-pleomorphic
adenoma
(Ca ex-PA) and PA.
We also compared the presence of EGFR and TGF-
alpha
and Ki-67 index with clinical data.
MATERIALS AND METHODS: The tissues were stained with monoclonal antibodies to EGFR, TGF-
alpha
and Ki-67.
RESULTS: As regards the association of patients' prognosis with EGFR staining and Ki-67 index, a significant increase was observed in patients who died or had residual
disease
compared with patients who were alive without
disease
.
In the immunohistochemical analysis of EGFR and TGF-
alpha
and Ki67 index, a significant increase was observed in Ca ex-PA, especially with adenocarcinoma, compared with PA and sialadenitis.
[MeSH-major]
Adenoma
, Pleomorphic / metabolism. Biomarkers,
Tumor
/ biosynthesis.
Cell
Transformation, Neoplastic. Ki-67 Antigen / genetics. Receptor, Epidermal Growth Factor / biosynthesis. Salivary Gland Neoplasms / metabolism. Transforming Growth Factor
alpha
/ biosynthesis
MedlinePlus Health Information.
consumer health - Salivary Gland Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17851915.001).
[ISSN]
0001-6489
[Journal-full-title]
Acta oto-laryngologica
[ISO-abbreviation]
Acta Otolaryngol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Norway
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Transforming Growth Factor alpha; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
35.
Brown RL, Muzzafar T, Wollman R, Weiss RE:
A pituitary carcinoma secreting TSH and prolactin: a non-secreting adenoma gone awry.
Eur J Endocrinol
; 2006 May;154(5):639-43
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A pituitary carcinoma secreting TSH and prolactin: a non-secreting
adenoma
gone awry.
To our knowledge, only one case
of a
TSH-secreting carcinoma has previously been reported.
We describe here a second patient with a pituitary carcinoma
producing
TSH and prolactin (PRL).
Except for mildly increased PRL and elevated
alpha
-subunit, hormone evaluation was normal.
Pathologic examination revealed a chromophobe
adenoma
with increased mitotic forms.
Nine months later, the patient underwent further debulking of metastatic
disease
.
Although development
of a
carcinoma from a pituitary
adenoma
is very rare (<0.5%), macroadenomas that become hormonally active should be suspect for transformation into pituitary cancer.
MedlinePlus Health Information.
consumer health - Pituitary Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16645009.001).
[ISSN]
0804-4643
[Journal-full-title]
European journal of endocrinology
[ISO-abbreviation]
Eur. J. Endocrinol.
[Language]
ENG
[Grant]
United States / NIDDK NIH HHS / DK / DK07011; United States / NCRR NIH HHS / RR / RR00055; United States / NCRR NIH HHS / RR / RR18372
[Publication-type]
Case Reports; Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
England
[Chemical-registry-number]
9002-62-4 / Prolactin; 9002-71-5 / Thyrotropin
36.
Ozenne V, Paradis V, Vullierme MP, Vilgrain V, Leblanc T, Belghiti J, Imbert A, Valla DC, Degos F:
Liver tumours in patients with Fanconi anaemia: a report of three cases.
Eur J Gastroenterol Hepatol
; 2008 Oct;20(10):1036-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Fanconi anaemia is an autosomal recessive
disease
, causing secondary aplastic anaemia and congenital abnormalities, associated with an increased risk of tumours.
Liver
cell adenoma
and hepatocellular carcinoma have rarely been described.
Alpha
-fetoprotein levels were normal in all cases.
Patient 2 had hepatic nodules diagnosed at routine examination with radiological features
of adenomas
.
The patient underwent resection, which showed liver
cell adenoma
with foci of carcinoma.
Patient 3 had three nodules, with radiological and histological
diagnosis of
adenoma
.
In patients with Fanconi anaemia, androgen therapy and iron overload may contribute to the development of liver
cell adenoma
and hepatocellular carcinoma.
Hepatocellular carcinoma may occur as a transformation of liver
cell adenoma
.
[MeSH-major]
Adenoma
, Liver
Cell
/ etiology. Carcinoma, Hepatocellular / etiology. Fanconi Anemia / complications. Liver Neoplasms / etiology
MedlinePlus Health Information.
consumer health - Liver Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18787475.001).
[ISSN]
1473-5687
[Journal-full-title]
European journal of gastroenterology & hepatology
[ISO-abbreviation]
Eur J Gastroenterol Hepatol
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
England
37.
Igaz P:
MEN1 clinical background.
Adv Exp Med Biol
; 2009;668:1-15
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Multiple endocrine neoplasia Type 1 (MEN1) is a rare hereditary
tumor syndrome
predisposing to
tumor
development in several endocrine organs.
Its major manifestations include hyperparathyroidism,
tumors of
endocrine
pancreas
and pituitary.
Beside these three, several other endocrine (adrenocortical, foregut carcinoid) and nonendocrine (lipoma, angiofibroma, collagenoma, ependymoma, meningioma)
tumors
have been described to be associated with this
syndrome
.
Both familial and sporadic forms of the
disease
are known.
The diagnosis
of MEN1 can be established if two of the three major manifestations are found in the same patient, whereas
the diagnosis
of familial MEN1 requires one MEN1 patient and a first degree relative with at least one MEN1 manifestation.
Both benign (parathyroid, anterior pituitary) and malignant (gastrinoma,
glucagonoma
) lesions may develop in MEN1 patients.
Regular surveillance of MEN1 gene mutation carriers is necessary to reveal
disease
manifestations.
Several diagnostic modalities can be used to screen for and to examine MEN1-related
tumors
.
The therapy of MEN1-associated
tumors
requires specific approach in some cases, as multiple
tumors
and recurrence is frequently observed.
[MeSH-minor]
Adult. Child. Child, Preschool.
Diagnosis
, Differential. Genetic Predisposition to
Disease
. Genetic Testing. Humans. Middle Aged. Multiple Endocrine Neoplasia Type 2a / genetics. Multiple Endocrine Neoplasia Type 2a / pathology. Multiple Endocrine Neoplasia Type 2a / physiopathology. Mutation. Young Adult
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20175448.001).
[ISSN]
0065-2598
[Journal-full-title]
Advances in experimental medicine and biology
[ISO-abbreviation]
Adv. Exp. Med. Biol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
38.
Paner GP, Luthringer DJ, Amin MB:
Best practice in diagnostic immunohistochemistry: prostate carcinoma and its mimics in needle core biopsies.
Arch Pathol Lab Med
; 2008 Sep;132(9):1388-96
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
CONTEXT: The unrelenting challenge encountered when differentiating limited-volume prostate carcinoma and sometimes subtle variants from its many
morphologic
mimics has increased the use of ancillary immunohistochemistry in routine prostate needle biopsies.
The availability of prostate cancer-associated and basal
cell
-associated markers has been an invaluable addition to diagnostic surgical pathology.
OBJECTIVE: To review commonly used immunohistochemical stains, including innovative combinations, for confirmation or differential
diagnosis of
prostate carcinoma, and to propose appropriately constructed panels using
morphologic
patterns in prostate needle biopsies.
CONCLUSIONS: Basal
cell
-associated markers p63, high-molecular-weight cytokeratin 34 beta E12, cytokeratin 5/6 or a cocktail containing p63 and high-molecular-weight cytokeratin 34 beta E12 or cytokeratin 5/6 and prostate carcinoma-specific marker
alpha
-methylacyl coenzyme A (coA) racemase alone or in combination are useful adjuncts in confirming prostatic carcinoma that either lacks diagnostic, qualitative or quantitative features or that has an unusual
morphologic
pattern (eg, atrophic, pseudohyperplastic) or is in the setting of prior treatment.
The combination of
alpha
-methylacyl coA racemase positivity with negative staining for basal
cell
-associated markers supports a malignant
diagnosis
in the appropriate
morphologic
context.
Dual chromogen basal
cell
- associated markers (p63 [nuclear] and high-molecular-weight cytokeratin 34 beta E12/cytokeratin 5/6 [cytoplasmic]) and
alpha
-methylacyl coA racemase in an antibody cocktail provide greater sensitivity for the basal
cell
layer, easing evaluation and minimizing loss of representation of the focal area interest because the staining is performed on one slide.
In the posttreatment setting, pancytokeratin facilitates detection of subtle-treated cancer
cells
.
Prostate-specific antigen and prostatic acid phosphatase markers are helpful in excluding secondary malignancies involving the prostate, such as urothelial carcinoma, and occasionally in excluding nonprostatic benign mimickers, such as nephrogenic
adenoma
, mesonephric gland hyperplasia, and Cowper glands.
[MeSH-major]
Biomarkers,
Tumor
/ analysis. Biopsy, Needle. Immunohistochemistry / methods. Prostatic Neoplasms /
diagnosis
[MeSH-minor]
Diagnosis
, Differential. Humans. Male
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18788849.001).
[ISSN]
1543-2165
[Journal-full-title]
Archives of pathology & laboratory medicine
[ISO-abbreviation]
Arch. Pathol. Lab. Med.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor
[Number-of-references]
47
39.
La Rosa S, Uccella S, Dainese L, Marchet S, Placidi C, Vigetti D, Capella C:
Characterization of c-kit (CD117) expression in human normal pituitary cells and pituitary adenomas.
Endocr Pathol
; 2008;19(2):104-11
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Characterization
of c
-kit (CD117) expression in human normal pituitary
cells
and pituitary
adenomas
.
c-kit (CD117) is a tyrosine kinase receptor involved in the proliferation, differentiation, and secretory functions of various
cells
.
In experimental animal models, c-kit has been detected in the pars intermedia of the normal pituitary gland and in
alpha
-melanocyte-stimulating-hormone-positive
adenomas
and it has been suggested that it plays a role in regulating adrenocorticotropic hormone (ACTH) secretion.
To the best of our knowledge, the expression
of c
-kit in normal human pituitary
cells
and in pituitary
adenomas
has never been reported, so the possible biological role of this receptor in the control of pituitary hormone secretion remains unclear.
The aim of this study was to evaluate the immunohistochemical expression
of c
-kit in normal human pituitary glands and in a series of 62 well-characterized pituitary
adenomas
.
In normal adenohypophyses, several
cells
, mainly located in the central mucoid wedge, showed
a c
-kit immunoreactivity (IR).
Double label immunostaining procedures showed that
the c
-kit-IR
cells
corresponded to ACTH
cells
.
Out of 62
adenomas
, 15 (24%) were c-kit-IR, including 7/16 (44%) ACTH
cell
, 3/7 (42%) null
cell
, 4/11 (36%)
alpha
-subunit
cell
, and 1/11 (10%) follicle-stimulating hormone-luteinizing hormone
cell
adenomas
.
By contrast, all ten prolactin
cell
and seven growth hormone
cell
adenomas
were c-kit negative.
[MeSH-major]
Adenoma
/ metabolism. Pituitary Gland / metabolism. Pituitary Neoplasms / metabolism. Proto-Oncogene Proteins c-kit / biosynthesis
[MeSH-minor]
ACTH-Secreting Pituitary
Adenoma
/ metabolism. ACTH-Secreting Pituitary
Adenoma
/ pathology. Adolescent. Adult. Aged. Blotting, Western. Child. Female. Follicle Stimulating Hormone / blood. Growth Hormone-Secreting Pituitary
Adenoma
/ metabolism. Growth Hormone-Secreting Pituitary
Adenoma
/ pathology. Humans. Immunohistochemistry. Luteinizing Hormone / blood. Male. Middle Aged. Paraffin Embedding. Prolactinoma / metabolism. Prolactinoma / pathology. Tissue Fixation
MedlinePlus Health Information.
consumer health - Pituitary Tumors
.
Hazardous Substances Data Bank.
MENOTROPINS
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
antibodies-online.
View related products from antibodies-online.com
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Histochem Cytochem. 1995 Jan;43(1):97-102
[
7822770.001
]
[Cites]
Br J Dermatol. 2004 Feb;150(2):384-5
[
14996126.001
]
[Cites]
Cancer Res. 1992 Nov 15;52(22):6139-43
[
1384954.001
]
[Cites]
Hum Pathol. 2003 Jan;34(1):18-27
[
12605362.001
]
[Cites]
J Histochem Cytochem. 1981 Apr;29(4):577-80
[
6166661.001
]
[Cites]
Endocrinology. 2005 Sep;146(9):3985-98
[
15932930.001
]
[Cites]
N Engl J Med. 2002 Aug 15;347(7):472-80
[
12181401.001
]
[Cites]
Blood. 1999 Sep 15;94(6):1979-86
[
10477727.001
]
[Cites]
Appl Immunohistochem Mol Morphol. 2001 Dec;9(4):319-28
[
11759058.001
]
[Cites]
EMBO J. 1987 Nov;6(11):3341-51
[
2448137.001
]
[Cites]
Ann Oncol. 2003 Jun;14(6):894-7
[
12796027.001
]
[Cites]
J Histochem Cytochem. 1994 Nov;42(11):1417-25
[
7523489.001
]
[Cites]
Endocr Pathol. 2000 Winter;11(4):315-329
[
12114756.001
]
[Cites]
Jpn J Clin Oncol. 2006 Aug;36(8):494-8
[
16844734.001
]
[Cites]
Virchows Arch. 2000 Sep;437(3):264-9
[
11037346.001
]
[Cites]
Oncogene. 1997 Jun 5;14(22):2661-70
[
9178764.001
]
[Cites]
Zentralbl Pathol. 1993 Jun;139(2):165-70
[
8396420.001
]
[Cites]
J Clin Endocrinol Metab. 1995 Nov;80(11):3361-7
[
7593452.001
]
[Cites]
Hum Pathol. 1998 May;29(5):498-504
[
9596274.001
]
[Cites]
Development. 1996 Oct;122(10):3023-33
[
8898216.001
]
[Cites]
Mod Pathol. 1998 Aug;11(8):728-34
[
9720500.001
]
[Cites]
Biochem Biophys Res Commun. 2005 Dec 23;338(3):1307-15
[
16226710.001
]
[Cites]
Mod Pathol. 2005 Mar;18(3):320-3
[
15502806.001
]
[Cites]
Neuroendocrinology. 2007;85(2):110-30
[
17337880.001
]
[Cites]
Mod Pathol. 2000 Oct;13(10):1134-42
[
11048809.001
]
[Cites]
Pathol Int. 1994 Sep;44(9):697-703
[
7804432.001
]
[Cites]
Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):205-20
[
16082245.001
]
[Cites]
Am J Dermatopathol. 2002 Aug;24(4):289-93
[
12142606.001
]
[Cites]
Am J Pathol. 1993 Jan;142(1):339-46
[
7678721.001
]
[Cites]
Clin Cancer Res. 2003 Apr;9(4):1469-73
[
12684421.001
]
[Cites]
Am J Surg Pathol. 2003 Dec;27(12):1551-8
[
14657715.001
]
[Cites]
J Neurosci. 1998 Feb 1;18(3):1056-71
[
9437026.001
]
[Cites]
Virchows Arch. 1994;424(2):135-41
[
7514077.001
]
[Cites]
J Cutan Pathol. 2004 Mar;31(3):254-61
[
14984578.001
]
[Cites]
Stem Cells. 2005;23(1):16-43
[
15625120.001
]
[Cites]
Endocr Relat Cancer. 2006 Jun;13(2):535-40
[
16728580.001
]
[Cites]
J Neuroimmunol. 1996 Apr;65(2):133-41
[
8964895.001
]
[Cites]
Am J Dermatopathol. 2004 Dec;26(6):458-62
[
15618926.001
]
(PMID = 18568298.001).
[ISSN]
1046-3976
[Journal-full-title]
Endocrine pathology
[ISO-abbreviation]
Endocr. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
40.
Gin VC, Zacharias M:
Glucagonoma: anaesthetic management.
Anaesth Intensive Care
; 2009 Mar;37(2):329-30
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Glucagonoma
: anaesthetic management.
[MeSH-major]
Anesthesia, General / methods.
Glucagonoma
/ surgery.
Pancreatic
Neoplasms / surgery
[MeSH-minor]
Blood Glucose / analysis. Female.
Glucagon
/ blood. Humans. Middle Aged
Genetic Alliance.
consumer health - Glucagonoma
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
Hazardous Substances Data Bank.
GLUCAGON
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19400510.001).
[ISSN]
0310-057X
[Journal-full-title]
Anaesthesia and intensive care
[ISO-abbreviation]
Anaesth Intensive Care
[Language]
eng
[Publication-type]
Case Reports; Letter
[Publication-country]
Australia
[Chemical-registry-number]
0 / Blood Glucose; 9007-92-5 / Glucagon
41.
Simonenko VB, Dulin PA, Beliaev LB, Makanin MA, Dem'ianenko AV, Zykova AA, Zhuravleva SI, Kolesnikova VN:
[A case of pancreatic glucagonoma].
Klin Med (Mosk)
; 2007;85(8):67-70
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[A case
of pancreatic glucagonoma
].
Neuroendocrine tumor
consisting
of pancreatic
alpha
-
cells
--
glucagonoma
-- is a very rare
finding
(one case per two million people a year).
This functionally active, usually malignant
tumor
has typical clinical manifestations.
Glucagonoma syndrome
is
a disease
that has an original clinical picture that includes necrolytic migrating erythema with secondary bullous dermatitis, glucose tolerance
disorder
or diabetes mellitus, weight loss, anemia, hypoaminoacidemia, venous thrombosis, and alimentary and mental disturbances.
By the time
diagnosis
is made, 60 to 70%
of glucagonomas
already give metastases, and even small
glucagonomas
should be considered
tumors
with unknown malignant potential or malignant
tumors
.
Glucagonomas
grow slowly, and patients live long (the survival median is approximately 15 years).
[MeSH-major]
Glucagonoma
/ pathology.
Pancreatic
Neoplasms / pathology
Genetic Alliance.
consumer health - Glucagonoma
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17926496.001).
[ISSN]
0023-2149
[Journal-full-title]
Klinicheskaia meditsina
[ISO-abbreviation]
Klin Med (Mosk)
[Language]
rus
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Russia (Federation)
42.
Tran N, McLean T, Zhang X, Zhao CJ, Thomson JM, O'Brien C, Rose B:
MicroRNA expression profiles in head and neck cancer cell lines.
Biochem Biophys Res Commun
; 2007 Jun 22;358(1):12-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
MicroRNA expression profiles in head and neck cancer
cell
lines.
In this study, the relative expression of 261 mature miRNA genes was determined in nine head and neck cancer
cell
lines using an oligonucleotide array platform.
Thirty-three miRNAs in the array were found to be highly expressed and 22 showed low levels of expression in all
cell
lines.
Potential targets of validated miRNAs included
tumor
suppressor genes, kinesin family member 1B isoform
alpha
(KIF1B), and hypermethylated in cancer 2 (HIC2), and pleomorphic
adenoma
gene 1 (PLAG1).
This study provides the largest genomewide survey of mature miRNA transcripts in head and neck cancer
cell
lines.
[MeSH-major]
Biomarkers,
Tumor
/ metabolism. Head and Neck Neoplasms / metabolism. MicroRNAs / metabolism
[MeSH-minor]
Cell
Line,
Tumor
. DNA-Binding Proteins / metabolism. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Kinesin / metabolism. Nerve Tissue Proteins / metabolism. Oligonucleotide Array Sequence Analysis
MedlinePlus Health Information.
consumer health - Head and Neck Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17475218.001).
[ISSN]
0006-291X
[Journal-full-title]
Biochemical and biophysical research communications
[ISO-abbreviation]
Biochem. Biophys. Res. Commun.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / KIF1B protein, human; 0 / MicroRNAs; 0 / Nerve Tissue Proteins; 0 / PLAG1 protein, human; EC 3.6.1.- / Kinesin
43.
Warner RR:
Enteroendocrine tumors other than carcinoid: a review of clinically significant advances.
Gastroenterology
; 2005 May;128(6):1668-84
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Enteroendocrine
tumors
other than carcinoid: a review of clinically significant advances.
Only relatively recently has there been an increased clinical recognition and characterization of the heterogeneous group of rare gastroenteropancreatic
neuroendocrine
neoplasms.
This review summarizes the derivation of these
tumors
and the advances in their
diagnosis
and treatment over the past decade and a half.
They are varied in their biological behavior and clinical courses and, depending on their
cell
type, can produce different hormones causing distinct clinical endocrine
syndromes
(insulinoma [hypoglycemia], gastrinoma [Zollinger-Ellison
syndrome
(ZES)], vasoactive intestinal peptideoma [VIPoma], watery diarrhea, hypokalemia-achlorhydria [WDHA],
glucagonoma
[
glucagonoma syndrome
], and so forth).
In addition to surgery for cure or palliation (by excision and a variety of other cytoreductive techniques), they each are treated with anti-hormonal agents or drugs targeted to each
tumor
's specific product or its effects.
Because of their usual slow rate of growth it is recommended that, even when they are advanced and incurable, unlike in patients with common and more malignant cancers, patients with
neuroendocrine tumors
often can be palliated and appear to survive longer when managed with an active approach using sequential multimodality treatment.
[MeSH-major]
Carcinoma,
Neuroendocrine
. Gastrointestinal Neoplasms
[MeSH-minor]
Carcinoid
Tumor
. Humans
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15887158.001).
[ISSN]
0016-5085
[Journal-full-title]
Gastroenterology
[ISO-abbreviation]
Gastroenterology
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
222
44.
Takehara K, Sakai H, Shono T, Irie J, Kanetake H:
Proliferative activity and genetic changes in adrenal cortical tumors examined by flow cytometry, fluorescence in situ hybridization and immunohistochemistry.
Int J Urol
; 2005 Feb;12(2):121-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Proliferative activity and genetic changes in adrenal cortical
tumors
examined by flow cytometry, fluorescence in situ hybridization and immunohistochemistry.
BACKGROUND: To determine differences in biological features among different adrenal
tumors
, we investigated the DNA ploidy, numerical chromosomal aberration and proliferative activity in human adrenal cortical neoplasms.
METHODS: Our study included six adrenal cortical
adenomas
with Cushing
syndrome
, 12
adenomas
with hyperaldosteronism, three non-functioning
adenomas
and three adrenal cortical carcinomas.
For FISH analysis, we used an
alpha
-centromeric enumeration probe for chromosome 17.
RESULTS: The mean Ki-67 labeling index (LI) of adrenal cortical carcinomas was markedly higher than that of adrenal cortical
adenomas
(209.4 vs 8.7).
In functional adrenal cortical
adenomas
, the LI was significantly lower in
adenomas
with hyperaldosteronism than in those with Cushing
syndrome
(P = 0.004), although FCM results indicated that tetraploid patterns were more frequently observed in the former type.
Tumor
size was significantly smaller in
adenomas
with hyperaldosteronism than in those with Cushing
syndrome
(P = 0.004).
Chromosome 17 showed disomy in all adrenal cortical
adenomas
, whereas chromosome 17 abnormalities were found in two of three adrenal cortical carcinomas.
CONCLUSIONS: Our study characterized various biological features of benign and malignant adrenal cortical
tumors
.
The use
of a
combination of markers might provide additional information to assist our understanding of the clinical behavior of an individual adrenal cortical
tumor
.
[MeSH-minor]
Adenoma
/ genetics.
Adenoma
/ metabolism.
Adenoma
/ pathology. Adult. Aged. Biomarkers,
Tumor
/ genetics. Biomarkers,
Tumor
/ metabolism. Carcinoma / genetics. Carcinoma / metabolism. Carcinoma / pathology.
Cell
Proliferation. Chromosomes, Human, Pair 17. Cushing
Syndrome
/ genetics. Cushing
Syndrome
/ metabolism. Cushing
Syndrome
/ pathology. DNA, Neoplasm / genetics. Female. Humans. Hyperaldosteronism / genetics. Hyperaldosteronism / metabolism. Hyperaldosteronism / pathology. Ki-67 Antigen / metabolism. Male. Middle Aged. Ploidies.
Tumor
Suppressor Protein p53 / metabolism
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15733104.001).
[ISSN]
0919-8172
[Journal-full-title]
International journal of urology : official journal of the Japanese Urological Association
[ISO-abbreviation]
Int. J. Urol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Australia
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
45.
Halsey MA, Calder KB, Mathew R, Schlauder S, Morgan MB:
Expression of alpha-methylacyl-CoA racemase (P504S) in sebaceous neoplasms.
J Cutan Pathol
; 2010 Apr;37(4):446-51
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of
alpha
-methylacyl-CoA racemase (P504S) in sebaceous neoplasms.
BACKGROUND:
Alpha
-methylacyl-CoA racemase (AMACR), also known as P504S, is a protein that plays an important role in mitochondrial and peroxisomal beta-oxidation of branched-chain fatty acid and bile acid intermediates.
AMACR has been established as a valuable diagnostic marker for prostate cancer and has recently been shown to be useful in
the diagnosis
of colorectal carcinoma.
METHODS: Five samples of normal sebaceous glands as well as five cases each of sebaceous hyperplasia (SH), sebaceous
adenoma
(SA), basal
cell
carcinoma (BCC) with sebaceous differentiation and extraocular sebaceous carcinoma (SC) were evaluated for immunohistochemical (IHC) expression of AMACR.
CONCLUSIONS: The expression of AMACR is increased in benign sebaceous glands and SH; with decreasing AMACR expression in
tumors
with less sebaceous differentiation (i.e.
[MeSH-major]
Adenoma
/ enzymology. Carcinoma / enzymology. Racemases and Epimerases / metabolism. Sebaceous Gland Neoplasms / enzymology. Sebaceous Glands / enzymology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19638170.001).
[ISSN]
1600-0560
[Journal-full-title]
Journal of cutaneous pathology
[ISO-abbreviation]
J. Cutan. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Denmark
[Chemical-registry-number]
EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
46.
Tomita T:
Lymphatic vessel endothelial hyaluronan receptor 1 immunocytochemical staining for pancreatic islets and pancreatic endocrine tumors.
Pancreas
; 2007 Nov;35(4):e18-22
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Lymphatic vessel endothelial hyaluronan receptor 1 immunocytochemical staining for
pancreatic
islets and
pancreatic
endocrine
tumors
.
OBJECTIVES: Immunocytochemical staining for lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) is able to recognize lymphatic vessel endothelium and
pancreatic
endocrine
cells
(PETs).
Pancreatic
endocrine
tumors
were studied for LYVE-1 immunocytochemical staining compared with normal
pancreatic
islets to detect possible presence of LYVE-1 in PETs.
METHODS: Twenty-five cases of primary and metastatic PETs were immunocytochemically stained for LYVE-1, including insulinomas,
glucagonomas
, somatostatinoma,
pancreatic
polypeptidomas, gastrinomas, and nonfunctioning
tumors
.
RESULTS: All normal
pancreatic islet cells
were positive for LYVE-1, whereas 2 cases of 25 PETs, 1 each of gastrinoma and nonfunctioning
tumor
, were positive for LYVE-1, retaining immunocytochemical reactivity
of islet cells
.
CONCLUSIONS: Normal
pancreatic
islets were positive for LYVE-1, whereas only 2 of 25 PETs were positive, suggesting that most PETs lost LYVE-1 or contained below detectable levels of LYVE-1.
The presence of LYVE-1 in
pancreatic
islets and in some PETs may suggest structure-function relationship of LYVE-1/lymphatic vessel in hormone synthesis and secretion.
[MeSH-major]
Gastrinoma / chemistry.
Glucagonoma
/ chemistry. Immunohistochemistry. Insulinoma / chemistry. Islets of Langerhans / chemistry.
Pancreatic
Neoplasms / chemistry. Somatostatinoma / chemistry. Vesicular Transport Proteins / analysis
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18090227.001).
[ISSN]
1536-4828
[Journal-full-title]
Pancreas
[ISO-abbreviation]
Pancreas
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / LYVE1 protein, human; 0 / Vesicular Transport Proteins
47.
Prout TM, Taylor AJ:
Case of the season: glucagonoma syndrome.
Semin Roentgenol
; 2005 Jan;40(1):4-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Case of the season:
glucagonoma syndrome
.
[MeSH-major]
Glucagonoma
/ radiography.
Pancreatic
Neoplasms / radiography
[MeSH-minor]
Diagnosis
, Differential. Female. Humans. Middle Aged.
Syndrome
. Tomography, X-Ray Computed
Genetic Alliance.
consumer health - Glucagonoma
.
Genetic Alliance.
consumer health - Glucagonoma Syndrome
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15732554.001).
[ISSN]
0037-198X
[Journal-full-title]
Seminars in roentgenology
[ISO-abbreviation]
Semin Roentgenol
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
48.
Marogy G, De Man M, Verslype C:
Necrolytic migratory erythaema and glucagonoma syndrome.
Acta Clin Belg
; 2009 Jan-Feb;64(1):70-1
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Necrolytic migratory erythaema and
glucagonoma syndrome
.
[MeSH-major]
Erythema / etiology.
Glucagonoma
/ pathology.
Pancreatic
Neoplasms / pathology
[MeSH-minor]
Female. Humans. Middle Aged.
Syndrome
Genetic Alliance.
consumer health - Glucagonoma
.
Genetic Alliance.
consumer health - Glucagonoma Syndrome
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19317246.001).
[ISSN]
1784-3286
[Journal-full-title]
Acta clinica Belgica
[ISO-abbreviation]
Acta Clin Belg
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Belgium
49.
Jalali M, Krishnamurthy S:
Comparison of immunomarkers for the identification of adrenocortical cells in cytology specimens.
Diagn Cytopathol
; 2005 Aug;33(2):78-82
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Comparison of immunomarkers for the identification of adrenocortical
cells
in cytology specimens.
We studied the immunoreactivity of three antibodies--A103, calretinin, and inhibin
alpha
in destained Papanicolaou (Pap) smears and
cell
-blocks of 40 fine-needle aspiration biopsy cases of adrenocortical lesions (35 cases of hyperplasia/
adenoma
and 5 cases of carcinoma).
Five cases of carcinoma (4) and melanoma (1) metastases to the adrenal gland and five cases of renal-
cell
carcinoma were also included for comparison.
In benign adrenocortical lesions, A103 staining was noted in 82% of the destained Pap smears and in 92% of
cell
-blocks.
In malignant adrenocortical lesions, A103 staining was noted in 50% of the destained Pap smears and in 80% of
cell
-blocks.
In comparison, calretinin staining was noted in 6% and 50% of destained smears and in 78% and 60% of the
cell
-blocks of benign and malignant adrenocortical lesions.
Inhibin
alpha
was not positive in any of the smears and showed the lowest level of positivity in the
cell
-block sections, namely in 11% of the benign lesions and 25% of the malignant lesions.
The sensitivity of A103 was 90% on
cell
-blocks and 74% on smears, that of calretinin 75% on
cell
-blocks and 11% on smears, and that of inhibin
alpha
, 13% on
cell
-blocks alone.
Our data show A103 to be the immunomarker with the highest sensitivity for identifying
cells of
adrenocortical origin in destained Pap's smears and
cell
-block sections with, however, a lower specificity when compared with calretinin and inhibin
alpha
.
Calretinin is comparable in sensitivity with A103 on
cell
-block sections alone and not on smears.
The results of this study suggest that if metastatic melanoma in adrenal gland is not a consideration then A103 is the marker of choice for identifying
cells of
adrenocortical origin in the limited material available for diagnostic purposes in cytology specimens.
[MeSH-major]
Adrenal Cortex / pathology. Adrenal Cortex Neoplasms / pathology. Biomarkers,
Tumor
/ metabolism. Inhibins / metabolism. Neoplasms / pathology. S100 Calcium Binding Protein G / metabolism
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2005 Wiley-Liss, Inc.
(PMID = 16007649.001).
[ISSN]
8755-1039
[Journal-full-title]
Diagnostic cytopathology
[ISO-abbreviation]
Diagn. Cytopathol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies; 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins
50.
Edwards RA, Witherspoon M, Wang K, Afrasiabi K, Pham T, Birnbaumer L, Lipkin SM:
Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer.
Cancer Res
; 2009 Aug 15;69(16):6423-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel
disease
-associated colorectal cancer.
However,
tumors
in germ-line MMR-deficient mouse models lack these histopathologic features.
Mice lacking the heterotrimeric G protein
alpha
subunit Gialpha2 develop chronic colitis and multifocal, right-sided cancers with mucinous histopathology, similar to human MMR-deficient colorectal cancer.
Chromatin immunoprecipitation identified increased binding of the transcriptional repressor DEC-1 to the proximal Mlh1 promoter in hypoxic YAMC
cells
and colitic Gialpha2-/- crypts.
Treating Gialpha2-/- mice with the histone deacetylase inhibitor suberoylanilide hydroxamic acid significantly decreased colitis activity and rescued MLH1 expression in crypt epithelial
cells
, which was associated with increased acetyl histone H3 levels and decreased DEC-1 binding at the proximal Mlh1 promoter, consistent with a histone deacetylase-dependent mechanism.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
Vorinostat
.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
antibodies-online.
View related products from antibodies-online.com
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Cell. 2004 Aug;6(2):139-50
[
15324697.001
]
[Cites]
J Pathol. 2004 Jul;203(3):808-13
[
15221940.001
]
[Cites]
J Clin Invest. 2004 Oct;114(8):1098-106
[
15489957.001
]
[Cites]
Cell. 1995 Jul 28;82(2):309-19
[
7628019.001
]
[Cites]
Cell. 1995 Jul 28;82(2):321-30
[
7628020.001
]
[Cites]
Nat Genet. 1995 Jun;10(2):143-50
[
7663509.001
]
[Cites]
Cell. 1996 Jun 28;85(7):1125-34
[
8674118.001
]
[Cites]
J Immunol. 1997 Feb 1;158(3):1068-77
[
9013944.001
]
[Cites]
Cell. 1997 Nov 14;91(4):467-77
[
9390556.001
]
[Cites]
Cancer Res. 1999 Mar 15;59(6):1301-7
[
10096563.001
]
[Cites]
Cancer Res. 1999 May 1;59(9):2029-33
[
10232580.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6850-5
[
10359802.001
]
[Cites]
Mutat Res. 2004 Dec 21;568(2):275-82
[
15542114.001
]
[Cites]
JAMA. 2005 Apr 27;293(16):1979-85
[
15855431.001
]
[Cites]
Cancer Res. 2005 Oct 1;65(19):8662-70
[
16204034.001
]
[Cites]
Inflamm Bowel Dis. 2006 Mar;12(3):153-65
[
16534415.001
]
[Cites]
J Immunol. 2006 Apr 15;176(8):5015-22
[
16585598.001
]
[Cites]
Hum Pathol. 2006 Jul;37(7):831-8
[
16784982.001
]
[Cites]
Nat Genet. 2006 Jul;38(7):787-93
[
16804544.001
]
[Cites]
N Engl J Med. 2006 Jun 29;354(26):2751-63
[
16807412.001
]
[Cites]
Cancer Sci. 2006 Jul;97(7):582-8
[
16827797.001
]
[Cites]
J Natl Cancer Inst. 2006 Dec 6;98(23):1731-8
[
17148775.001
]
[Cites]
Oncogene. 2007 Feb 8;26(6):802-12
[
16878149.001
]
[Cites]
Clin Genet. 2007 Jun;71(6):499-500
[
17539898.001
]
[Cites]
Gastroenterology. 2007 Jul;133(1):48-56
[
17631130.001
]
[Cites]
J Mol Med (Berl). 2007 Dec;85(12):1295-300
[
18026919.001
]
[Cites]
Gut. 2008 May;57(5):613-22
[
18194985.001
]
[Cites]
Inflamm Bowel Dis. 2008 Jul;14(7):898-907
[
18340649.001
]
[Cites]
PLoS Genet. 2008 Jun;4(6):e1000092
[
18551179.001
]
[Cites]
Oncogene. 2008 Jul 10;27(30):4200-9
[
18345027.001
]
[Cites]
Mutat Res. 2008 Jul-Aug;659(1-2):40-8
[
18407786.001
]
[Cites]
Stem Cells. 2008 Aug;26(8):2052-62
[
18511603.001
]
[Cites]
Curr Opin Genet Dev. 2008 Jun;18(3):273-9
[
18662779.001
]
[Cites]
Nat Genet. 2009 Jan;41(1):112-7
[
19098912.001
]
[Cites]
Gastroenterology. 2009 Mar;136(3):780-98
[
19263594.001
]
[Cites]
Cancer Res. 2000 Feb 15;60(4):803-7
[
10706084.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9082-7
[
10922063.001
]
[Cites]
Am J Pathol. 2001 Feb;158(2):527-35
[
11159189.001
]
[Cites]
Oncogene. 2000 Dec 14;19(54):6297-305
[
11175344.001
]
[Cites]
Methods Enzymol. 2002;352:3-31
[
12125356.001
]
[Cites]
Nat Genet. 2002 Aug;31(4):385-90
[
12091911.001
]
[Cites]
Mol Cell Biol. 2003 May;23(9):3265-73
[
12697826.001
]
[Cites]
Am J Surg Pathol. 2003 May;27(5):563-70
[
12717242.001
]
[Cites]
EMBO J. 2003 May 1;22(9):2245-54
[
12727890.001
]
[Cites]
N Engl J Med. 2003 Jul 17;349(3):247-57
[
12867608.001
]
[Cites]
Mol Carcinog. 2003 Dec;38(4):155-9
[
14639654.001
]
[Cites]
J Natl Cancer Inst. 2004 Feb 18;96(4):261-8
[
14970275.001
]
[Cites]
Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):11-27
[
15000146.001
]
[Cites]
Fam Cancer. 2004;3(2):93-100
[
15340259.001
]
(PMID = 19638594.001).
[ISSN]
1538-7445
[Journal-full-title]
Cancer research
[ISO-abbreviation]
Cancer Res.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA98626; United States / NIEHS NIH HHS / ES / Z01 ES101643; United States / NCI NIH HHS / CA / R01 CA098626; United States / NIDDK NIH HHS / DK / K08 DK59816; United States / NIDDK NIH HHS / DK / R21 DK071591-01A2; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / R56 CA098626; United States / NCI NIH HHS / CA / P30 CA062203; United States / NIDDK NIH HHS / DK / K08 DK059816; United States / NIDDK NIH HHS / DK / R21 DK071591; United States / NIDDK NIH HHS / DK / DK071591-01A2
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Adaptor Proteins, Signal Transducing; 0 / DNA-Binding Proteins; 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Mlh1 protein, mouse; 0 / Nuclear Proteins; 58IFB293JI / vorinostat; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / Pms2 protein, mouse; EC 3.6.5.1 / GTP-Binding Protein alpha Subunit, Gi2; EC 6.5.1.- / DNA Repair Enzymes
[Other-IDs]
NLM/ NIHMS127354; NLM/ PMC2748849
51.
El-Rayes BF, Ali S, Philip PA, Sarkar FH:
Protein kinase C: a target for therapy in pancreatic cancer.
Pancreas
; 2008 May;36(4):346-52
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Protein kinase C: a target for therapy in
pancreatic
cancer.
OBJECTIVES: Protein kinase C (PKC) is involved in
tumor
growth and apoptosis and hence represents a potential target for cancer therapy.
This study investigated the expression of PKC in
pancreatic tumor
tissue in comparison to adjacent normal tissue and determined the modulation of PKC by bryostatin-1 (BRYO) on
pancreatic
cancer
cell
lines.
METHODS:
Pancreatic
tissue was obtained from 18 patients who had a resection (14 with ductal adenocarcinoma and 4 with
adenoma
and high-grade dysplasia).
HPAC
cells
were treated with gemcitabine and BRYO and in sequential and concomitant combination.
To evaluate
cell
viability, apoptosis, and electrophoretic mobility shift assay, 3-(4,5-dimetylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, enzyme-linked immunosorbent assay, and nuclear factor kappaB (NF-kappaB) assays were used.
RESULTS: As compared with the adjacent normal tissue, PKC-
alpha
, PKC-beta1, and PKC-delta were higher in
the tumor
; PKC-epsilon was higher in the normal tissue.
Pretreatment with gemcitabine followed by BRYO resulted in decreased
cell
viability, increased apoptosis, and inhibited NF-kappaB than either agent alone or BRYO followed by gemcitabine.
CONCLUSION: Protein kinase C is overexpressed and activated in
pancreatic
cancer as compared with normal tissue.
Inhibition of PKC could sensitize
pancreatic
cancer
cell
lines to the effects of gemcitabine.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Isoenzymes / antagonists & inhibitors.
Pancreatic
Neoplasms / drug therapy.
Pancreatic
Neoplasms / enzymology. Protein Kinase C / antagonists & inhibitors
[MeSH-minor]
Adenocarcinoma / drug therapy. Adenocarcinoma / enzymology. Adenocarcinoma / pathology.
Adenoma
/ drug therapy.
Adenoma
/ enzymology.
Adenoma
/ pathology. Bryostatins / administration & dosage.
Cell
Survival / drug effects. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Humans. Protein Kinase Inhibitors / therapeutic use. Reference Values
Genetic Alliance.
consumer health - Pancreatic cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18437080.001).
[ISSN]
1536-4828
[Journal-full-title]
Pancreas
[ISO-abbreviation]
Pancreas
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Bryostatins; 0 / Isoenzymes; 0 / Protein Kinase Inhibitors; 0W860991D6 / Deoxycytidine; 37O2X55Y9E / bryostatin 1; B76N6SBZ8R / gemcitabine; EC 2.7.11.13 / Protein Kinase C
52.
Jarufe NP, Coldham C, Orug T, Mayer AD, Mirza DF, Buckels JA, Bramhall SR:
Neuroendocrine tumours of the pancreas: predictors of survival after surgical treatment.
Dig Surg
; 2005;22(3):157-62
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Neuroendocrine
tumours of the
pancreas
: predictors of survival after surgical treatment.
AIMS:
Neuroendocrine
tumours
of pancreatic
and duodenal origin (NETP) are rare and we present a significant experience from a single centre.
RESULTS: Twenty-four patients had functioning tumours (16 insulinomas, 3 gastrinomas, 2 somatostatinomas, 1 vipoma, 1
glucagonoma
and 1 carcinoid
tumour
).
[MeSH-major]
Neuroendocrine Tumors
/ surgery.
Pancreatic
Neoplasms / surgery
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2005 S. Karger AG, Basel.
(PMID = 16043962.001).
[ISSN]
0253-4886
[Journal-full-title]
Digestive surgery
[ISO-abbreviation]
Dig Surg
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Switzerland
53.
Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J:
MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations.
Hepatology
; 2008 Jun;47(6):1955-63
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
MicroRNA profiling in hepatocellular
tumors
is associated with clinical features and oncogene/
tumor
suppressor gene mutations.
Molecular classifications defining new
tumor
subtypes have been recently refined with genetic and transcriptomic analyses of benign and malignant hepatocellular
tumors
.
Here, we performed microRNA (miRNA) profiling in two series of fully annotated liver
tumors
to uncover associations between oncogene/
tumor
suppressor mutations and clinical and pathological features.
Expression levels of 250 miRNAs in 46 benign and malignant hepatocellular
tumors
were compared to those of 4 normal liver samples with quantitative reverse-transcriptase polymerase chain reaction. miRNAs associated with genetic and clinical characteristics were validated in a second series of 43 liver
tumor
samples and 16 nontumor samples. miRNA profiling unsupervised analysis classified samples in unique clusters characterized by histological features (
tumor
/nontumor, P < 0.001; benign/malignant
tumors
, P < 0.01; inflammatory
adenoma
and focal nodular hyperplasia, P < 0.01), clinical characteristics [hepatitis B virus (HBV) infection, P < 0.001; alcohol consumption, P < 0.05], and oncogene/
tumor
suppressor gene mutations [beta-catenin, P < 0.01; hepatocyte nuclear factor 1alpha (HNF1alpha), P < 0.01].
Our study identified and validated miR-224 overexpression in all
tumors
and miR-200c, miR-200, miR-21, miR-224, miR-10b, and miR-222 specific deregulation in benign or malignant
tumors
.
Moreover, miR-96 was overexpressed in HBV
tumors
, and miR-126* was down-regulated in alcohol-related hepatocellular carcinoma.
Down-regulations of miR-107 and miR-375 were specifically associated with HNF1alpha and beta-catenin gene mutations, respectively. miR-375 expression was highly correlated to that of beta-catenin-targeted genes as miR-107 expression was correlated to that of HNF1alpha in a small interfering RNA
cell
line model.
CONCLUSION: Hepatocellular
tumors
may have a distinct miRNA expression fingerprint according to malignancy, risk factors, and oncogene/
tumor
suppressor gene alterations.
[MeSH-major]
Carcinoma, Hepatocellular / genetics. Gene Expression Profiling / methods. Genes,
Tumor
Suppressor. Liver Neoplasms / genetics. MicroRNAs / genetics. Mutation / genetics
[MeSH-minor]
Gene Expression Regulation, Neoplastic. Hepatocyte Nuclear Factor 1-
alpha
/ genetics. Hepatocyte Nuclear Factor 1-
alpha
/ metabolism. Humans. Phenotype. Risk Factors.
Tumor Cells
, Cultured. beta Catenin / genetics. beta Catenin / metabolism
MedlinePlus Health Information.
consumer health - Liver Cancer
.
HAL archives ouvertes.
Full text from
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Hepatology. 2008 Jun;47(6):1807-9
[
18506877.001
]
(PMID = 18433021.001).
[ISSN]
1527-3350
[Journal-full-title]
Hepatology (Baltimore, Md.)
[ISO-abbreviation]
Hepatology
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Hepatocyte Nuclear Factor 1-alpha; 0 / MicroRNAs; 0 / beta Catenin
54.
Miyai S, Yoshimura S, Iwasaki Y, Takekoshi S, Lloyd RV, Osamura RY:
Induction of GH, PRL, and TSH beta mRNA by transfection of Pit-1 in a human pituitary adenoma-derived cell line.
Cell Tissue Res
; 2005 Nov;322(2):269-77
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Induction of GH, PRL, and TSH beta mRNA by transfection of Pit-1 in a human pituitary
adenoma
-derived
cell
line.
The functional development of pituitary
cells
depends on the expression
of a
combination of transcription factors and co-factors.
The glycoprotein hormone
alpha
subunit (
alpha
SU) is the first hormone to be expressed during pituitary development.
In addition to being expressed in follicle-stimulating hormone, luteinizing hormone (LH), and TSH
cells
,
alpha
SU is reported to co-localize with GH in pituitary
cells
.
These findings have led to the suggestion that the expression of Pit-1 in
cells of
the
alpha
SU-based gonadotropin
cell
lineage might also lead to the expression of GH.
In this study, we transfected HP 75
cells
(derived from a human non-functioning pituitary
adenoma
that expressed
alpha
SU and LH beta) with Pit-1 by using an adenovirus FLAG-Pit-1 construct.
Most of the transfected
cells
expressed GH mRNA, with fewer
cells
expressing PRL and TSH beta mRNA.
The HP 75
cells
expressed the genes for ER and GATA-2, thus allowing their expression of GH, PRL, and TSH beta mRNA in response to Pit-1.
These results support the hypothesis that GH can be induced in
cells
that possess an active
alpha
SU gene and shed light on the basic molecular mechanism that drives the development of GH, PRL, and TSH beta expression in the
alpha
SU-based gonadotroph lineage.
[MeSH-major]
Adenoma
/ metabolism. Human Growth Hormone / metabolism. Pituitary Neoplasms / metabolism. Prolactin / metabolism. RNA, Messenger / metabolism. Thyrotropin, beta Subunit / metabolism. Transcription Factor Pit-1 / metabolism
[MeSH-minor]
Animals.
Cell
Line,
Tumor
.
Cell
Lineage. GATA2 Transcription Factor / genetics. GATA2 Transcription Factor / metabolism. Glycoprotein Hormones,
alpha
Subunit / genetics. Glycoprotein Hormones,
alpha
Subunit / metabolism. Humans. Pituitary Gland / cytology. Pituitary Gland / growth & development. Pituitary Gland / metabolism. Receptors, Estrogen / genetics. Receptors, Estrogen / metabolism. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / metabolism
MedlinePlus Health Information.
consumer health - Pituitary Tumors
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16133148.001).
[ISSN]
0302-766X
[Journal-full-title]
Cell and tissue research
[ISO-abbreviation]
Cell Tissue Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / GATA2 Transcription Factor; 0 / Glycoprotein Hormones, alpha Subunit; 0 / RNA, Messenger; 0 / Receptors, Estrogen; 0 / Recombinant Fusion Proteins; 0 / Thyrotropin, beta Subunit; 0 / Transcription Factor Pit-1; 12629-01-5 / Human Growth Hormone; 9002-62-4 / Prolactin
55.
Frulio N, Laumonier H, Balabaud C, Trillaud H, Bioulac-Sage P:
Hepatic congestion plays a role in liver stiffness.
Hepatology
; 2009 Nov;50(5):1674-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[MeSH-minor]
Adenoma
, Liver
Cell
/ blood supply.
Adenoma
, Liver
Cell
/ metabolism.
Adenoma
, Liver
Cell
/ physiopathology. Hepatocyte Nuclear Factor 1-
alpha
/ metabolism. Humans. Liver Neoplasms / blood supply. Liver Neoplasms / metabolism. Liver Neoplasms / physiopathology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentOn]
Hepatology. 2008 Dec;48(6):2089
[
19003902.001
]
(PMID = 19670411.001).
[ISSN]
1527-3350
[Journal-full-title]
Hepatology (Baltimore, Md.)
[ISO-abbreviation]
Hepatology
[Language]
eng
[Publication-type]
Comment; Letter
[Publication-country]
United States
[Chemical-registry-number]
0 / Hepatocyte Nuclear Factor 1-alpha
56.
Ju J, Hao X, Lee MJ, Lambert JD, Lu G, Xiao H, Newmark HL, Yang CS:
A gamma-tocopherol-rich mixture of tocopherols inhibits colon inflammation and carcinogenesis in azoxymethane and dextran sulfate sodium-treated mice.
Cancer Prev Res (Phila)
; 2009 Feb;2(2):143-52
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We investigated the effects
of a
gamma-tocopherol-rich mixture of tocopherols (gamma-TmT, containing 57% gamma-T, 24% delta-T, and 13%
alpha
-T) on colon carcinogenesis in azoxymethane (AOM)/dextran sulfate sodium (DSS)-treated mice.
In the AOM/DSS-treated mice, dietary gamma-TmT treatment resulted in a significantly lower colon inflammation index (52% of the control) on day 7 and number of colon
adenomas
(9% of the control) on week 7. gamma-TmT treatment also resulted in higher apoptotic index in
adenomas
, lower prostaglandin E2, leukotriene B4, and nitrotyrosine levels in the colon, and lower prostaglandin E2, leukotriene B4, and 8-isoprostane levels in the plasma on week 7.
In experiment 2 with AOM/DSS- treated mice sacrificed on week 21, dietary 0.17% or 0.3% gamma-TmT treatment, starting 1 week before the AOM injection, significantly inhibited adenocarcinoma and
adenoma
formation in the colon (to 17-33% of the control).
MedlinePlus Health Information.
consumer health - Antioxidants
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
PROSTAGLANDIN F2ALPHA
.
Hazardous Substances Data Bank.
L-TYROSINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11494-9
[
11005841.001
]
[Cites]
Mol Aspects Med. 2007 Oct-Dec;28(5-6):668-91
[
17316780.001
]
[Cites]
Dig Dis Sci. 2002 Jun;47(6):1266-78
[
12064801.001
]
[Cites]
Carcinogenesis. 2002 Jun;23(6):993-1001
[
12082021.001
]
[Cites]
Free Radic Biol Med. 2002 Dec 1;33(11):1534-42
[
12446211.001
]
[Cites]
FASEB J. 2002 Dec;16(14):1952-4
[
12368234.001
]
[Cites]
J Nutr. 2003 Feb;133(2):528-32
[
12566495.001
]
[Cites]
Am J Epidemiol. 2003 Feb 15;157(4):335-44
[
12578804.001
]
[Cites]
Am J Clin Nutr. 2003 Mar;77(3):700-6
[
12600864.001
]
[Cites]
FASEB J. 2003 May;17(8):816-22
[
12724340.001
]
[Cites]
Cancer Sci. 2003 Nov;94(11):965-73
[
14611673.001
]
[Cites]
Nutr Cancer. 2003;46(2):172-8
[
14690793.001
]
[Cites]
Free Radic Biol Med. 2004 Jan 1;36(1):1-15
[
14732286.001
]
[Cites]
BMC Cancer. 2003 Oct 1;3:25
[
14521714.001
]
[Cites]
Mutat Res. 2004 Jul 13;551(1-2):245-54
[
15225597.001
]
[Cites]
Nutr Cancer. 2004;49(1):72-80
[
15456638.001
]
[Cites]
Cancer Sci. 2004 Sep;95(9):721-7
[
15471557.001
]
[Cites]
Lab Invest. 1974 Apr;30(4):505-13
[
4363166.001
]
[Cites]
Cancer Res. 1980 Apr;40(4):1329-31
[
7357560.001
]
[Cites]
J Natl Cancer Inst. 1983 Jun;70(6):1107-11
[
6574281.001
]
[Cites]
Anal Biochem. 1985 Feb 15;145(1):21-6
[
4003760.001
]
[Cites]
J Natl Cancer Inst. 1986 May;76(5):939-42
[
3457978.001
]
[Cites]
J Natl Cancer Inst. 1986 Jun;76(6):1157-62
[
3458951.001
]
[Cites]
Cancer Lett. 1987 Apr;35(1):71-7
[
3567889.001
]
[Cites]
Am J Clin Nutr. 1989 Mar;49(3):517-26
[
2923084.001
]
[Cites]
Am J Clin Nutr. 1991 Apr;53(4 Suppl):1068S-1070S
[
1845366.001
]
[Cites]
Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1771-5
[
8446589.001
]
[Cites]
Hum Pathol. 1994 Nov;25(11):1160-71
[
7959660.001
]
[Cites]
J Appl Physiol (1985). 1994 Dec;77(6):2912-7
[
7896640.001
]
[Cites]
N Engl J Med. 1995 May 4;332(18):1198-203
[
7700313.001
]
[Cites]
Free Radic Biol Med. 1995 Sep;19(3):259-69
[
7557540.001
]
[Cites]
Nutr Cancer. 1996;26(1):99-109
[
8844726.001
]
[Cites]
Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3217-22
[
9096373.001
]
[Cites]
Chem Res Toxicol. 1997 Apr;10(4):401-7
[
9114976.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 1997 Jul;6(7):487-91
[
9232334.001
]
[Cites]
Am J Epidemiol. 1997 Aug 1;146(3):231-43
[
9247007.001
]
[Cites]
Nutr Cancer. 1998;31(3):168-77
[
9795968.001
]
[Cites]
Cancer Res. 1999 Mar 15;59(6):1225-30
[
10096552.001
]
[Cites]
Jpn J Cancer Res. 1999 Apr;90(4):399-405
[
10363577.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17825-30
[
15596715.001
]
[Cites]
Food Chem Toxicol. 1999 Sep-Oct;37(9-10):985-92
[
10541455.001
]
[Cites]
Ann N Y Acad Sci. 2004 Dec;1031:399-400
[
15753180.001
]
[Cites]
J Natl Cancer Inst. 2005 Apr 6;97(7):481-8
[
15812073.001
]
[Cites]
BMC Cancer. 2005;5:46
[
15892897.001
]
[Cites]
JAMA. 2005 Jul 6;294(1):56-65
[
15998891.001
]
[Cites]
Carcinogenesis. 2006 Jan;27(1):162-9
[
16081511.001
]
[Cites]
BMC Cancer. 2006;6:13
[
16417629.001
]
[Cites]
Arch Biochem Biophys. 2006 Mar 15;447(2):97-106
[
16530159.001
]
[Cites]
J Am Coll Nutr. 2006 Aug;25(4):292-9
[
16943450.001
]
[Cites]
Nutr Cancer. 2006;56(1):82-5
[
17176221.001
]
[Cites]
Nutr Cancer. 2007;59(1):62-9
[
17927503.001
]
[Cites]
Nutr Cancer. 2007;59(1):76-81
[
17927505.001
]
[Cites]
Environ Mol Mutagen. 2002;39(2-3):271-8
[
11921198.001
]
(PMID = 19155443.001).
[ISSN]
1940-6215
[Journal-full-title]
Cancer prevention research (Philadelphia, Pa.)
[ISO-abbreviation]
Cancer Prev Res (Phila)
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P30 CA072720; United States / NIEHS NIH HHS / ES / ES05022; United States / NIEHS NIH HHS / ES / P30 ES005022; United States / NCI NIH HHS / CA / P30 CA072720-12; United States / NIEHS NIH HHS / ES / ES005022-109003; United States / NIEHS NIH HHS / ES / P30 ES005022-109003; United States / NCI NIH HHS / CA / CA72720; United States / NCI NIH HHS / CA / CA072720-12
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antioxidants; 0 / Carcinogens; 1HGW4DR56D / Leukotriene B4; 27415-26-5 / 8-epi-prostaglandin F2alpha; 3604-79-3 / 3-nitrotyrosine; 42HK56048U / Tyrosine; 8EF1Z1238F / gamma-Tocopherol; 9042-14-2 / Dextran Sulfate; B7IN85G1HY / Dinoprost; K7Q1JQR04M / Dinoprostone; MO0N1J0SEN / Azoxymethane
[Other-IDs]
NLM/ NIHMS172441; NLM/ PMC2821738
57.
Jeannot E, Mellottee L, Bioulac-Sage P, Balabaud C, Scoazec JY, Tran Van Nhieu J, Bacq Y, Michalak S, Buob D, Groupe d'étude Génétique des Tumeurs Hépatiques (INSERM Network), Laurent-Puig P, Rusyn I, Zucman-Rossi J:
Spectrum of HNF1A somatic mutations in hepatocellular adenoma differs from that in patients with MODY3 and suggests genotoxic damage.
Diabetes
; 2010 Jul;59(7):1836-44
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Spectrum of HNF1A somatic mutations in hepatocellular
adenoma
differs from that in patients with MODY3 and suggests genotoxic damage.
A subtype of hepatocellular
adenoma
(HCA) is also caused by biallelic somatic HNF1A mutations (H-HCA), and rare HCA may be related to MODY3.
MedlinePlus Health Information.
consumer health - Diabetes Type 2
.
MedlinePlus Health Information.
consumer health - Liver Cancer
.
COS Scholar Universe.
author profiles
.
antibodies-online.
View related products from antibodies-online.com
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Bacteriol. 1996 Jul;178(13):3885-92
[
8682794.001
]
[Cites]
Cancer Res. 1994 Sep 15;54(18):4855-78
[
8069852.001
]
[Cites]
Science. 1996 Oct 18;274(5286):430-2
[
8832894.001
]
[Cites]
Nature. 1996 Dec 5;384(6608):455-8
[
8945470.001
]
[Cites]
Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10937-42
[
9380738.001
]
[Cites]
Oncogene. 1998 Mar 12;16(10):1241-7
[
9546425.001
]
[Cites]
Hum Mol Genet. 1999;8(10):1893-900
[
10469842.001
]
[Cites]
Hum Mol Genet. 2005 Mar 1;14(5):603-14
[
15649945.001
]
[Cites]
Hepatology. 2006 Mar;43(3):515-24
[
16496320.001
]
[Cites]
Hum Mol Genet. 2006 Jul 15;15(14):2216-24
[
16760222.001
]
[Cites]
Hum Mutat. 2006 Sep;27(9):854-69
[
16917892.001
]
[Cites]
Cancer Res. 2007 Mar 15;67(6):2611-6
[
17363580.001
]
[Cites]
J Biol Chem. 2007 May 11;282(19):14437-46
[
17379603.001
]
[Cites]
J Biol Chem. 1999 Dec 10;274(50):35639-46
[
10585442.001
]
[Cites]
Mol Pharmacol. 2000 May;57(5):940-7
[
10779377.001
]
[Cites]
J Biol Chem. 2000 Sep 1;275(35):27117-22
[
10852923.001
]
[Cites]
Cancer Res. 2000 Sep 1;60(17):4740-4
[
10987279.001
]
[Cites]
Carcinogenesis. 2001 Mar;22(3):367-74
[
11238174.001
]
[Cites]
Hepatology. 2007 Sep;46(3):740-8
[
17663417.001
]
[Cites]
Diabetes. 2008 Feb;57(2):503-8
[
18003757.001
]
[Cites]
Nature. 2009 Jan 8;457(7226):200-4
[
19020503.001
]
[Cites]
Nat Genet. 2001 Apr;27(4):375-82
[
11279518.001
]
[Cites]
J Biol Chem. 2001 Mar 16;276(11):7963-7
[
11121425.001
]
[Cites]
J Clin Invest. 2002 Jan;109(1):3-6
[
11781342.001
]
[Cites]
Nat Genet. 2002 Feb;30(2):227-32
[
11818965.001
]
[Cites]
Methods. 2001 Dec;25(4):402-8
[
11846609.001
]
[Cites]
Mod Pathol. 2002 Mar;15(3):189-96
[
11904335.001
]
[Cites]
Nat Genet. 2002 Oct;32(2):312-5
[
12355088.001
]
[Cites]
Mol Cell. 2002 Nov;10(5):1129-37
[
12453420.001
]
[Cites]
Gastroenterology. 2003 Nov;125(5):1470-5
[
14598263.001
]
[Cites]
Diabetes. 2004 Feb;53(2):500-4
[
14747304.001
]
[Cites]
Cancer Res. 2004 Feb 1;64(3):1050-7
[
14871837.001
]
[Cites]
J Clin Endocrinol Metab. 2004 Mar;89(3):1476-80
[
15001650.001
]
[Cites]
Lancet. 1973 Oct 27;2(7835):926-9
[
4126557.001
]
[Cites]
Ann Intern Med. 1977 Feb;86(2):180-2
[
835939.001
]
[Cites]
Gastroenterology. 1985 Nov;89(5):1132-8
[
2412930.001
]
[Cites]
Nature. 1991 Apr 4;350(6317):427-8
[
1849234.001
]
[Cites]
Nature. 1991 Apr 4;350(6317):429-31
[
1672732.001
]
[Cites]
Genes Dev. 1991 Jun;5(6):1042-56
[
2044952.001
]
[Cites]
Science. 1991 Jul 5;253(5015):49-53
[
1905840.001
]
[Cites]
J Bacteriol. 1992 Oct;174(20):6321-5
[
1328155.001
]
[Cites]
Annu Rev Pharmacol Toxicol. 1996;36:203-32
[
8725388.001
]
(PMID = 20393147.001).
[ISSN]
1939-327X
[Journal-full-title]
Diabetes
[ISO-abbreviation]
Diabetes
[Language]
ENG
[Grant]
United States / NIEHS NIH HHS / ES / P30 ES010126; United States / NIEHS NIH HHS / ES / R01-ES-15241; United States / NIEHS NIH HHS / ES / R01 ES015241; United States / NIAAA NIH HHS / AA / R01-AA-16258; United States / NIAAA NIH HHS / AA / R01 AA016258
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / HNF1A protein, human; 0 / Hepatocyte Nuclear Factor 1-alpha
[Other-IDs]
NLM/ PMC2889786
58.
van den Broek FJ, de Graaf EJ, Dijkgraaf MG, Reitsma JB, Haringsma J, Timmer R, Weusten BL, Gerhards MF, Consten EC, Schwartz MP, Boom MJ, Derksen EJ, Bijnen AB, Davids PH, Hoff C, van Dullemen HM, Heine GD, van der Linde K, Jansen JM, Mallant-Hent RC, Breumelhof R, Geldof H, Hardwick JC, Doornebosch PG, Depla AC, Ernst MF, van Munster IP, de Hingh IH, Schoon EJ, Bemelman WA, Fockens P, Dekker E:
Transanal endoscopic microsurgery versus endoscopic mucosal resection for large rectal adenomas (TREND-study).
BMC Surg
; 2009;9:4
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Transanal endoscopic microsurgery versus endoscopic mucosal resection for large rectal
adenomas
(TREND-study).
BACKGROUND: Recent non-randomized studies suggest that extended endoscopic mucosal resection (EMR) is equally effective in removing large rectal
adenomas
as transanal endoscopic microsurgery (TEM).
Furthermore, EMR appears to be associated with fewer complications.The aim of this study is to compare the cost-effectiveness and cost-utility of TEM and EMR for the resection of large rectal
adenomas
.
Patients with a rectal
adenoma
> or = 3 cm, located between 1-15 cm ab ano, will be randomized to a TEM- or EMR-treatment strategy.
For TEM, patients will be treated under general anesthesia,
adenomas
will be dissected en-bloc by a full-thickness excision, and patients will be admitted to the hospital.
Residual
adenoma
that is visible during the first surveillance endoscopy at 3 months will be removed endoscopically in both treatment strategies and is considered as part of the primary treatment.
4)
disease
specific and general quality of life;.
A cost-effectiveness and cost-utility analysis of EMR against TEM for large rectal
adenomas
will be performed from a societal perspective with respectively the costs per recurrence free patient and the cost per quality adjusted life year as outcome measures.
Based on comparable recurrence rates for TEM and EMR of 3.3% and considering an upper-limit of 10% for EMR to be non-inferior (beta-error 0.2 and one-sided
alpha
-error 0.05), 89 patients are needed per group.
DISCUSSION: The TREND study is the first randomized trial evaluating whether TEM or EMR is more cost-effective for the treatment of large rectal
adenomas
.
[MeSH-major]
Adenoma
/ surgery. Endoscopy / economics. Rectal Neoplasms / surgery
MedlinePlus Health Information.
consumer health - Endoscopy
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Ned Tijdschr Geneeskd. 2006 Dec 16;150(50):2739-44
[
17225784.001
]
[Cites]
Br J Surg. 2007 May;94(5):627-33
[
17335125.001
]
[Cites]
Colorectal Dis. 2007 Jul;9(6):553-8
[
17573752.001
]
[Cites]
Endoscopy. 2007 Aug;39(8):701-5
[
17661244.001
]
[Cites]
Clin Gastroenterol Hepatol. 2007 Aug;5(8):982-90
[
17553754.001
]
[Cites]
Colorectal Dis. 2006 Sep;8(7):581-5
[
16919110.001
]
[Cites]
Dis Colon Rectum. 2006 Sep;49(9):1384-92
[
16897333.001
]
[Cites]
Endoscopy. 2006 Sep;38(9):902-6
[
16981107.001
]
[Cites]
Colorectal Dis. 2006 Nov;8(9):795-9
[
17032328.001
]
[Cites]
N Engl J Med. 2006 Nov 2;355(18):1863-72
[
17079760.001
]
[Cites]
Z Gastroenterol. 2002 Feb;40(2):67-72
[
11857100.001
]
[Cites]
Gastrointest Endosc. 2002 Mar;55(3):371-5
[
11868011.001
]
[Cites]
World J Gastroenterol. 2002 Jun;8(3):488-92
[
12046076.001
]
[Cites]
Gastroenterology. 2003 Feb;124(2):544-60
[
12557158.001
]
[Cites]
Endoscopy. 2003 Oct;35(10):845-9
[
14551863.001
]
[Cites]
Ann Surg Oncol. 2003 Nov;10(9):1106-11
[
14597451.001
]
[Cites]
Dis Colon Rectum. 2003 Dec;46(12):1626-32
[
14668587.001
]
[Cites]
J Clin Oncol. 2004 Jan 15;22(2):244-53
[
14665610.001
]
[Cites]
Scand J Gastroenterol Suppl. 2003;(239):34-9
[
14743881.001
]
[Cites]
BMJ. 2004 Feb 14;328(7436):360-1
[
14962852.001
]
[Cites]
Surg Endosc. 2003 Sep;17(9):1461-3
[
12739115.001
]
[Cites]
JSLS. 2004 Apr-Jun;8(2):123-6
[
15119655.001
]
[Cites]
Hong Kong Med J. 2004 Aug;10(4):239-43
[
15299168.001
]
[Cites]
Gut. 2004 Sep;53(9):1334-9
[
15306595.001
]
[Cites]
Chirurg. 1984 Oct;55(10):677-80
[
6510078.001
]
[Cites]
Surg Endosc. 1988;2(2):71-5
[
3413659.001
]
[Cites]
Gastrointest Endosc. 1991 Mar-Apr;37(2):128-32
[
2032596.001
]
[Cites]
Dis Colon Rectum. 1992 Dec;35(12):1183-91
[
1473424.001
]
[Cites]
N Engl J Med. 1993 Dec 30;329(27):1977-81
[
8247072.001
]
[Cites]
Surg Endosc. 1995 Jan;9(1):56-60
[
7725216.001
]
[Cites]
Tumori. 1995 May-Jun;81(3 Suppl):50-6
[
7571054.001
]
[Cites]
Surg Endosc. 1995 Oct;9(10):1106-12
[
8553213.001
]
[Cites]
Semin Surg Oncol. 1995 Nov-Dec;11(6):399-405
[
8607008.001
]
[Cites]
Dis Colon Rectum. 1996 Aug;39(8):886-92
[
8756844.001
]
[Cites]
Dis Colon Rectum. 1996 Sep;39(9):969-76
[
8797643.001
]
[Cites]
Gastrointest Endosc. 1996 Mar;43(3):189-95
[
8857132.001
]
[Cites]
Hepatogastroenterology. 1997 May-Jun;44(15):698-702
[
9222674.001
]
[Cites]
Dis Colon Rectum. 1997 Oct;40(10 Suppl):S80-5
[
9378018.001
]
[Cites]
Med Care. 1997 Nov;35(11):1095-108
[
9366889.001
]
[Cites]
Praxis (Bern 1994). 1998 Aug 12;87(33):1014-8
[
9747130.001
]
[Cites]
Ned Tijdschr Geneeskd. 1998 Nov 21;142(47):2577-81
[
10028355.001
]
[Cites]
J Gastrointest Surg. 2004 Dec;8(8):1032-9; discussion 1039-40
[
15585391.001
]
[Cites]
J Gastroenterol Hepatol. 2005 Jan;20(1):51-5
[
15610446.001
]
[Cites]
Int J Colorectal Dis. 2005 Mar;20(2):126-36
[
15449078.001
]
[Cites]
Cell Oncol. 2005;27(1):17-29
[
15750204.001
]
[Cites]
Surg Endosc. 2004 Dec;18(12):1730-7
[
15809779.001
]
[Cites]
Dis Colon Rectum. 2005 Feb;48(2):270-84
[
15711865.001
]
[Cites]
Hepatogastroenterology. 2005 Mar-Apr;52(62):429-32
[
15816450.001
]
[Cites]
J Surg Oncol. 2007 Dec 15;96(8):644-50
[
18081069.001
]
[Cites]
Dis Colon Rectum. 2008 Jan;51(1):38-42
[
18038181.001
]
[Cites]
Gastroenterology. 2000 Apr;118(4):670-7
[
10734018.001
]
[Cites]
Dis Colon Rectum. 2000 May;43(5):662-7; discussion 667-8
[
10826428.001
]
[Cites]
Health Econ. 2001 Mar;10(2):179-84
[
11252048.001
]
[Cites]
Endoscopy. 2001 Apr;33(4):367-73
[
11315901.001
]
[Cites]
Gastrointest Endosc. 2001 Jul;54(1):62-6
[
11427843.001
]
[Cites]
Gastrointest Endosc Clin N Am. 2001 Jul;11(3):519-35
[
11778753.001
]
[Cites]
Dis Colon Rectum. 2002 Feb;45(2):200-6
[
11852333.001
]
[Cites]
Dig Surg. 2005;22(3):182-9; discussion 189-90
[
16137996.001
]
[Cites]
Ann R Coll Surg Engl. 2005 Nov;87(6):432-6
[
16263010.001
]
[Cites]
Cochrane Database Syst Rev. 2006;(1):CD004276
[
16437481.001
]
[Cites]
Dig Liver Dis. 2006 Mar;38(3):202-7
[
16461025.001
]
[Cites]
Endoscopy. 2006 Mar;38(3):231-5
[
16528648.001
]
[Cites]
Int J Colorectal Dis. 2006 Sep;21(6):533-7
[
16133003.001
]
[Cites]
Colorectal Dis. 2005 Jul;7(4):339-44
[
15932555.001
]
[Cites]
Dis Colon Rectum. 2005 Jun;48(6):1182-92
[
15793641.001
]
[Cites]
Ned Tijdschr Geneeskd. 2005 Jul 9;149(28):1574-8
[
16038162.001
]
[Cites]
J Clin Oncol. 2005 Sep 1;23(25):6199-206
[
16135487.001
]
[Cites]
Asian J Surg. 2006 Oct;29(4):227-32
[
17098653.001
]
[Cites]
Ned Tijdschr Geneeskd. 2006 Nov 11;150(45):2490-6
[
17137098.001
]
(PMID = 19284647.001).
[ISSN]
1471-2482
[Journal-full-title]
BMC surgery
[ISO-abbreviation]
BMC Surg
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Other-IDs]
NLM/ PMC2664790
59.
Kazanjian KK, Reber HA, Hines OJ:
Resection of pancreatic neuroendocrine tumors: results of 70 cases.
Arch Surg
; 2006 Aug;141(8):765-9; discussion 769-70
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Resection
of pancreatic neuroendocrine tumors
: results of 70 cases.
HYPOTHESIS:
Neuroendocrine tumors
of the
pancreas
can be managed surgically with excellent outcomes.
PATIENTS: Seventy consecutive patients who underwent resection for
pancreatic neuroendocrine tumors
between January 1, 1990, and December 31, 2005.
RESULTS: Of the 70 patients, 50 (71.4%) had nonfunctional
tumors
.
Thirty-seven patients (52.9%) had
neuroendocrine
carcinomas and 13 (18.6%) had benign
islet
cell
neoplasms.
Twenty patients had functional
tumors
.
Of these 20 patients, 16 had insulinomas, 2 had
glucagonomas
, and 2 had gastrinomas.
Patients undergoing enucleation as compared with those not undergoing enucleation were younger (mean age, 39 vs 51 years, respectively; P = .009) and had smaller
tumors
(mean
tumor
size, 2 vs 5 cm, respectively; P<.001).
With a median follow-up of 50 months, the 5-year actuarial survival for the patients with malignant
neuroendocrine
carcinomas (n = 37) was 77%, and all of the patients with functional
tumors
are alive.
CONCLUSIONS: This single-institutional case series demonstrates that
pancreatic neuroendocrine tumors
can be safely resected without mortality and with minimal morbidity.
The presence of lymphovascular invasion can be used to classify
neuroendocrine tumors
as malignant, and this appears to predict survival.
Patients with malignant
tumors
can expect long-term survival even in the setting of metastatic
disease
.
[MeSH-major]
Neuroendocrine Tumors
/ surgery. Pancreatectomy / methods.
Pancreatic
Neoplasms / surgery. Pancreaticoduodenectomy / methods
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16924083.001).
[ISSN]
0004-0010
[Journal-full-title]
Archives of surgery (Chicago, Ill. : 1960)
[ISO-abbreviation]
Arch Surg
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
60.
Chen YT, Tu JJ, Kao J, Zhou XK, Mazumdar M:
Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma.
Clin Cancer Res
; 2005 Sep 15;11(18):6558-66
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Messenger RNA expression ratios among four genes predict subtypes of renal
cell
carcinoma and distinguish oncocytoma from carcinoma.
PURPOSE:
Morphologic
distinction among clear
cell
, papillary, and chromophobe types of renal
cell
carcinoma (RCC) can be difficult, as is the differential
diagnosis
between oncocytoma and RCC.
Whether these renal
tumors
can be distinguished by their mRNA expression profile
of a
few selected genes was examined.
EXPERIMENTAL DESIGN: The expression of four genes in renal
tumor
was evaluated by quantitative reverse transcription-PCR: carbonic anhydrase IX (CA9), methylacyl-CoA racemase (AMACR), parvalbumin (PVALB), and chloride channel kb (CLCNKB).
Thirty-one fresh-frozen and 63 formalin-fixed, paraffin-embedded
tumor
specimens were analyzed.
RESULTS: CA9 expression was highest in clear
cell
carcinoma and lowest in chromophobe RCC and in oncocytoma.
PVALB was highest in chromophobe RCC, variable in oncocytoma, and low in clear
cell
and papillary types.
The mRNA expression ratios among these genes (i.e., CA9/AMACR and AMACR/CLCNKB ratios) further accentuate the gene expression differences among these
tumors
, and a molecular diagnostic algorithm was established.
This algorithm accurately classified the 31 fresh-frozen
tumors
into 14 clear
cell
, 5 papillary, 6 chromophobe, and 6 oncocytomas.
In the formalin-fixed group, the molecular criteria accurately classified the cases into 15 clear
cell
, 16 papillary, and 32 in the chromophobe/oncocytoma group but could only separate some, but not all, oncocytomas from chromophobe RCC.
[MeSH-minor]
Adenocarcinoma, Clear
Cell
/ genetics. Adenocarcinoma, Clear
Cell
/ pathology.
Adenoma
, Oxyphilic / genetics.
Adenoma
, Oxyphilic / pathology. Algorithms. Anion Transport Proteins / genetics. Antigens, Neoplasm / genetics. Carbonic Anhydrases / genetics. Carcinoma, Renal
Cell
/ genetics. Carcinoma, Renal
Cell
/ pathology. Chloride Channels / genetics.
Diagnosis
, Differential. Humans. Membrane Proteins / genetics. Racemases and Epimerases / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. beta-Defensins / genetics
Genetic Alliance.
consumer health - Oncocytoma renal
.
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16166433.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Anion Transport Proteins; 0 / Antigens, Neoplasm; 0 / CLCNKB protein, human; 0 / Chloride Channels; 0 / DEFB1 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / beta-Defensins; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
61.
Technau K, Renkl A, Norgauer J, Ziemer M:
Necrolytic migratory erythema with myelodysplastic syndrome without glucagonoma.
Eur J Dermatol
; 2005 Mar-Apr;15(2):110-2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Necrolytic migratory erythema with myelodysplastic
syndrome
without
glucagonoma
.
Necrolytic migratory erythema is a cutaneous paraneoplastic manifestation, which is usually associated with
a glucagon
-secreting
pancreatic tumor
.
However, it also may occur in other circumstances in which serum
glucagon
is elevated, as in hepatic cirrhosis.
Rarely, necrolytic migratory erythema is reported in association with a jejunal and rectal adenocarcinoma or villous atrophy of the small intestine without any evidence for increased serum
glucagon
levels.
In this context we report the case of an 85-year-old male with myelodysplastic
syndrome
who developed typical necrolytic migratory erythema without
glucagonoma syndrome
or evidence for other
pancreatic
or liver
disease
.
We suggest that, in addition to the diseases listed, myelodysplastic
syndrome
might be able to cause necrolytic migratory erythema.
[MeSH-major]
Erythema / complications.
Glucagonoma
/ complications. Myelodysplastic
Syndromes
/ complications.
Pancreatic
Neoplasms / complications. Paraneoplastic
Syndromes
/ complications
Genetic Alliance.
consumer health - Glucagonoma
.
Genetic Alliance.
consumer health - Glucagonoma Syndrome
.
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15757825.001).
[ISSN]
1167-1122
[Journal-full-title]
European journal of dermatology : EJD
[ISO-abbreviation]
Eur J Dermatol
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
France
62.
Luo F, Brooks DG, Ye H, Hamoudi R, Poulogiannis G, Patek CE, Winton DJ, Arends MJ:
Mutated K-ras(Asp12) promotes tumourigenesis in Apc(Min) mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways.
Int J Exp Pathol
; 2009 Oct;90(5):558-74
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Summary K-ras mutations are found in 40-50% of human colorectal
adenomas
and carcinomas, but their functional contribution remains incompletely understood.
Here, we show that a conditional mutant K-ras mouse model (K-ras(Asp12)/Cre), with transient intestinal Cre activation by beta-Naphthoflavone (beta-NF) treatment, displayed transgene recombination and K-ras(Asp12) expression in the murine intestines, but developed few intestinal
adenomas
over 2 years.
The numbers
of adenomas
in the small intestine and large intestine were significantly (P < 0.01) increased by 1.5-fold and 5.7-fold, respectively, in K-ras(Asp12)/Cre/Apc(Min/+) mice compared with Apc(Min/+) mice, with the more marked increase in
adenoma
prevalence in the large intestine.
K-ras(Asp12) increased activation of Mapk and Akt signalling pathway targets phospho-extracellular signal-regulated kinase (pErk) and pAkt, and increased relative expression levels of Wnt pathway targets vascular endothelial growth factor (VEGF), gastrin, cyclo-oxygenase 2 (Cox2) and T-
cell
lymphoma invasion and metastasis 1 (Tiam1) in K-ras(Asp12)/Cre/Apc(Min/+)
adenomas
compared with that of Apc(Min/+)
adenomas
, although other Wnt signalling pathway target genes such as Peroxisome proliferator-activated receptor delta (PPARd), matrix metalloproteinase 7 (MMP7), protein phosphatase 1
alpha
(PP1A) and c-myc remained unchanged.
In conclusion, intestinal expression of K-ras(Asp12) promotes mutant Apc-initiated intestinal
adenoma
formation in vivo more in the large intestine than the small intestine, with evidence of synergistic co-operation between mutant K-ras and Apc involving increased expression of some Wnt-pathway target genes.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Science. 2006 Oct 13;314(5797):268-74
[
16959974.001
]
[Cites]
Cell Signal. 2007 Mar;19(3):511-8
[
17011750.001
]
[Cites]
Oncogene. 2007 Jun 28;26(30):4415-27
[
17297472.001
]
[Cites]
Science. 2007 Nov 16;318(5853):1108-13
[
17932254.001
]
[Cites]
Gene Expr. 2007;14(2):101-15
[
18257393.001
]
[Cites]
J Clin Invest. 2000 Aug;106(4):533-9
[
10953028.001
]
[Cites]
Cancer Res. 2001 Mar 15;61(6):2670-5
[
11289146.001
]
[Cites]
Nature. 2001 Apr 26;410(6832):1111-6
[
11323676.001
]
[Cites]
Oncogene. 2001 Apr 19;20(17):2144-52
[
11360198.001
]
[Cites]
Cancer Res. 2001 Aug 15;61(16):6050-4
[
11507052.001
]
[Cites]
Gastroenterology. 2001 Sep;121(3):599-611
[
11522744.001
]
[Cites]
Br J Cancer. 2001 Sep 1;85(5):692-6
[
11531254.001
]
[Cites]
Nature. 2002 Jun 20;417(6891):867-71
[
12075356.001
]
[Cites]
Gastroenterology. 2002 Aug;123(2):492-504
[
12145803.001
]
[Cites]
Cancer Res. 2003 Feb 1;63(3):728-34
[
12566320.001
]
[Cites]
Nat Rev Cancer. 2003 Jun;3(6):459-65
[
12778136.001
]
[Cites]
Cancer Cell. 2003 Aug;4(2):111-20
[
12957286.001
]
[Cites]
Mol Cancer Res. 2003 Sep;1(11):820-5
[
14517344.001
]
[Cites]
Clin Cancer Res. 2004 Feb 15;10(4):1235-40
[
14977820.001
]
[Cites]
Cancer Cell. 2004 Apr;5(4):375-87
[
15093544.001
]
[Cites]
Gastroenterology. 2004 May;126(5):1236-46
[
15131783.001
]
[Cites]
Cancer Res. 2004 May 15;64(10):3694-700
[
15150130.001
]
[Cites]
Nature. 1984 Aug 9-15;310(5977):469-75
[
6462235.001
]
[Cites]
Proc Natl Acad Sci U S A. 1985 Dec;82(24):8488-92
[
3909146.001
]
[Cites]
Nature. 1987 May 28-Jun 3;327(6120):293-7
[
3587348.001
]
[Cites]
Annu Rev Biochem. 1987;56:779-827
[
3304147.001
]
[Cites]
Science. 1987 Oct 9;238(4824):193-7
[
2889267.001
]
[Cites]
Development. 1989 Jun;106(2):407-19
[
2686960.001
]
[Cites]
Cell. 1990 Jun 1;61(5):759-67
[
2188735.001
]
[Cites]
Science. 1992 May 1;256(5057):668-70
[
1350108.001
]
[Cites]
Nature. 1992 Sep 17;359(6392):235-7
[
1528264.001
]
[Cites]
Oncogene. 1993 Sep;8(9):2399-405
[
8395678.001
]
[Cites]
J Cell Biol. 1993 Nov;123(4):877-93
[
8227147.001
]
[Cites]
Br J Cancer. 1993 Dec;68(6):1127-33
[
8260364.001
]
[Cites]
Am J Pathol. 1994 May;144(5):1045-57
[
8178928.001
]
[Cites]
Cancer Res. 1994 Nov 15;54(22):5953-8
[
7954428.001
]
[Cites]
N Engl J Med. 1994 Dec 22;331(25):1694-702
[
7969362.001
]
[Cites]
Oncogene. 1995 Oct 19;11(8):1639-47
[
7478589.001
]
[Cites]
Mol Cell Biol. 1996 Mar;16(3):884-91
[
8622690.001
]
[Cites]
J Pathol. 1996 Dec;180(4):357-63
[
9014854.001
]
[Cites]
Br J Cancer. 1997;75(3):341-7
[
9020477.001
]
[Cites]
Cancer Lett. 1997 May 1;115(1):39-46
[
9097977.001
]
[Cites]
Gut. 1997 May;40(5):660-3
[
9203947.001
]
[Cites]
J Natl Cancer Inst. 1998 May 6;90(9):675-84
[
9586664.001
]
[Cites]
Gastroenterology. 1998 Nov;115(5):1144-53
[
9797369.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
[
9843981.001
]
[Cites]
Cancer Res. 1999 Oct 1;59(19):4804-7
[
10519388.001
]
[Cites]
Dis Colon Rectum. 2004 Nov;47(11):1915-21
[
15622585.001
]
[Cites]
J Cell Sci. 2005 Jan 15;118(Pt 2):313-22
[
15615777.001
]
[Cites]
Gastroenterology. 2005 Jun;128(7):1907-18
[
15940626.001
]
[Cites]
Biochem Biophys Res Commun. 2005 Oct 14;336(1):190-6
[
16139800.001
]
[Cites]
Biochim Biophys Acta. 2005 Nov 25;1756(2):145-54
[
16126346.001
]
[Cites]
J Biol Chem. 2006 Jan 6;281(1):543-8
[
16249175.001
]
[Cites]
Methods Enzymol. 2006;407:556-74
[
16757353.001
]
[Cites]
Lab Invest. 2006 Sep;86(9):968-78
[
16751780.001
]
[Cites]
Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14122-7
[
16959882.001
]
[Cites]
Gastroenterology. 2006 Oct;131(4):1096-109
[
17030180.001
]
[Cites]
Int J Cancer. 2008 Jun 1;122(11):2462-70
[
18271008.001
]
[Cites]
Nat Genet. 2008 May;40(5):600-8
[
18372904.001
]
(PMID = 19765110.001).
[ISSN]
1365-2613
[Journal-full-title]
International journal of experimental pathology
[ISO-abbreviation]
Int J Exp Pathol
[Language]
ENG
[Grant]
United Kingdom / Cancer Research UK / /
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Adenomatous Polyposis Coli Protein; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / Wnt Proteins; EC 3.6.5.2 / Kras2 protein, mouse; EC 3.6.5.2 / Oncogene Protein p21(ras); EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
[Other-IDs]
NLM/ PMC2768154
63.
Krysiak R, Okopień B, Herman ZS:
[Rare pancreatic endocrine tumors].
Przegl Lek
; 2008;65(4):209-16
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Rare
pancreatic
endocrine
tumors
].
[Transliterated title]
Rzadkie guzy endokrynne
trzustki
.
Functional
pancreatic
endocrine
tumors
other than gastrinoma and insulinoma are quite rare.
Some of these
tumors
may be part of multiple endocrine neoplasia type one (MEN-1)
syndrome
or phakomatoses.
Depending on their
cell
type, functional
pancreatic
endocrine
tumors
may cause distinct clinical endocrine
syndromes
, such as the '
glucagonoma syndrome
', Verner-Morrison
syndrome
and the 'somatostatinoma
syndrome
'.
Currently, the only curative treatment for
islet
cell
tumors
is complete surgical resection.
The medical treatment of endocrine
pancreatic
tumours consists of somatostatin analogues, chemotherapy, and interferon-
alpha
.
The purpose of this manuscript is to provide an overview of the contemporary etiopathogenesis,
diagnosis
and treatment of rare
pancreatic
endocrine
tumors
.
[MeSH-major]
Glucagonoma
/
diagnosis
.
Glucagonoma
/ therapy.
Pancreatic
Neoplasms /
diagnosis
.
Pancreatic
Neoplasms / therapy. Somatostatinoma /
diagnosis
. Somatostatinoma / therapy. Vipoma /
diagnosis
. Vipoma / therapy
[MeSH-minor]
Humans. Rare Diseases /
diagnosis
. Rare Diseases / therapy
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18724549.001).
[ISSN]
0033-2240
[Journal-full-title]
Przegla̧d lekarski
[ISO-abbreviation]
Prz. Lek.
[Language]
pol
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Poland
[Number-of-references]
47
64.
Xue HD, Liu W, Sun H, Merges R, Wang X, Zhang XN, Wang Y, Zhao WM, Chen JH, Jin ZY:
Spectrum of functioning islet cell tumor on multislice computed tomography: experience on 70 patients.
Chin Med Sci J
; 2008 Mar;23(1):1-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Spectrum of functioning
islet
cell
tumor
on multislice computed tomography: experience on 70 patients.
OBJECTIVE: To review experience in preoperative detection
of islet
cell
tumors
using multislice computed tomography (MSCT) and summarize various imaging features of functioning
islet
cell
tumors
on enhanced MSCT.
METHODS: Seventy patients with clinical or pathological
diagnosis of
functioning
pancreatic islet
cell
tumor
between October 2003 and February 2007 were included in this retrospective study.
Surgery and pathology reports were used to confirm
the diagnosis
, localization, and size
of tumors
.
RESULTS: Totally, 73 functioning
islet
cell
tumors
including 65 benign insulinomas, 2 benign
glucagonomas
, 3 malignant insulinomas, and 3 malignant
glucagonomas
were pathologically diagnosed.
Tumors
in only two cases were not found by MSCT.
In 67 benign lesions, 32 showed typical enhancement style, 21 showed prolonged enhancement in portal venous phase, 4 showed delayed enhancement, 4 had iso-dense enhancement with normal
pancreatic
parenchyma, 2 had no enhancement at all in arterial phase and portal venous phase, and 4 had inhomogeneous enhancement with necrosis or cyst-formation.
Patchy or spotty calcifications were found in 3 of the 67
tumors
.
In 6 malignant
islet
cell
tumors
, vessel invasion (2/6) and bowel invasion (1/6) were seen.
CONCLUSIONS:
Pancreatic islet
cell
tumor
may display a wide spectrum of presentations in MSCT.
Tumors
with unusual appearances often present as diagnostic challenges.
Non-contrast and post-contrast multiphase scans are recommended for the localization of functioning
islet
cell
tumors
.
MedlinePlus Health Information.
consumer health - CT Scans
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18437902.001).
[ISSN]
1001-9294
[Journal-full-title]
Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
[ISO-abbreviation]
Chin. Med. Sci. J.
[Language]
ENG
[Publication-type]
Journal Article
[Publication-country]
China
65.
Gentschev I, Fensterle J, Schmidt A, Potapenko T, Troppmair J, Goebel W, Rapp UR:
Use of a recombinant Salmonella enterica serovar Typhimurium strain expressing C-Raf for protection against C-Raf induced lung adenoma in mice.
BMC Cancer
; 2005 Feb 9;5:15
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Use
of a
recombinant Salmonella enterica serovar Typhimurium strain expressing C-Raf for protection against C-Raf induced lung
adenoma
in mice.
Therefore these proteins are potential targets for immunotherapy and a possible basis for vaccine development against
tumors
.
In this study we analyzed the functionality
of a
new live C-Raf vaccine based on an attenuated Salmonella enterica serovar Typhimurium aroA strain in two Raf dependent lung
tumor
mouse models.
METHODS: The antigen C-Raf has been fused to
the C
-terminal secretion signal of Escherichia coli
alpha
-hemolysin and expressed in secreted form by an attenuated aroA Salmonella enterica serovar Typhimurium strain via the
alpha
-hemolysin secretion pathway.
The effect of the immunization with this recombinant C-Raf strain on wild-type C57BL/6 or lung
tumor
bearing transgenic BxB mice was analyzed using western blot and FACS analysis as well as specific
tumor
growth assays.
Immunization of wild-type C57BL/6 or
tumor
bearing mice provoked specific C-Raf antibody and T-
cell
responses.
Most importantly, the vaccine strain significantly reduced
tumor
growth in two transgenic mouse models of Raf oncogene-induced lung
adenomas
.
[MeSH-major]
Adenoma
/ prevention & control. Cancer Vaccines / immunology. Escherichia coli Proteins / immunology. Hemolysin Proteins / immunology. Lung Neoplasms / prevention & control. Proto-Oncogene Proteins c-raf / immunology. Salmonella typhimurium / immunology
MedlinePlus Health Information.
consumer health - Lung Cancer
.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Vaccine. 2003 Jan 17;21(5-6):401-18
[
12531639.001
]
[Cites]
Cancer Res. 2002 Nov 1;62(21):6297-303
[
12414660.001
]
[Cites]
Cancer Res. 2004 Aug 1;64(15):5456-60
[
15289355.001
]
[Cites]
BMC Cancer. 2004 Sep 12;4:62
[
15361259.001
]
[Cites]
Nature. 1970 Aug 15;227(5259):680-5
[
5432063.001
]
[Cites]
Gene. 1979 May;6(1):23-8
[
383576.001
]
[Cites]
Nucleic Acids Res. 1986 Jan 24;14(2):1009-15
[
3003687.001
]
[Cites]
Mol Gen Genet. 1988 Apr;212(1):76-84
[
3287099.001
]
[Cites]
Nucleic Acids Res. 1990 Oct 25;18(20):6169
[
2235524.001
]
[Cites]
Clin Microbiol Rev. 1992 Jul;5(3):328-42
[
1498769.001
]
[Cites]
Trends Biochem Sci. 1994 Jul;19(7):279-83
[
8048167.001
]
[Cites]
Oncogene. 1994 Sep;9(9):2751-6
[
8058342.001
]
[Cites]
Dev Biol Stand. 1994;82:35-42
[
7958481.001
]
[Cites]
Trends Biochem Sci. 1994 Nov;19(11):474-80
[
7855890.001
]
[Cites]
J Exp Med. 1995 Aug 1;182(2):477-86
[
7629507.001
]
[Cites]
J Exp Med. 1996 Jul 1;184(1):19-29
[
8691133.001
]
[Cites]
Gene. 1996 Nov 7;179(1):133-40
[
8955639.001
]
[Cites]
Oncogene. 1999 Jan 21;18(3):813-22
[
9989833.001
]
[Cites]
Int J Med Microbiol. 2004 Oct;294(6):363-71
[
15595386.001
]
[Cites]
Exp Cell Res. 1999 Nov 25;253(1):34-46
[
10579909.001
]
[Cites]
Mol Med Today. 2000 Feb;6(2):66-71
[
10652479.001
]
[Cites]
Cell Growth Differ. 2000 Apr;11(4):185-90
[
10775035.001
]
[Cites]
Br J Cancer. 2001 Nov 30;85(11):1753-8
[
11742498.001
]
[Cites]
Trends Microbiol. 2002 Jan;10(1):39-45
[
11755084.001
]
[Cites]
Curr Opin Immunol. 2002 Apr;14(2):178-82
[
11869889.001
]
[Cites]
Nature. 2002 Jun 27;417(6892):949-54
[
12068308.001
]
[Cites]
Immunol Rev. 2004 Jun;199:181-90
[
15233734.001
]
(PMID = 15703070.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Cancer Vaccines; 0 / Escherichia coli Proteins; 0 / Hemolysin Proteins; 0 / Hlya protein, E coli; 0 / Recombinant Proteins; 0 / Vaccines, Attenuated; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf
[Other-IDs]
NLM/ PMC549196
66.
Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC:
Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.
Endocr Relat Cancer
; 2007 Mar;14(1):91-102
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces
cell
viability in non-functioning pituitary
adenomas
by inhibiting vascular endothelial growth factor secretion.
Somatostatin (SRIF) analogs have been employed in medical therapy of non-functioning pituitary
adenomas
(NFA), with contrasting results.
Previous evidence showed that SRIF can exert its antiproliferative effects by reducing vascular endothelial growth factor (VEGF) secretion and action, and that VEGF expression may be related to pituitary
tumor
growth.
The aim of our study was to clarify the possible effects
of a
multireceptor SRIF ligand on VEGF secretion and
cell
proliferation in human NFA primary cultures.
We assessed the expression of SRIF receptors (SSTR1-5), the in vitro effects on VEGF secretion, and on
cell
viability of SRIF and of the stable SRIF analog pasireotide (SOM230), which activates SSTR1, 2, 3, and 5.
Twenty-five NFA were examined by RT-PCR for expression of
alpha
-subunit, SSTR, VEGF, and VEGF receptors 1 (VEGF-R1) and 2 (VEGF-R2).
All NFA samples expressed
alpha
-sub, VEGF and VEGFR-1 and 2, while SSTR expression pattern was highly variable.
VEGF secretion and
cell
viability were reduced by SRIF and pasireotide in the 'responder' group, but not in the 'non-responder' group, including NFA expressing SSTR5.
In addition, SRIF and pasireotide completely abrogated the promoting effects of VEGF on NFA
cell
viability.
Our data demonstrate that pasireotide can inhibit NFA
cell
viability by inhibiting VEGF secretion, and suggest that the multireceptor-SSTR agonist pasireotide might be useful in medical therapy of selected NFA.
[MeSH-major]
Adenoma
/ secretion. Oligopeptides / pharmacology. Pituitary Neoplasms / secretion. Somatostatin / pharmacology. Vascular Endothelial Growth Factor A / secretion
[MeSH-minor]
Adult. Aged.
Cell
Survival / drug effects. Female. Hormones / pharmacology. Humans. Ligands. Male. RNA, Messenger / metabolism. Receptors, Somatostatin / genetics. Receptors, Somatostatin / metabolism
MedlinePlus Health Information.
consumer health - Pituitary Tumors
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17395978.001).
[ISSN]
1351-0088
[Journal-full-title]
Endocrine-related cancer
[ISO-abbreviation]
Endocr. Relat. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Hormones; 0 / Ligands; 0 / Oligopeptides; 0 / RNA, Messenger; 0 / Receptors, Somatostatin; 0 / Vascular Endothelial Growth Factor A; 51110-01-1 / Somatostatin; 98H1T17066 / pasireotide
67.
Hanson PL, Aylwin SJ, Monson JP, Burrin JM:
FSH secretion predominates in vivo and in vitro in patients with non-functioning pituitary adenomas.
Eur J Endocrinol
; 2005 Mar;152(3):363-70
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
FSH secretion predominates in vivo and in vitro in patients with non-functioning pituitary
adenomas
.
OBJECTIVE: Non-functioning pituitary
adenomas
(NFPAs) are characterised by the lack of symptoms of hormone hypersecretory
syndromes
but in vitro studies have demonstrated that
tumour cells
may stain for gonadotrophins and/or their
alpha
- or beta-subunits.
In this study, we aimed to examine the pattern of secretion of LH and FSH from a series of pituitary
adenomas
cultured in vitro and where data were available to relate the results to pre-operative serum gonadotrophin levels.
Peritumorous 'normal' pituitary
cell
cultures from 20 additional pituitary
tumour
patients were used for comparison with the NFPA group.
Peritumorous 'normal' pituitary
cells
released LH and FSH in a reversed ratio (median LH:FSH ratio = 3.6:1, P < 0.01 compared with NFPAs).
By demonstrating that NFPAs cultured in vitro reflect the in vivo situation of preferential secretion of FSH, it may be possible in future to perform functional studies using this system to elucidate the cellular and molecular mechanisms involved in the development of an imbalance in gonadotroph
cells
preferentially overproducing FSH in NFPAs.
MedlinePlus Health Information.
consumer health - Pituitary Tumors
.
Hazardous Substances Data Bank.
MENOTROPINS
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15757852.001).
[ISSN]
0804-4643
[Journal-full-title]
European journal of endocrinology
[ISO-abbreviation]
Eur. J. Endocrinol.
[Language]
ENG
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
68.
Shia J, Klimstra DS, Nitzkorski JR, Low PS, Gonen M, Landmann R, Weiser MR, Franklin WA, Prendergast FG, Murphy L, Tang LH, Temple L, Guillem JG, Wong WD, Paty PB:
Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance.
Hum Pathol
; 2008 Apr;39(4):498-505
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Immunohistochemical expression of folate receptor
alpha
in colorectal carcinoma: patterns and biological significance.
Folate receptor
alpha
(FRalpha) has emerged as a potential cancer therapy target with several folate-linked therapeutic agents currently undergoing clinical trials.
In addition, FRalpha expression in
tumors
may offer prognostic significance.
We used tissue microarrays containing 152 normal colorectal mucosa samples, 42
adenomas
, 177 primary, and 52 metastatic colorectal carcinomas.
FRalpha positivity was more frequent in carcinomas (33% in primaries and 44% in metastases) than in normal mucosa or
adenoma
(7% in both) (P < .001).
Positive staining in primary carcinomas also correlated with a worse 5-year
disease
-specific survival (P = .04) on univariate but not multivariate analysis.
Thus, our data show that there is selective expression of FRalpha in some colorectal cancers, providing a foundation for investigating the use of folate conjugates for imaging and therapy of colorectal
tumors
.
[MeSH-major]
Carcinoma /
diagnosis
. Carrier Proteins / analysis. Colorectal Neoplasms /
diagnosis
. Receptors,
Cell
Surface / analysis
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18342661.001).
[ISSN]
0046-8177
[Journal-full-title]
Human pathology
[ISO-abbreviation]
Hum. Pathol.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / 2 P01 CA65930-05A2
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Carrier Proteins; 0 / Folate Receptors, GPI-Anchored; 0 / Receptors, Cell Surface
69.
Rao VP, Poutahidis T, Ge Z, Nambiar PR, Horwitz BH, Fox JG, Erdman SE:
Proinflammatory CD4+ CD45RB(hi) lymphocytes promote mammary and intestinal carcinogenesis in Apc(Min/+) mice.
Cancer Res
; 2006 Jan 1;66(1):57-61
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Here, we apply a widely used T-
cell
transfer paradigm, involving adoptive transfer of proinflammatory CD4+ CD45RB(hi) (T(E))
cells
to induce inflammatory bowel
disease
(IBD) in mice, to investigate roles of inflammation on carcinogenesis in the Apc(Min/+) mouse model of intestinal polyposis.
We find that transfer of T(E)
cells
significantly increases
adenoma
multiplicity and features of malignancy in recipient Apc(Min/+) mice.
Surprisingly, we find that female Apc(Min/+) recipients of T(E)
cells
also rapidly develop mammary
tumors
.
Both intestinal polyposis and mammary adenocarcinoma are abolished by cotransfer of anti-inflammatory CD4+ CD45RB(lo) regulatory lymphocytes or by neutralization of key proinflammatory cytokine
tumor
necrosis factor-
alpha
.
Lastly, down-regulation of cyclooxygenase-2 and c-Myc expression is observed coincident with
tumor
regression.
These findings define a novel mouse model of inflammation-driven mammary carcinoma and suggest that epithelial carcinogenesis can be mitigated by anti-inflammatory
cells
and cytokines known to regulate IBD in humans and mice.
[MeSH-minor]
Adenocarcinoma / genetics. Adenocarcinoma / immunology.
Adenoma
/ genetics.
Adenoma
/ immunology. Adoptive Transfer. Animals.
Disease
Models, Animal. Down-Regulation. Epithelial
Cells
/ immunology. Epithelial
Cells
/ pathology. Female. Genes, APC. Genes, myc / genetics. Inflammatory Bowel Diseases / immunology. Intestinal Polyps / genetics. Intestinal Polyps / immunology. Male. Mice. Mice, Inbred C57BL.
Tumor
Necrosis Factor-
alpha
/ antagonists & inhibitors.
Tumor
Necrosis Factor-
alpha
/ immunology
COS Scholar Universe.
author profiles
.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16397216.001).
[ISSN]
0008-5472
[Journal-full-title]
Cancer research
[ISO-abbreviation]
Cancer Res.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / P01CA26731; United States / NIEHS NIH HHS / ES / P30ES02109; United States / NIAID NIH HHS / AI / R01 AI50952; United States / NIDDK NIH HHS / DK / R01 DK52413; United States / NCI NIH HHS / CA / R01CA108854; United States / NCI NIH HHS / CA / R01CA67529; United States / NCRR NIH HHS / RR / T32RR07036
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / Tumor Necrosis Factor-alpha; EC 3.1.3.48 / Antigens, CD45
70.
Furuse C, Sousa SO, Nunes FD, Magalhães MH, Araújo VC:
Myoepithelial cell markers in salivary gland neoplasms.
Int J Surg Pathol
; 2005 Jan;13(1):57-65
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Myoepithelial
cell
markers in salivary gland neoplasms.
We compared the immunoexpression of 5 myoepithelial
cell
(MEC) markers (
alpha
-smooth-muscle actin, calponin, h-caldesmon, vimentin, and S-100-protein) using 16 pleomorphic
adenomas
(PA), 15 adenoid cystic carcinomas (ACC), and 3 epithelial-myoepithelial carcinomas (EMC) of salivary glands.
The
alpha
-smooth-muscle actin was useful for identification of MECs, especially in cribriform and tubular ACC, followed by EMC.
Calponin was similar to
alpha
-smooth-muscle actin, except for polygonal and plasmacytoid
cells of
PA and for solid ACC, which showed
alpha
-smooth-muscle actin negative and calponin positive.
Vimentin immunostained all MEC types, and was negative in luminal
cells
.
S-100 protein was expressed both in the nuclei and cytoplasm of MECs and luminal
cells
, especially in PA.
The best way to identify MEC is using
alpha
-smooth-muscle actin or calponin, plus vimentin, since in
tumors
MECs are hardly ever fully differentiated.
[MeSH-major]
Adenoma
, Pleomorphic / metabolism. Biomarkers,
Tumor
/ metabolism. Carcinoma, Adenoid Cystic / metabolism. Myoepithelioma / metabolism. Salivary Gland Neoplasms / metabolism
MedlinePlus Health Information.
consumer health - Salivary Gland Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15735856.001).
[ISSN]
1066-8969
[Journal-full-title]
International journal of surgical pathology
[ISO-abbreviation]
Int. J. Surg. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Actins; 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Microfilament Proteins; 0 / S100 Proteins; 0 / Vimentin; 0 / calponin
71.
Mikkelsen CS, Mikkelsen DB, Vestergaard V, Clemmensen O, Nielsen HO, Bygum A:
[Glucagonoma syndrome without diabetes mellitus].
Ugeskr Laeger
; 2008 Nov 17;170(47):3876
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Glucagonoma syndrome
without diabetes mellitus].
Computerised tomography and endoscopic ultrasound showed a solid
tumour of the pancreas
.
A blood sample showed an increased level
of glucagon
without diabetes.
Glucagonoma syndrome
is characterized by
glucagon
overproduction, diabetes, depression, deep venous thrombosis and necrolytic migrating erythema.
Glucagonoma
is frequently diagnosed late which increases the risk of metastases.
It is important not to rule out
glucagonoma
in patients with a relevant clinical picture but without diabetes.
[MeSH-major]
Glucagonoma
/
diagnosis
.
Pancreatic
Neoplasms /
diagnosis
Genetic Alliance.
consumer health - Diabetes
.
Genetic Alliance.
consumer health - Glucagonoma
.
Genetic Alliance.
consumer health - Glucagonoma Syndrome
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Ugeskr Laeger. 2008 Dec 15;170(51):4241; author reply 4241
[
19160469.001
]
(PMID = 19014744.001).
[ISSN]
1603-6824
[Journal-full-title]
Ugeskrift for laeger
[ISO-abbreviation]
Ugeskr. Laeg.
[Language]
dan
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Denmark
72.
Yang J, Zhou GW, Chen X, Wei Y, Peng CH, Ning G, Li HW:
[Diagnosis and treatment of multiple endocrine neoplasia type 1 related pancreatic endocrine tumors].
Zhonghua Wai Ke Za Zhi
; 2009 Mar 1;47(5):329-32
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Diagnosis
and treatment of multiple endocrine neoplasia type 1 related
pancreatic
endocrine
tumors
].
OBJECTIVE: To summarize the experience on
diagnosis
and treatment of multiple endocrine neoplasia type 1 (MEN-1) related
pancreatic
endocrine
tumors
(PET).
The other patient was diagnosed as
glucagonoma
clinically.
[MeSH-major]
Multiple Endocrine Neoplasia Type 1 /
diagnosis
. Multiple Endocrine Neoplasia Type 1 / surgery.
Pancreatic
Neoplasms /
diagnosis
.
Pancreatic
Neoplasms / surgery
Genetic Alliance.
consumer health - Multiple Endocrine Neoplasia
.
Genetic Alliance.
consumer health - Multiple endocrine neoplasia type 1
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19595004.001).
[ISSN]
0529-5815
[Journal-full-title]
Zhonghua wai ke za zhi [Chinese journal of surgery]
[ISO-abbreviation]
Zhonghua Wai Ke Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
73.
Bioulac-Sage P, Rebouissou S, Thomas C, Blanc JF, Saric J, Sa Cunha A, Rullier A, Cubel G, Couchy G, Imbeaud S, Balabaud C, Zucman-Rossi J:
Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry.
Hepatology
; 2007 Sep;46(3):740-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Hepatocellular
adenoma
subtype classification using molecular markers and immunohistochemistry.
Hepatocellular
adenomas
(HCA) with activated beta-catenin present a high risk of malignant transformation.
To permit robust routine
diagnosis
to allow for HCA subtype classification, we searched new useful markers.
We analyzed the expression of candidate genes by quantitative reverse transcription polymerase chain reaction QRT-PCR followed by immunohistochemistry to validate their specificity and sensitivity according to hepatocyte nuclear factor 1
alpha
(HNF1alpha) and beta-catenin mutations as well as inflammatory phenotype.
Previously described associations were confirmed and in particular the significant association between beta-catenin-activated HCA and hepatocellular carcinomas (HCC) at
diagnosis
or during follow-up (P < 10(-5)).
CONCLUSION: We refined HCA classification and its phenotypic correlations, providing a routine test to classify hepatocellular
adenomas
using simple and robust immunohistochemistry.
[MeSH-major]
Adenoma
, Liver
Cell
/ classification.
Adenoma
, Liver
Cell
/ pathology. Biomarkers,
Tumor
/ analysis. Liver Neoplasms / classification. Liver Neoplasms / pathology
[MeSH-minor]
Adult. Fatty Acid-Binding Proteins / analysis. Fatty Acid-Binding Proteins / genetics. Fatty Acid-Binding Proteins / metabolism. Female. Glucuronosyltransferase / analysis. Glucuronosyltransferase / genetics. Glucuronosyltransferase / metabolism. Glutamate-Ammonia Ligase / analysis. Glutamate-Ammonia Ligase / genetics. Glutamate-Ammonia Ligase / metabolism. Hepatocyte Nuclear Factor 1-
alpha
/ analysis. Hepatocyte Nuclear Factor 1-
alpha
/ genetics. Hepatocyte Nuclear Factor 1-
alpha
/ metabolism. Humans. Immunohistochemistry / methods. Male. beta Catenin / metabolism
MedlinePlus Health Information.
consumer health - Liver Cancer
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17663417.001).
[ISSN]
0270-9139
[Journal-full-title]
Hepatology (Baltimore, Md.)
[ISO-abbreviation]
Hepatology
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / FABP1 protein, human; 0 / Fatty Acid-Binding Proteins; 0 / HNF1A protein, human; 0 / Hepatocyte Nuclear Factor 1-alpha; 0 / beta Catenin; EC 2.4.1.- / UGT2B7 protein, human; EC 2.4.1.17 / Glucuronosyltransferase; EC 6.3.1.2 / Glutamate-Ammonia Ligase
74.
Rotondo F, Kovacs K, Scheithauer BW, Horvath E, Bell CD, Lloyd RV, Cusimano M:
Immunohistochemical expression of SNAP-25 protein in adenomas of the human pituitary.
Appl Immunohistochem Mol Morphol
; 2008 Oct;16(5):477-81
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Immunohistochemical expression of SNAP-25 protein in
adenomas of
the human pituitary.
SNAP-25, a synaptosome-associated exocytosis protein of 25 kd mw, plays an important role in the secretory activity of several endocrine
cells
.
In the present study, we investigated surgically removed pituitary
adenomas
including 40 prolactin (PRL), 31 growth hormone, 5 adrenocorticotropic hormone, 5 thyroid-stimulating hormone, 14 follicle-stimulating hormone/luteinizing hormone/
alpha
-subunit-
producing tumors
, and 5 null
cell
adenomas
.
Among the 40 patients with PRL-
producing
pituitary
adenoma
, 16 had been preoperatively treated with the dopamine agonist bromocriptine.
Similarly, of the 31 patients with GH-
producing
pituitary
adenomas
, 15 had been treated with the long-acting somatostatin analog, octreotide.
All
tumors
were subjected to transsphenoidal surgery, formalin-fixed, routinely processed, and paraffin-embedded.
Immunostaining for SNAP-25 (streptavidin-biotin peroxidase complex method) showed that 10 PRL-
producing adenomas
were strongly immunoreactive.
Immunopositivity was mainly
cell
membrane in distribution but several
cells
showed mild cytoplasmic staining.
Among GH-
producing adenomas
, SNAP-25 was seen in 5 cases; reactivity being mild-to-moderate, membrane-bound, and cytoplasmic.
Other
adenoma
types were virtually immunonegative.
It is conceivable that SNAP-25 plays an important role in PRL release and is involved in the bromocriptine-induced suppression of PRL secretion from PRL-
producing
adenoma
cells
.
MedlinePlus Health Information.
consumer health - Pituitary Tumors
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18633321.001).
[ISSN]
1533-4058
[Journal-full-title]
Applied immunohistochemistry & molecular morphology : AIMM
[ISO-abbreviation]
Appl. Immunohistochem. Mol. Morphol.
[Language]
ENG
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / SNAP25 protein, human; 0 / Synaptosomal-Associated Protein 25; 12629-01-5 / Human Growth Hormone; 3A64E3G5ZO / Bromocriptine; 9002-62-4 / Prolactin; RWM8CCW8GP / Octreotide
75.
Cooper O, Ben-Shlomo A, Bonert V, Bannykh S, Mirocha J, Melmed S:
Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes.
Horm Cancer
; 2010 Apr;1(2):80-92
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Silent corticogonadotroph
adenomas
: clinical and cellular characteristics and long-term outcomes.
Silent corticotrophins
adenomas
(SCAs) are clinically silent and non-secreting but immunostain positively for ACTH.
We compared preoperative and postoperative clinical results and
tumor
cytogenesis in 25 SCAs and 84 nonfunctioning
adenomas
in 109 consecutive patients diagnosed pre-operatively with nonfunctioning pituitary
adenomas
.
Preoperative SCA presentation was similar to that observed for nonfunctioning
adenomas
.
However, SCAs recurred postoperatively at a median of 3 years vs. 8 years for nonfunctioning
adenomas
(p<0.0001).
Fifty-four percent of patients with SCAs had new onset postoperative hypopituitarism vs. 17% of nonfunctioning
adenomas
(p<0.025).
SCAs (n=18) were immunopositive for ACTH, cytoplasmic and nuclear SF-1, NeuroD1, DAX-1, and
alpha
-gonadotropin subunit, but Tpit negative, and co-expression
of tumor
ACTH with either SF-1 or LH was detected.
In contrast, functional corticotroph
adenomas
(n=11) were immunopositive for ACTH, nuclear SF-1, NeuroD1, and Tpit, but negative for DAX-1, a gonadotroph
cell
transcription factor.
Gonadotroph
adenomas
(n=23) were immunonegative for ACTH and Tpit but positive for nuclear SF-1, NeuroD1, and DAX-1.
SCA electron microscopy demonstrated ultrastructural features consistent with corticotroph and gonadotroph
cells
.
As SCAs exhibit features consistent with both corticotroph and gonadotroph cytologic origin, we propose a pathologic and clinically distinct classification of SCAs as silent corticogonadotroph
adenomas
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Endocrinol Metab. 2000 Jul;85(7):2537-42
[
10902805.001
]
[Cites]
Clin Endocrinol (Oxf). 1998 May;48(5):647-54
[
9666878.001
]
[Cites]
Cell. 2001 Mar 23;104(6):849-59
[
11290323.001
]
[Cites]
J Clin Endocrinol Metab. 2001 Jun;86(6):2476-83
[
11397843.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8674-9
[
11447259.001
]
[Cites]
Mod Pathol. 2001 Sep;14(9):892-9
[
11557786.001
]
[Cites]
Acta Neuropathol. 2001 Oct;102(4):398-403
[
11603817.001
]
[Cites]
Neuropathology. 2001 Dec;21(4):288-93
[
11837535.001
]
[Cites]
Endocr Pathol. 2002 Summer;13(2):125-30
[
12165660.001
]
[Cites]
Endocr J. 2002 Jun;49(3):285-92
[
12201210.001
]
[Cites]
Clin Endocrinol (Oxf). 2003 Jan;58(1):59-64
[
12519413.001
]
[Cites]
Genes Dev. 2003 Mar 15;17(6):738-47
[
12651892.001
]
[Cites]
J Clin Endocrinol Metab. 2003 Jul;88(7):3050-6
[
12843142.001
]
[Cites]
Pituitary. 2002;5(4):221-3
[
14558669.001
]
[Cites]
Neurosurgery. 2003 Nov;53(5):1076-84; discussion 1084-5
[
14580274.001
]
[Cites]
J Clin Invest. 2003 Dec;112(11):1603-18
[
14660734.001
]
[Cites]
Endocr Pathol. 2003 Winter;14(4):363-8
[
14739492.001
]
[Cites]
Hum Pathol. 2004 Sep;35(9):1137-47
[
15343517.001
]
[Cites]
Am J Pathol. 1980 Mar;98(3):617-38
[
6244736.001
]
[Cites]
J Pathol. 1985 Jan;145(1):59-62
[
3881578.001
]
[Cites]
J Neurosurg. 1987 Feb;66(2):244-50
[
3543255.001
]
[Cites]
Virchows Arch A Pathol Anat Histopathol. 1988;413(1):61-8
[
2453972.001
]
[Cites]
Acta Endocrinol (Copenh). 1988 Aug;118(4):533-7
[
2840793.001
]
[Cites]
Pathol Res Pract. 1988 Sep;183(5):601-5
[
2467268.001
]
[Cites]
Pathol Res Pract. 1988 Sep;183(5):610-2
[
2467270.001
]
[Cites]
Neurosurgery. 1990 Mar;26(3):397-403
[
1690866.001
]
[Cites]
Am J Pathol. 1990 Aug;137(2):479-88
[
2167013.001
]
[Cites]
Virchows Arch A Pathol Anat Histopathol. 1990;417(4):361-7
[
2173251.001
]
[Cites]
Hum Pathol. 1991 Jul;22(7):719-21
[
1649119.001
]
[Cites]
Pathol Res Pract. 1991 Jun;187(5):637-41
[
1717963.001
]
[Cites]
Neurol Med Chir (Tokyo). 1992;32(7 Spec No):381-547
[
1381065.001
]
[Cites]
Ultrastruct Pathol. 1999 May-Jun;23(3):141-8
[
10445280.001
]
[Cites]
Mol Endocrinol. 1999 Aug;13(8):1267-84
[
10446902.001
]
[Cites]
Br J Neurosurg. 2005 Feb;19(1):38-42
[
16147581.001
]
[Cites]
Endocr Pathol. 2005 Fall;16(3):239-44
[
16299407.001
]
[Cites]
Pathol Res Pract. 2006;202(6):457-64
[
16497445.001
]
[Cites]
Neurosurgery. 2006 Aug;59(2):341-53; discussion 341-53
[
16883174.001
]
[Cites]
Clin Genet. 2007 Sep;72(3):175-82
[
17718852.001
]
[Cites]
Neurosurgery. 2007 Sep;61(3):580-4; discussion 584-5
[
17881972.001
]
[Cites]
Exp Clin Endocrinol Diabetes. 2007 Oct;115(9):610-5
[
17943697.001
]
[Cites]
Eur J Endocrinol. 2007 Dec;157(6):717-24
[
18057378.001
]
[Cites]
Endocr J. 2007 Dec;54(6):961-8
[
18079591.001
]
[Cites]
J Clin Endocrinol Metab. 2008 May;93(5):1526-40
[
18334580.001
]
[Cites]
Mol Endocrinol. 2008 Jul;22(7):1647-57
[
18388149.001
]
[Cites]
Neuro Endocrinol Lett. 2008 Jun;29(3):347-50
[
18580839.001
]
[Cites]
Endocr Pathol. 2008 Spring;19(1):17-26
[
18228160.001
]
[Cites]
Clin Endocrinol (Oxf). 2010 May;72(5):648-53
[
19650787.001
]
[Cites]
Pathol Int. 1994 Sep;44(9):697-703
[
7804432.001
]
[Cites]
Eur J Endocrinol. 1995 Jul;133(1):25-32
[
7542980.001
]
[Cites]
J Clin Endocrinol Metab. 1996 Jun;81(6):2165-70
[
8964846.001
]
[Cites]
J Clin Endocrinol Metab. 1997 Mar;82(3):818-24
[
9062489.001
]
[Cites]
Endocr J. 1997 Apr;44(2):329-33
[
9228470.001
]
[Cites]
Clin Endocrinol (Oxf). 1997 Jun;46(6):669-79
[
9274697.001
]
[Cites]
Mol Cell Biol. 1997 Nov;17(11):6673-82
[
9343431.001
]
[Cites]
Endocrinol Metab Clin North Am. 1997 Dec;26(4):741-62
[
9429858.001
]
[Cites]
Neurosurgery. 2000 Sep;47(3):723-9; discussion 729-30
[
10981760.001
]
(PMID = 20717480.001).
[ISSN]
1868-8500
[Journal-full-title]
Hormones & cancer
[ISO-abbreviation]
Horm Cancer
[Language]
ENG
[Grant]
United States / NIDDK NIH HHS / DK / T32 DK007770-08; United States / NCI NIH HHS / CA / R01 CA075979-08; United States / NIDDK NIH HHS / DK / T32 DK007770; United States / NIDDK NIH HHS / DK / T32 DK07770; United States / NIDDK NIH HHS / DK / DK007770-08; United States / NCI NIH HHS / CA / CA 075979; United States / NCI NIH HHS / CA / R01 CA075979; United States / NCI NIH HHS / CA / CA075979-08
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Gonadotropins
[Keywords]
NOTNLM ; Corticotroph adenoma / Gonadotroph adenoma / Nonfunctioning adenoma / Pituitary adenoma
76.
Oda E, Nakamura Y, Yamamoto M, Kojiro M:
Immunohistochemical distribution of tubulin beta II in human normal and neoplastic tissues.
Kurume Med J
; 2005;52(4):117-25
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In mammals, there are seven beta-tubulins and six
alpha
-tubulins.
Tubulin beta II was detected in various normal tissues, particularly in fetal and neonatal tissues, such as the nervous system, pulmonary alveoli, bronchioles and bronchi, colon,
pancreatic
ducts and acini, renal convoluted tubuli, skin epidermis, body cavity mesothelial
cells
, smooth muscle and thymus.
In neoplastic tissues, tubulin beta II immunoreactivity was detected in various nervous system neoplasms and other neoplasms such as
pancreatic
solid cystic carcinoma, pleomorphic
adenoma
, Warthin'
s tumor
, nephroblastoma, basal
cell
carcinoma and malignant mesothelioma.
We conclude that our monoclonal antibody, KNY379, may be useful as a marker of nervous system neoplasm,
pancreatic
solid cystic carcinoma, pleomorphic
adenoma
, Warthin'
s tumor
, nephroblastoma, basal
cell
carcinoma and malignant mesothelioma.
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers,
Tumor
/ analysis. Blotting, Western. Child, Preschool. Humans. Immunohistochemistry. Infant. Mesothelioma / chemistry. Middle Aged. Protein Isoforms
MedlinePlus Health Information.
consumer health - Cancer in Children
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16639982.001).
[ISSN]
0023-5679
[Journal-full-title]
The Kurume medical journal
[ISO-abbreviation]
Kurume Med J
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Protein Isoforms; 0 / Tubulin
77.
Salcedo R, Worschech A, Cardone M, Jones Y, Gyulai Z, Dai RM, Wang E, Ma W, Haines D, O'hUigin C, Marincola FM, Trinchieri G:
MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18.
J Exp Med
; 2010 Aug 2;207(8):1625-36
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The inability of Myd88(-/-) mice to heal ulcers generated upon injury creates an altered inflammatory environment that induces early alterations in expression of genes encoding proinflammatory factors, as well as pathways regulating
cell
proliferation, apoptosis, and DNA repair, resulting in a dramatic increase in
adenoma
formation and progression to infiltrating adenocarcinomas with frequent clonal mutations in the beta-catenin gene.
COS Scholar Universe.
author profiles
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nat Genet. 2000 Mar;24(3):227-35
[
10700174.001
]
[Cites]
PLoS One. 2009;4(6):e6026
[
19551144.001
]
[Cites]
Cancer Res. 2002 Jul 1;62(13):3581-6
[
12097256.001
]
[Cites]
Clin Genet. 2009 Jul;76(1):1-18
[
19659756.001
]
[Cites]
Cancer Cell. 2009 Sep 8;16(3):208-19
[
19732721.001
]
[Cites]
Nat Rev Cancer. 2009 Nov;9(11):798-809
[
19851315.001
]
[Cites]
Immunity. 2010 Mar 26;32(3):379-91
[
20303296.001
]
[Cites]
Immunity. 2010 Mar 26;32(3):367-78
[
20226691.001
]
[Cites]
Carcinogenesis. 2003 Jan;24(1):91-7
[
12538353.001
]
[Cites]
Scand J Gastroenterol. 2003 Aug;38(8):837-44
[
12940437.001
]
[Cites]
Cell. 2004 Jul 23;118(2):229-41
[
15260992.001
]
[Cites]
Cell. 2004 Aug 6;118(3):285-96
[
15294155.001
]
[Cites]
Eur J Immunol. 2004 Sep;34(9):2347-55
[
15307167.001
]
[Cites]
Science. 1997 Mar 21;275(5307):1790-2
[
9065403.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
[
9843981.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):99-104
[
15615857.001
]
[Cites]
J Gastroenterol. 2005 Jan;40(1):16-23
[
15692785.001
]
[Cites]
J Clin Invest. 2005 Mar;115(3):695-702
[
15765149.001
]
[Cites]
Am J Physiol Gastrointest Liver Physiol. 2005 May;288(5):G1055-65
[
15826931.001
]
[Cites]
Nat Med. 2005 Aug;11(8):845-52
[
16041381.001
]
[Cites]
Gastroenterology. 2005 Sep;129(3):913-27
[
16143131.001
]
[Cites]
Cancer Res. 2006 Mar 15;66(6):2953-61
[
16540643.001
]
[Cites]
J Exp Med. 2006 Jun 12;203(6):1391-7
[
16717119.001
]
[Cites]
Nat Rev Immunol. 2006 Nov;6(11):836-48
[
17063185.001
]
[Cites]
J Clin Invest. 2007 Jan;117(1):258-69
[
17200722.001
]
[Cites]
Semin Nephrol. 2007 Jan;27(1):98-114
[
17336692.001
]
[Cites]
Nature. 2007 Mar 29;446(7135):557-61
[
17361131.001
]
[Cites]
Immunity. 2007 Apr;26(4):461-75
[
17398123.001
]
[Cites]
Science. 2007 Jul 6;317(5834):121-4
[
17615358.001
]
[Cites]
Science. 2007 Jul 6;317(5834):124-7
[
17615359.001
]
[Cites]
Cell Cycle. 2007 Oct 1;6(19):2344-7
[
17700066.001
]
[Cites]
World J Gastroenterol. 2007 Nov 14;13(42):5560-70
[
17948929.001
]
[Cites]
Gastroenterology. 2007 Dec;133(6):1869-81
[
18054559.001
]
[Cites]
J Clin Invest. 2007 Dec;117(12):3909-21
[
18008007.001
]
[Cites]
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):652-6
[
18178624.001
]
[Cites]
J Clin Invest. 2008 May;118(5):1727-38
[
18431520.001
]
[Cites]
Am J Hum Genet. 2008 May;82(5):1202-10
[
18439550.001
]
[Cites]
Curr Drug Targets. 2008 May;9(5):369-74
[
18473764.001
]
[Cites]
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20858-63
[
19075245.001
]
[Cites]
Cancer Cell. 2009 Feb 3;15(2):103-13
[
19185845.001
]
[Cites]
Mol Med. 2000 Dec;6(12):1016-27
[
11474118.001
]
(PMID = 20624890.001).
[ISSN]
1540-9538
[Journal-full-title]
The Journal of experimental medicine
[ISO-abbreviation]
J. Exp. Med.
[Language]
ENG
[Grant]
United States / CCR NIH HHS / RC / HHSN261200800001C; United States / NCI NIH HHS / CA / HHSN261200800001E; United States / PHS HHS / / HHSN261200800001E; United States / Intramural NIH HHS / /
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Il18r1 protein, mouse; 0 / Interleukin-18; 0 / Interleukin-18 Receptor alpha Subunit; 0 / Myd88 protein, mouse; 0 / Myeloid Differentiation Factor 88; 0 / Receptors, Interleukin-1 Type I; 0 / STAT3 Transcription Factor; 0 / Stat3 protein, mouse; 0 / beta Catenin; 9042-14-2 / Dextran Sulfate; EC 1.14.99.- / Ptgs2 protein, mouse; EC 1.14.99.1 / Cyclooxygenase 2; EC 6.5.1.- / DNA Repair Enzymes; MO0N1J0SEN / Azoxymethane
[Other-IDs]
NLM/ PMC2916129
78.
Hsu HH, Cheng SF, Chen LM, Liu JY, Chu CH, Weng YJ, Li ZY, Lin CS, Lee SD, Kuo WW, Huang CY:
Over-expressed estrogen receptor-alpha up-regulates hTNF-alpha gene expression and down-regulates beta-catenin signaling activity to induce the apoptosis and inhibit proliferation of LoVo colon cancer cells.
Mol Cell Biochem
; 2006 Sep;289(1-2):101-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Over-expressed estrogen receptor-
alpha
up-regulates hTNF-
alpha
gene expression and down-regulates beta-catenin signaling activity to induce the apoptosis and inhibit proliferation of LoVo colon cancer
cells
.
Patients that received E(2) replacement therapy were found to have a reduction in the incidence of colon
adenoma
and carcinoma.
However, the mechanisms of ERalpha effects on colorectal cancer
cells
remained un-clear.
LoVo
cells
were transient transfected to overexpress ERalpha, DNA fragmentation and the activated caspases measurements were performed to evaluate apoptotic effects.
The results clearly demonstrated that overexpressed ERalpha with or without E(2) (10(-8) M) treatment could activate caspase -8, -9, and 3 and induce DNA fragmentation in LoVo
cell
.
At the same time, overexpressed ERalpha plus E(2) significantly increases the expression and promoter activity of hTNF-
alpha
, and the DNA fragmentation effect induced by E(2) plus ERalpha were reduced by the addition of hTNF antibody (0.1 ng(ml).
In addition, E(2) plus ERalpha significantly upregulated p21 and p27 levels and downregulated the beta-catenin and its target genes, cyclin D1 and Rb, which regulate the
cell
cycle and
cell
proliferation.
The results indicate that E(2) plus overexpressed ERalpha induce LoVo
cell
apoptosis might mediate through the increase of hTNF-
alpha
gene expression, which in turn activate caspase-8, -9 and caspase-3 and lead to the DNA fragmentation and apoptosis.
E(2) plus ERalpha also showed the downregulation of beta-catenin signalings implicating the suppression of proliferation and metastasis of colorectal
cells
.
[MeSH-major]
Apoptosis. Colonic Neoplasms / pathology. Estrogen Receptor
alpha
/ metabolism. Gene Expression Regulation. Signal Transduction.
Tumor
Necrosis Factor-
alpha
/ genetics. beta Catenin / metabolism
[MeSH-minor]
Adenomatous Polyposis Coli Protein / metabolism. Caspases / metabolism.
Cell
Cycle Proteins / metabolism.
Cell
Line,
Tumor
.
Cell
Proliferation. DNA Fragmentation. Down-Regulation / genetics. Estrogens / pharmacology. Female. Humans. Male. Middle Aged. Promoter Regions, Genetic / drug effects. Transfection.
Tumor Cells
, Cultured.
Tumor
Suppressor Protein p53 / metabolism. Up-Regulation / genetics. Wnt Proteins / metabolism
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Toxicol Lett. 2001 Mar 31;120(1-3):301-6
[
11323188.001
]
[Cites]
Science. 1998 Sep 4;281(5382):1509-12
[
9727977.001
]
[Cites]
Oncogene. 1999 May 6;18(18):2883-91
[
10362259.001
]
[Cites]
Cancer Treat Rev. 1998 Jun;24(3):221-40
[
9767736.001
]
[Cites]
Mol Cell. 2001 May;7(5):915-26
[
11389839.001
]
[Cites]
Cancer Res. 2003 Feb 1;63(3):621-6
[
12566305.001
]
[Cites]
Eur J Cancer. 2002 May;38(7):867-71
[
11978510.001
]
[Cites]
J Gastroenterol. 2001 Sep;36(9):587-94
[
11578061.001
]
[Cites]
Cancer. 1998 Mar 15;82(6):1197-207
[
9506368.001
]
[Cites]
Genes Dev. 2000 Aug 1;14 (15):1837-51
[
10921899.001
]
[Cites]
Trends Biochem Sci. 1997 Aug;22(8):299-306
[
9270303.001
]
[Cites]
J Biol Chem. 2001 Oct 5;276(40):36869-72
[
11459850.001
]
[Cites]
Nature. 1999 Apr 1;398(6726):422-6
[
10201372.001
]
[Cites]
Cancer Causes Control. 1997 Mar;8(2):146-58
[
9134238.001
]
[Cites]
Science. 1997 Feb 21;275(5303):1132-6
[
9027315.001
]
[Cites]
Genes Dev. 1997 Dec 15;11(24):3286-305
[
9407023.001
]
[Cites]
Cancer Cell. 2002 Apr;1(3):289-98
[
12086865.001
]
[Cites]
Mol Pathol. 2001 Aug;54(4):206-14
[
11477132.001
]
[Cites]
Carcinogenesis. 1999 Aug;20(8):1397-401
[
10426783.001
]
[Cites]
J Clin Invest. 1999 Jul;104(2):155-62
[
10411544.001
]
[Cites]
Endocrinology. 1997 Mar;138(3):863-70
[
9048584.001
]
[Cites]
CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33
[
10735013.001
]
[Cites]
EMBO Rep. 2001 Sep;2(9):775-81
[
11559590.001
]
[Cites]
Nucleic Acids Res. 1994 Dec 11;22(24):5506-7
[
7816645.001
]
[Cites]
Int J Cancer. 1999 Sep 24;83(1):18-29
[
10449602.001
]
[Cites]
Gastroenterology. 2002 Mar;122(3):659-66
[
11874999.001
]
[Cites]
Nat Cell Biol. 2002 Apr;4(4):E101-8
[
11944044.001
]
[Cites]
Anticancer Res. 2002 May-Jun;22(3):1635-9
[
12168847.001
]
[Cites]
Anal Biochem. 1976 May 7;72:248-54
[
942051.001
]
[Cites]
Cancer Res. 2001 Feb 15;61(4):1645-51
[
11245478.001
]
[Cites]
Mol Cell Endocrinol. 2003 Mar 28;201(1-2):165-75
[
12706304.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1603-8
[
9990071.001
]
[Cites]
Steroids. 1998 May-Jun;63(5-6):335-9
[
9618797.001
]
[Cites]
J Biol Chem. 2000 Mar 10;275(10):7337-42
[
10702305.001
]
(PMID = 16628468.001).
[ISSN]
0300-8177
[Journal-full-title]
Molecular and cellular biochemistry
[ISO-abbreviation]
Mol. Cell. Biochem.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Adenomatous Polyposis Coli Protein; 0 / Cell Cycle Proteins; 0 / Estrogen Receptor alpha; 0 / Estrogens; 0 / TNF protein, human; 0 / Tumor Necrosis Factor-alpha; 0 / Tumor Suppressor Protein p53; 0 / Wnt Proteins; 0 / beta Catenin; EC 3.4.22.- / Caspases
79.
Clemo NK, Collard TJ, Southern SL, Edwards KD, Moorghen M, Packham G, Hague A, Paraskeva C, Williams AC:
BAG-1 is up-regulated in colorectal tumour progression and promotes colorectal tumour cell survival through increased NF-kappaB activity.
Carcinogenesis
; 2008 Apr;29(4):849-57
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
BAG-1 is up-regulated in colorectal
tumour
progression and promotes colorectal
tumour
cell
survival through increased NF-kappaB activity.
Although expression of the anti-apoptotic protein Bcl-2-associated athanogene-1 (BAG-1) has been reported as up-regulated in a number of malignancies, we show for the first time that BAG-1 is over-expressed in medium/large-sized colorectal
adenomas
and carcinomas compared with normal epithelium.
To investigate whether expression of BAG-1 is important for colorectal
tumour
cell
survival, microarray analysis was carried out on the HCT116 colorectal carcinoma
cell
line following transfection with BAG-1 small interfering RNA (siRNA).
Analysis identified altered expression
of a
subset of potential nuclear factor-kappaB (NF-kappaB)-regulated genes.
Inhibition of NF-kappaB activity using BAG-1 siRNA or the NF-kappaB inhibitor BAY-117082 suppressed HCT116
cell
yield and induced apoptosis; combined treatment had no additive effect, suggesting that the decrease in
cell
yield associated with knock down of BAG-1 expression is mediated via inhibition of NF-kappaB.
Of clinical relevance, BAG-1 siRNA sensitized colorectal carcinoma
cells
to apoptosis induced by potential therapeutic agent TRAIL as well as
tumour
necrosis factor-
alpha
, both inducers of NF-kappaB activity.
It is proposed that, by inhibiting NF-kappaB, suppression of BAG-1 could represent a novel strategy to impede colorectal cancer
cell
survival and as an adjuvant increase sensitivity to current therapeutic regimes.
[MeSH-minor]
Adenoma
/ genetics.
Adenoma
/ pathology. Carcinoma / genetics. Carcinoma / pathology.
Cell
Line,
Tumor
.
Cell
Survival / genetics.
Disease
Progression. Humans. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction. Transfection.
Tumor Cells
, Cultured
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18204076.001).
[ISSN]
1460-2180
[Journal-full-title]
Carcinogenesis
[ISO-abbreviation]
Carcinogenesis
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / BCL2-associated athanogene 1 protein; 0 / DNA-Binding Proteins; 0 / NF-kappa B; 0 / RNA, Small Interfering; 0 / Transcription Factors
80.
Law AY, Lai KP, Ip CK, Wong AS, Wagner GF, Wong CK:
Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells.
Exp Cell Res
; 2008 May 1;314(8):1823-30
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer
cells
.
Here we reported that STC2 expression was sporadically abrogated in human cancer
cells
by transcriptional silencing associated with CpG island promoter hypermethylation.
Direct sequencing of bisulfite-modified DNA from a panel of seven human cancer
cell
lines revealed that CpG dinucleotides in STC2 promoter was methylated in human ovarian epithelial cancer (SKOV3, OVCAR3 and CaOV3),
pancreatic
cancer (BxP3), colon
adenoma
(HT29), and leukemia (Jurkat
cells
).
Treatment of these cancer
cells
with 5-aza-2'-deoxycytidine (5-aza-CdR), an inhibitor of DNA methylation significantly induced STC2 expression.
Using SKOV3
cells
as a model, the link between DNA demethylation and STC2 expression was consistently demonstrated with hydralazine treatment, which was shown to reduce the protein level of DNA methyltransferase 1 (DNMT1) but stimulated STC2 expression.
Two human normal surface ovarian
cell
-lines (i.e.
Hypoxia stimulated STC2 expression in SKOV3
cells
was markedly increased in 5-aza-CdR pretreated
cells
, showing that DNA methylation may hinder the HIF-1 mediated activation.
To elucidate this possibility, RNA interference studies confirmed that endogenous HIF-1
alpha
was a key factor for STC2 gene activation as well as in the synergistic induction of STC2 expression in 5-aza-CdR pretreated
cells
.
Chromatin immunoprecipitation (ChIP) assay demonstrated the binding of HIF-1
alpha
to STC2 promoter.
The binding was increased in 5-aza-CdR pretreated
cells
.
Collectively, this is the first report to show that STC2 was aberrantly hypermethylated in human cancer
cells
.
[MeSH-major]
Gene Expression Regulation, Neoplastic. Gene Silencing. Glycoproteins / genetics. Hypoxia-Inducible Factor 1,
alpha
Subunit / metabolism. Intercellular Signaling Peptides and Proteins / genetics
[MeSH-minor]
Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Base Sequence.
Cell
Hypoxia.
Cell
Line,
Tumor
. CpG Islands. DNA Methylation. Humans. Hydralazine / pharmacology. Molecular Sequence Data. Promoter Regions, Genetic. RNA Interference. Transcriptional Activation
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
HYDRALAZINE HYDROCHLORIDE
.
Hazardous Substances Data Bank.
AZACITIDINE
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18394600.001).
[ISSN]
0014-4827
[Journal-full-title]
Experimental cell research
[ISO-abbreviation]
Exp. Cell Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Glycoproteins; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Intercellular Signaling Peptides and Proteins; 0 / STC2 protein, human; 26NAK24LS8 / Hydralazine; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
81.
Evans CO, Yao C, Laborde D, Oyesiku NM:
Folate receptor expression in pituitary adenomas cellular and molecular analysis.
Vitam Horm
; 2008;79:235-66
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Folate receptor expression in pituitary
adenomas
cellular and molecular analysis.
Clinically nonfunctional pituitary
adenomas
cause hypopituitarism or compression of regional structures.
Unlike functional
tumors
, there is no available medical treatment or specific imaging technique for these
tumors
.
We have recently discovered that both folate receptor (FR)
alpha
mRNA and protein are uniquely overexpressed in nonfunctional pituitary
tumors
, but not in functional
adenomas
.
Here, we used murine pituitary
tumor
cell
line alphaT3-1 as a model to investigate the biological significance of FRalpha and its mutant FR67.
We demonstrate that overexpression of FR facilitated
tumor
cell
growth and anchorage-independent growth in soft agar.
More colonies were observed in FR overexpressing
cells
than in mutant FR67 clones in soft agar.
Cell
proliferation rate was increased, the percentage
of cells
in S-phase was increased, and high PCNA staining was detected in
cells
overexpressing the receptor.
In alphaT3-1
cells
transfected with mutant FR67,
cell
proliferation rate was reduced, the percentage
of cells
residing in S-phase was slightly decreased, and low PCNA staining was observed.
By real-time quantitative PCR, the genes involved in NOTCH3 pathway including NOTCH3, HES-1, and TLE2 were altered; the mRNA expression of FGFR1 was upregulated, and ERbeta mRNA was downregulated in FR overexpressing
cells
.
Our findings suggest that FRalpha plays a role in pituitary
tumor
formation, and this effect may in part be due to its regulation of the NOTCH3 pathway.
[MeSH-major]
Adenoma
/ metabolism. Pituitary Neoplasms / metabolism. Receptors,
Cell
Surface / metabolism
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Animals.
Cell
Line.
Cell
Proliferation. Female. Folate Receptor 1. Folic Acid / metabolism. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Male. Mice. Middle Aged. Mutation. Protein Binding. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Notch / metabolism
MedlinePlus Health Information.
consumer health - Pituitary Tumors
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
FOLIC ACID
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18804697.001).
[ISSN]
0083-6729
[Journal-full-title]
Vitamins and hormones
[ISO-abbreviation]
Vitam. Horm.
[Language]
eng
[Grant]
United States / NINDS NIH HHS / NS / R01-NS5143901
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Folate Receptor 1; 0 / Folr1 protein, mouse; 0 / Notch3 protein, mouse; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / Receptors, Notch; 935E97BOY8 / Folic Acid
82.
Tomita T, Masuzaki H, Noguchi M, Iwakura H, Fujikura J, Tanaka T, Ebihara K, Kawamura J, Komoto I, Kawaguchi Y, Fujimoto K, Doi R, Shimada Y, Hosoda K, Imamura M, Nakao K:
GPR40 gene expression in human pancreas and insulinoma.
Biochem Biophys Res Commun
; 2005 Dec 30;338(4):1788-90
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
GPR40 gene expression in human
pancreas
and insulinoma.
To assess gene expression
of a
membrane-bound G-protein-coupled fatty acid receptor, GPR40, in the human
pancreas
and
islet
cell
tumors
obtained at surgery were analyzed.
The mRNA level of the GPR40 gene in isolated
pancreatic
islets was approximately 20-fold higher than that in
the pancreas
, and the level was comparable to or rather higher than that of the sulfonylurea receptor 1 gene, which is known to be expressed abundantly in human
pancreatic
beta
cells
.
A large amount of GPR40 mRNA was detected in tissue extracts from two cases of insulinoma, whereas the expression was undetectable in
glucagonoma
or gastrinoma.
The present study demonstrates that GPR40 mRNA is expressed predominantly in
pancreatic
islets in humans and that GPR40 mRNA is expressed solely in human insulinoma among
islet
cell
tumors
.
These results indicate that GPR40 is probably expressed in
pancreatic
beta
cells
in the human
pancreas
.
[MeSH-major]
Insulinoma / metabolism.
Pancreas
/ metabolism.
Pancreatic
Neoplasms / metabolism. Receptors, G-Protein-Coupled / biosynthesis
Genetic Alliance.
consumer health - Insulinoma
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16289108.001).
[ISSN]
0006-291X
[Journal-full-title]
Biochemical and biophysical research communications
[ISO-abbreviation]
Biochem. Biophys. Res. Commun.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / FFAR1 protein, human; 0 / RNA, Messenger; 0 / Receptors, G-Protein-Coupled
83.
Freda PU, Chung WK, Matsuoka N, Walsh JE, Kanibir MN, Kleinman G, Wang Y, Bruce JN, Post KD:
Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission.
Pituitary
; 2007;10(3):275-82
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Analysis of GNAS mutations in 60 growth hormone secreting pituitary
tumors
: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission.
Although the molecular mechanisms underlying GH secreting pituitary
tumor
formation are not well understood, mutations in the
alpha
-subunit of the stimulatory G gene, GNAS, have been identified in up to 40%.
As these mutations could play a role in
tumor
growth, we screened 60 GH secreting
tumors
for GNAS mutations and assessed whether mutation status correlated with their clinical and pathological characteristics.
Tumor
specimens obtained at surgery were snap frozen.
Tumor
DNA was extracted, and PCR was used to amplify regions containing 2 sites of recurrent activating somatic mutations in codons 201 and 227 in GNAS.
GNAS mutations were present in 24/60 (40%)
of tumors
; these were arg201cys(n = 15), arg201ser(n = 2), arg201his(n = 2), gln227leu(n = 4), gln227arg(n = 1).
Mutation positive
tumors
were somewhat smaller than negative
tumors
(p = 0.07).
The proportion
of tumors
>2 cm was somewhat less among positive (8.3%) vs. negative
tumors
(25%) (p = 0.10).
Neither mib proliferation index, the proportion of invasive
tumors
nor surgical remission rates differed in the groups.
GH secreting
tumors
harboring GNAS mutations had higher preoperative IGF-I levels, somewhat higher preoperative GH levels and tended to be smaller than
tumors
without mutations.
Presence
of a
GNAS mutation did not predict a difference in a proliferation marker, surgical remission or response to somatostatin analog therapy.
[MeSH-major]
GTP-Binding Protein
alpha
Subunits, Gs / genetics. Growth Hormone-Secreting Pituitary
Adenoma
/ genetics. Growth Hormone-Secreting Pituitary
Adenoma
/ pathology. Human Growth Hormone / blood. Insulin-Like Growth Factor I / metabolism. Mutation / physiology. Pituitary Neoplasms / genetics. Pituitary Neoplasms / pathology
[MeSH-minor]
Acromegaly / etiology. Adult. Aged.
Cell
Proliferation / drug effects. Chromogranins. Cohort Studies. Female. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome
MedlinePlus Health Information.
consumer health - Pituitary Tumors
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Invest. 2003 Dec;112(11):1603-18
[
14660734.001
]
[Cites]
Oncogene. 1990 Jul;5(7):1059-61
[
2115641.001
]
[Cites]
J Clin Endocrinol Metab. 1999 Aug;84(8):2759-65
[
10443675.001
]
[Cites]
J Clin Endocrinol Metab. 1988 Jul;67(1):69-73
[
2897974.001
]
[Cites]
J Clin Invest. 2001 Mar;107(6):R31-6
[
11254676.001
]
[Cites]
J Clin Endocrinol Metab. 1990 Dec;71(6):1427-33
[
1977759.001
]
[Cites]
Cancer. 1993 Aug 15;72(4):1386-93
[
8339229.001
]
[Cites]
J Endocrinol. 2001 Feb;168(2):221-6
[
11182759.001
]
[Cites]
Pituitary. 1999 May;1(3-4):181-5
[
11081196.001
]
[Cites]
Nature. 1989 Aug 31;340(6236):692-6
[
2549426.001
]
[Cites]
Metabolism. 1996 Aug;45(8 Suppl 1):117-9
[
8769403.001
]
[Cites]
J Clin Invest. 1990 Jul;86(1):336-40
[
1973174.001
]
[Cites]
J Pediatr Endocrinol Metab. 1999 May-Jun;12(3):381-7
[
10821217.001
]
[Cites]
Neurosurgery. 1993 Aug;33(2):198-203; discussion 203
[
8396223.001
]
[Cites]
Eur J Endocrinol. 1996 Jun;134(6):720-6
[
8766942.001
]
[Cites]
Science. 1990 Aug 10;249(4969):655-9
[
2116665.001
]
[Cites]
Nature. 1987 Dec 10-16;330(6148):566-8
[
2825031.001
]
[Cites]
J Clin Endocrinol Metab. 1990 Dec;71(6):1421-6
[
1977758.001
]
[Cites]
J Clin Endocrinol Metab. 1990 Dec;71(6):1416-20
[
2121775.001
]
[Cites]
Mol Endocrinol. 1995 Jul;9(7):777-83
[
7476961.001
]
[Cites]
Clin Endocrinol (Oxf). 1995 Mar;42(3):295-301
[
7758235.001
]
[Cites]
J Clin Endocrinol Metab. 1998 May;83(5):1624-8
[
9589667.001
]
[Cites]
Chin Med J (Engl). 1998 Oct;111(10):891-4
[
11189233.001
]
[Cites]
J Clin Endocrinol Metab. 1992 Sep;75(3):918-23
[
1517386.001
]
[Cites]
J Clin Endocrinol Metab. 1998 May;83(5):1604-10
[
9589663.001
]
[Cites]
Growth Horm IGF Res. 2005 Feb;15(1):28-32
[
15701569.001
]
[Cites]
Acta Endocrinol (Copenh). 1993 Oct;129(4):301-6
[
8237246.001
]
(PMID = 17594522.001).
[ISSN]
1386-341X
[Journal-full-title]
Pituitary
[ISO-abbreviation]
Pituitary
[Language]
eng
[Grant]
United States / NIDDK NIH HHS / DK / DK 073040; United States / NIDDK NIH HHS / DK / DK02561; United States / NIDDK NIH HHS / DK / DK064720; United States / NCRR NIH HHS / RR / RR-00645; United States / NIDDK NIH HHS / DK / R01 DK064720; United States / NIDDK NIH HHS / DK / K24 DK073040
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Chromogranins; 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I; EC 3.6.1.- / GNAS protein, human; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs
84.
Deng J, Fujimoto J, Ye XF, Men TY, Van Pelt CS, Chen YL, Lin XF, Kadara H, Tao Q, Lotan D, Lotan R:
Knockout of the tumor suppressor gene Gprc5a in mice leads to NF-kappaB activation in airway epithelium and promotes lung inflammation and tumorigenesis.
Cancer Prev Res (Phila)
; 2010 Apr;3(4):424-37
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Knockout of the
tumor
suppressor gene Gprc5a in mice leads to NF-kappaB activation in airway epithelium and promotes lung inflammation and tumorigenesis.
We explored the role of inflammation in lung
tumor
development in mice with knockout of the
tumor
suppressor Gprc5a.
Examination of normal lung tissue and
tumors
from 51 Gprc5a(+/+) (
adenoma
incidence, 9.8%; adenocarcinoma, 0%) and 38 Gprc5a(-/-) mice (
adenoma
, 63%; adenocarcinoma, 21%) revealed macrophage infiltration into lungs of 45% of the Gprc5a(-/-) mice and 8% of Gprc5a(+/+) mice and the direct association of macrophages with 42%
of adenomas
and 88% of adenocarcinomas in the knockout mice.
Studies with epithelial
cells
cultured from tracheas of Gprc5a(-/-) and Gprc5a(+/+) mice revealed that Gprc5a loss is associated with increased
cell
proliferation, resistance to
cell
death in suspension, and increased basal,
tumor
necrosis factor
alpha
-induced, and lipopolysaccharide-induced NF-kappaB activation, which were reversed partially in Gprc5a(-/-) adenocarcinoma
cells
by reexpression of Gprc5a.
Compared with Gprc5a(+/+)
cells
, the Gprc5a(-/-)
cells
produced higher levels of chemokines and cytokines and their conditioned medium induced more extensive macrophage migration.
Silencing Gprc5a and the p65 subunit of NF-kappaB in Gprc5a(+/+) and Gprc5a(-/-)
cells
, respectively, reversed these effects.
Thus, Gprc5a loss enhances NF-kappaB activation in lung epithelial
cells
, leading to increased autocrine and paracrine interactions,
cell
autonomy, and enhanced inflammation, which may synergize in the creation
of a tumor
-promoting microenvironment.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
MedlinePlus Health Information.
consumer health - Pneumonia
.
Guide to Pharmacology.
gene/protein/disease-specific - Class C Orphans - overview and references
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2010 AACR.
[CommentIn]
Cancer Prev Res (Phila). 2010 Apr;3(4):403-5
[
20354166.001
]
(PMID = 20354164.001).
[ISSN]
1940-6215
[Journal-full-title]
Cancer prevention research (Philadelphia, Pa.)
[ISO-abbreviation]
Cancer Prev Res (Phila)
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P30 CA16672
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / NF-kappa B; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Receptors, G-Protein-Coupled
85.
Kress E, Skah S, Sirakov M, Nadjar J, Gadot N, Scoazec JY, Samarut J, Plateroti M:
Cooperation between the thyroid hormone receptor TRalpha1 and the WNT pathway in the induction of intestinal tumorigenesis.
Gastroenterology
; 2010 May;138(5):1863-74
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND & AIMS: Colorectal tumorigenesis is a multistep process involving the alteration of oncogenes and
tumor
suppressor genes, leading to the deregulation of molecular pathways that govern intestinal homeostasis.
More precisely, TRalpha1 directly enhances the transcription of several components of this pathway, allowing increased expression of beta-catenin/Tcf4 target genes and stimulation of
cell
proliferation.
Because the WNT pathway is a major player in controlling intestinal homeostasis, we addressed whether the TRalpha1 receptor has
tumor
-inducing potential.
RESULTS: The intestine of vil-TRalpha1 mice presents aberrant intestinal mucosal architecture and increased
cell
proliferation and develops
adenoma
at a low rate.
This is the first report describing
the tumor
-inducing function of TRalpha1 in the intestine.
[MeSH-major]
Adenoma
/ metabolism.
Cell
Transformation, Neoplastic / metabolism. Intestinal Mucosa / metabolism. Intestinal Neoplasms / metabolism. Signal Transduction. Thyroid Hormone Receptors
alpha
/ metabolism. Wnt Proteins / metabolism
[MeSH-minor]
Animals.
Cell
Proliferation.
Disease
Models, Animal. Gene Expression Regulation, Neoplastic. Genes, APC. Genotype. Mice. Mice, Inbred C57BL. Mice, Transgenic. Phenotype. Time Factors. beta Catenin / metabolism
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
(PMID = 20114049.001).
[ISSN]
1528-0012
[Journal-full-title]
Gastroenterology
[ISO-abbreviation]
Gastroenterology
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / CTNNB1 protein, mouse; 0 / Thyroid Hormone Receptors alpha; 0 / Wnt Proteins; 0 / beta Catenin
86.
Vanderlan WB, Zhang Z, Abouljoud MS:
Duodenal enteroglucagonoma revealed by differential comparison of serum and tissue glucagon reactivity with Siemens' Double Glucagon Antibody and DakoCytomation's Polyclonal Rabbit Anti-Human Glucagon: a case report.
J Med Case Rep
; 2010;4:178
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Duodenal enteroglucagonoma revealed by differential comparison of serum and tissue
glucagon
reactivity with Siemens' Double
Glucagon
Antibody and DakoCytomation's Polyclonal Rabbit Anti-Human
Glucagon
: a case report.
INTRODUCTION: This case report demonstrates that the differential immunohistochemical reactivities of Siemens' Double Antibody
Glucagon
compared to DakoCytomation's Polyclonal Rabbit Anti-Human
Glucagon
allow for pathologic distinction of enteral versus
pancreatic glucagonoma
.
He had a low serum
glucagon
level using Siemens' Double Antibody
Glucagon
, a clinical
syndrome
consistent with
glucagon
hypersecretion.
A periampullary mass biopsy proved to be
a neuroendocrine tumor
, with positive immunohistochemical reactivity to DakoCytomation's Polyclonal Rabbit Anti-Human
Glucagon
.
CONCLUSIONS: Differential comparison of the immunohistochemical reactivities of Siemens' Double Antibody
Glucagon
and DakoCytomation's Polyclonal Rabbit Anti-Human
Glucagon
discerns enteroglucagon from
pancreatic glucagon
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Hum Pathol. 1979 May;10(3):350-3
[
89070.001
]
[Cites]
Gut. 1971 Oct;12(10):773-82
[
4941684.001
]
[Cites]
Endocr Rev. 1981 Summer;2(3):347-61
[
6268399.001
]
[Cites]
Gut. 1984 Jul;25(7):784-91
[
6329923.001
]
[Cites]
Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):807-17
[
16253902.001
]
[Cites]
Gastrointest Endosc. 2000 Oct;52(4):562-4
[
11023587.001
]
[Cites]
J Surg Res. 2004 Jul;120(1):139-61
[
15172200.001
]
[Cites]
Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):753-81
[
16253899.001
]
[Cites]
Annu Rev Physiol. 1997;59:257-71
[
9074764.001
]
(PMID = 20550685.001).
[ISSN]
1752-1947
[Journal-full-title]
Journal of medical case reports
[ISO-abbreviation]
J Med Case Rep
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Other-IDs]
NLM/ PMC2896376
87.
Chen M:
Amended final report of the safety assessment of t-Butyl Alcohol as used in cosmetics.
Int J Toxicol
; 2005;24 Suppl 2:1-20
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Subchronic oral dosing with t-BuOH increased the mineralization of the kidney, nephropathy, and urinary bladder transitional
cell
epithelial hyperplasia in rats; and liver damage, chronic inflammation, hyperplasia of transitional
cell
epithelium urinary, and proliferative changes including hyperplasia and neoplasia in the thyroid in mice.
Male rats exposed to t-BuOH were susceptible to
alpha
2mu-globulin nephropathy. t-BuOH (99.9%) was a moderate to severe ocular irritant to rabbits and caused mild to moderate dermal irritation to rabbits.
The principal effects from 2 years of exposure to t-BuOH in drinking water (up to 10 mg/ml for rats and 20 mg/ml for mice) were proliferative lesions (hyperplasia,
adenoma
, and carcinoma) in the kidneys of exposed male rats, and nephropathy in all exposed groups of female rats.
In addition, the renal tubule effects found in male rats were likely an effect of
alpha
2mu-globulin.
MedlinePlus Health Information.
consumer health - Cosmetics
.
Hazardous Substances Data Bank.
T-BUTYL ALCOHOL
.
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16154913.001).
[ISSN]
1091-5818
[Journal-full-title]
International journal of toxicology
[ISO-abbreviation]
Int. J. Toxicol.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Cosmetics; 0 / Irritants; 0 / Teratogens; MD83SFE959 / tert-Butyl Alcohol
[Number-of-references]
110
88.
Mizokami Y, Egashira N, Takekoshi S, Itoh J, Itoh Y, Osamura RY, Matsumae M:
Expression of MSX1 in human normal pituitaries and pituitary adenomas.
Endocr Pathol
; 2008;19(1):54-61
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of MSX1 in human normal pituitaries and pituitary
adenomas
.
Transcription factors play specific roles in the development and differentiation of normal pituitary tissues and pituitary
adenoma
.
The transcription factor, muscle segment homeobox 1 (MSX1), which belongs to the homeobox gene family, binds the promoter region of the glycoprotein hormone
alpha
-subunit (SU) in TSH-
producing cells
in the mouse pituitary and regulates
alpha
-SU expression.
In addition, 50 pituitary
adenomas
were examined using immunohistochemistry and reverse transcription polymerase chain reaction (RT-PCR) to clarify the role of MSX1 in the development and functional differentiation of pituitary
adenoma
cells
.
In the normal pituitary, MSX1 was predominantly expressed in the cytoplasm of GH-
producing cells
.
Furthermore, MSX1 immunoreactivity was observed in the cytoplasm of some
alpha
-SU-
producing cells
.
It is interesting to note that, in the pituitary
adenoma
, MSX1 was expressed in the nucleus of GH- and TSH-
producing adenomas
.
RT-PCR using RNA extracted and purified from formalin-fixed paraffin-embedded pituitary
adenoma
specimens revealed MSX1 mRNA expressed in GH- and TSH-
producing adenomas
.
These results suggest that MSX1 plays a specific role in human pituitary
adenoma
.
[MeSH-major]
Adenoma
/ genetics. MSX1 Transcription Factor / genetics. Pituitary Gland / physiology. Pituitary Neoplasms / genetics
[MeSH-minor]
Animals. Autopsy. Blotting, Western.
Cell
Differentiation. DNA Primers. Humans. Immunohistochemistry. Mice. Microscopy, Immunoelectron. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction
MedlinePlus Health Information.
consumer health - Pituitary Tumors
.
antibodies-online.
View related products from antibodies-online.com
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Clin Cancer Res. 1999 Aug;5(8):2133-9
[
10473097.001
]
[Cites]
Pathol Int. 1996 Oct;46(10 ):726-37
[
8916141.001
]
[Cites]
Exp Cell Res. 1999 Apr 10;248(1):1-9
[
10094807.001
]
[Cites]
Clin Cancer Res. 2001 Apr;7(4):892-5
[
11309338.001
]
[Cites]
J Histochem Cytochem. 2003 Aug;51(8):989-94
[
12871980.001
]
[Cites]
Acta Neurochir (Wien). 1996;138(10):1186-92
[
8955438.001
]
[Cites]
J Electron Microsc Tech. 1988 Apr;8(4):401-32
[
3058887.001
]
[Cites]
Genes Dev. 1989 Jan;3(1):26-37
[
2565278.001
]
[Cites]
Int J Cancer. 1992 Jul 30;51(6):892-7
[
1379214.001
]
[Cites]
Science. 1998 Nov 6;282(5391):1136-8
[
9804553.001
]
[Cites]
J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):195-205
[
15300013.001
]
[Cites]
Br Med Bull. 2006 May 09;75-76:81-97
[
16684928.001
]
[Cites]
J Cell Biol. 1999 Jun 14;145(6):1119-31
[
10366586.001
]
[Cites]
Trends Genet. 1995 Oct;11(10):405-11
[
7482767.001
]
[Cites]
Expert Rev Anticancer Ther. 2006 Sep;6 Suppl 9:S3-14
[
17004855.001
]
[Cites]
J Neuroendocrinol. 2006 Jan;18(1):50-6
[
16451220.001
]
[Cites]
Eur J Surg Oncol. 2007 Mar;33(2):129-32
[
17045774.001
]
[Cites]
Gene. 2003 Nov 13;319:1-19
[
14597167.001
]
[Cites]
Annu Rev Genet. 1995;29:577-605
[
8825487.001
]
[Cites]
J Histochem Cytochem. 1995 Jan;43(1):11-9
[
7822759.001
]
[Cites]
Mol Cell Endocrinol. 1998 Nov 25;146(1-2):77-86
[
10022765.001
]
[Cites]
J Clin Pathol. 1998 Jul;51(7):506-11
[
9797726.001
]
[Cites]
Blood. 1991 Dec 1;78(11):2996-3003
[
1683261.001
]
[Cites]
Mol Endocrinol. 1997 Nov;11(12):1782-94
[
9369446.001
]
[Cites]
Biochem Biophys Res Commun. 1993 Jul 15;194(1):187-93
[
7687426.001
]
[Cites]
Development. 2003 Dec;130(26):6441-52
[
14627721.001
]
[Cites]
Development. 2001 Jun;128(12):2373-84
[
11493556.001
]
[Cites]
Nat Rev Cancer. 2002 Nov;2(11):836-49
[
12415254.001
]
[Cites]
Bioessays. 1999 Oct;21(10):824-32
[
10497332.001
]
[Cites]
Mod Pathol. 1996 May;9(5):526-33
[
8733768.001
]
[Cites]
Mol Endocrinol. 2006 Nov;20(11):2796-805
[
16840539.001
]
[Cites]
EMBO J. 1989 Jan;8(1):91-100
[
2565810.001
]
[Cites]
Gene. 2000 Apr 18;247(1-2):17-31
[
10773441.001
]
[Cites]
Virchows Arch A Pathol Anat Histopathol. 1987;411(4):323-30
[
2442884.001
]
[Cites]
Biochem Biophys Res Commun. 2001 Mar;281(5):1234-40
[
11243867.001
]
[Cites]
Endocrine. 2005 Oct;28(1):43-7
[
16311409.001
]
[Cites]
Science. 2002 Mar 22;295(5563):2231-5
[
11910101.001
]
[Cites]
Genes Dev. 1997 Jun 1;11(11):1370-80
[
9192866.001
]
[Cites]
Science. 1998 Apr 24;280(5363):547-53
[
9554838.001
]
[Cites]
Mod Pathol. 2000 Oct;13(10):1097-108
[
11048804.001
]
[Cites]
Exp Biol Med (Maywood). 2003 Oct;228(9):1004-17
[
14530508.001
]
[Cites]
Mol Cell Biol. 1991 Jan;11(1):554-7
[
1670897.001
]
(PMID = 18379900.001).
[ISSN]
1559-0097
[Journal-full-title]
Endocrine pathology
[ISO-abbreviation]
Endocr. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / DNA Primers; 0 / MSX1 Transcription Factor; 0 / MSX1 protein, human; 0 / Msx1 protein, mouse; 0 / RNA, Messenger; 0 / RNA, Neoplasm
89.
Yen TH, Chen Y, Fu JF, Weng CH, Tian YC, Hung CC, Lin JL, Yang CW:
Proliferation of myofibroblasts in the stroma of renal oncocytoma.
Cell Prolif
; 2010 Jun;43(3):287-96
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
RESULTS: Renal oncocytomas were composed of oncocytes, large
cells
with granular eosinophilic cytoplasm, arranged mostly in sheets, in tubulocystic or combined pattern.
MIB-1 and active caspase 3 indices were low, but higher in
tumour
than in surrounding non-
tumour
parenchyma (MIB-1: 0.93 +/- 0.09 versus 0.46 +/- 0.07, P < 0.001 and active caspase 3: 0.76 +/- 0.08 versus 0.41 +/- 0.09, P < 0.001).
Wnt/beta-catenin signalling was not implicated in this neoplasm, as there was no loss of E-cadherin membranous localization or expression of intranuclear beta-catenin in
the cells
.
Importantly,
alpha
-smooth muscle actin (SMA)-immunostaining established the myofibroblastic nature of many of the stromal
cells
.
[MeSH-major]
Adenoma
, Oxyphilic / pathology. Fibroblasts / pathology. Kidney Neoplasms / pathology
[MeSH-minor]
Aged. Biomarkers,
Tumor
/ metabolism.
Cell
Proliferation. Extracellular Matrix / metabolism. Extracellular Matrix / pathology. Extracellular Matrix Proteins / metabolism. Female. Humans. Male. Middle Aged. Myoblasts / metabolism. Myoblasts / pathology. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Stromal
Cells
/ metabolism. Stromal
Cells
/ pathology
Genetic Alliance.
consumer health - Oncocytoma renal
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20412129.001).
[ISSN]
1365-2184
[Journal-full-title]
Cell proliferation
[ISO-abbreviation]
Cell Prolif.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Extracellular Matrix Proteins
90.
McGevna L, McFadden D, Ritvo J, Rabinowitz T:
Glucagonoma-associated neuropsychiatric and affective symptoms: diagnostic dilemmas raised by paraneoplastic phenomena.
Psychosomatics
; 2009 Sep-Oct;50(5):548-50
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Glucagonoma
-associated neuropsychiatric and affective symptoms: diagnostic dilemmas raised by paraneoplastic phenomena.
[MeSH-major]
Glucagonoma
/
diagnosis
.
Pancreatic
Neoplasms /
diagnosis
. Paraneoplastic
Syndromes
/
diagnosis
[MeSH-minor]
Bipolar
Disorder
/
diagnosis
.
Diagnosis
, Differential. Female. Humans. Lupus Erythematosus, Systemic /
diagnosis
. Middle Aged
Genetic Alliance.
consumer health - Glucagonoma
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19855043.001).
[ISSN]
1545-7206
[Journal-full-title]
Psychosomatics
[ISO-abbreviation]
Psychosomatics
[Language]
eng
[Publication-type]
Case Reports; Letter
[Publication-country]
United States
91.
Miyakoshi T, Takei M, Kajiya H, Egashira N, Takekoshi S, Teramoto A, Osamura RY:
Expression of Wnt4 in human pituitary adenomas regulates activation of the beta-catenin-independent pathway.
Endocr Pathol
; 2008;19(4):261-73
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of Wnt4 in human pituitary
adenomas
regulates activation of the beta-catenin-independent pathway.
A member of the Wnt family of genes, Wnt4, has been known to regulate proliferation of anterior pituitary
cell
types in the mouse during embryonic development.
In order to elucidate the roles of Wnt signaling in human pituitary
adenomas
, we examined the expression of Wnt4 and its putative receptor Frizzled6 (Fzd6) by immunohistochemistry in pituitary
adenomas
and normal pituitaries.
Expression of Wnt4 was higher in growth hormone-
producing adenomas
(GHomas), prolactin-
producing adenomas
(PRLomas), and thyroid-stimulating hormone-
producing adenomas
(TSHomas) than in the normal pituitary.
Fzd6 was widely expressed in GHomas, PRLomas, TSHomas, and gonadotropin subunit (GnSU)-positive
adenomas
.
In normal pituitary glands, Wnt4 and Fzd6 were colocalized predominantly in follicle-stimulating hormone-, luteinizing hormone-, and
alpha
-subunits of glycoprotein hormone-positive
cells
.
The canonical Wnt/beta-catenin signaling pathway was analyzed by beta-catenin immunohistochemistry. beta-Catenin was localized at the
cell
membrane in all pituitary
adenomas
, but not in the nuclei.
These results suggested that activation of Wnt4/Fzd6 signaling through a "beta-catenin-independent" pathway played a role in proliferation and survival of the pituitary
adenoma
cells
.
[MeSH-major]
Adenoma
/ metabolism. Biomarkers,
Tumor
/ metabolism. Pituitary Neoplasms / metabolism. Wnt Proteins / metabolism. beta Catenin / metabolism
MedlinePlus Health Information.
consumer health - Pituitary Tumors
.
Guide to Pharmacology.
gene/protein/disease-specific - FZD6 - data and references
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Mech Dev. 2000 Nov;98(1-2):121-5
[
11044615.001
]
[Cites]
Cancer Res. 1994 May 15;54(10):2615-21
[
8168088.001
]
[Cites]
Development. 2006 Jan;133(1):151-61
[
16319116.001
]
[Cites]
Nature. 1994 Dec 15;372(6507):679-83
[
7990960.001
]
[Cites]
Cell Growth Differ. 1997 Dec;8(12 ):1349-58
[
9419423.001
]
[Cites]
J Clin Oncol. 2005 Dec 1;23 (34):8765-73
[
16314637.001
]
[Cites]
Trends Genet. 2000 Jul;16(7):279-83
[
10858654.001
]
[Cites]
Genome Biol. 2002;3(1):REVIEWS3001
[
11806834.001
]
[Cites]
J Biol Chem. 1996 Sep 20;271(38):23512-9
[
8798560.001
]
[Cites]
Cell Signal. 2007 Apr;19(4):659-71
[
17188462.001
]
[Cites]
Endocr Rev. 1998 Dec;19(6):798-827
[
9861546.001
]
[Cites]
Cancer. 2001 Jan 1;91(1):42-8
[
11148558.001
]
[Cites]
Acta Neuropathol. 2005 Jun;109(6):589-97
[
15891929.001
]
[Cites]
Biochem Biophys Res Commun. 1998 Feb 13;243(2):622-7
[
9480858.001
]
[Cites]
Oncogene. 2001 Aug 23;20(37):5093-9
[
11526497.001
]
[Cites]
Genes Dev. 2000 Mar 15;14(6):650-4
[
10733525.001
]
[Cites]
J Dent Res. 2004 Apr;83(4):327-32
[
15044508.001
]
[Cites]
Oncogene. 2002 Sep 26;21(43):6598-605
[
12242657.001
]
[Cites]
Endocr Pathol. 2008 Summer;19(2):104-11
[
18568298.001
]
[Cites]
Science. 1997 Mar 21;275(5307):1787-90
[
9065402.001
]
[Cites]
Oncol Rep. 2005 Dec;14(6):1583-8
[
16273260.001
]
[Cites]
Cancer. 2004 Aug 1;101(3):613-9
[
15274075.001
]
[Cites]
Genes Dev. 1997 Dec 15;11(24):3286-305
[
9407023.001
]
[Cites]
Mol Cell Biol. 1996 May;16(5):2128-34
[
8628279.001
]
[Cites]
Mech Dev. 2000 May;93(1-2):195-200
[
10781956.001
]
[Cites]
Genes Dev. 1998 Jun 1;12(11):1691-704
[
9620855.001
]
[Cites]
Mol Cell Biol. 1994 Sep;14(9):6278-86
[
8065359.001
]
[Cites]
J Biol Chem. 1996 Feb 23;271(8):4468-76
[
8626800.001
]
[Cites]
J Neurooncol. 2005 Jul;73(3):205-9
[
15980970.001
]
[Cites]
Biochem Biophys Res Commun. 2001 Apr 6;282(3):750-6
[
11401527.001
]
[Cites]
J Biol Chem. 2004 Apr 9;279(15):14879-88
[
14747478.001
]
[Cites]
Oncol Rep. 2006 Mar;15(3):701-7
[
16465433.001
]
[Cites]
Dev Biol. 1995 Aug;170(2):553-63
[
7649383.001
]
[Cites]
Endocrinology. 2008 Mar;149(3):1235-42
[
18079202.001
]
[Cites]
Development. 1998 Nov;125(21):4225-34
[
9753677.001
]
[Cites]
Exp Cell Res. 2004 Aug 15;298(2):369-87
[
15265686.001
]
[Cites]
Dev Dyn. 2008 Apr;237(4):1006-20
[
18351662.001
]
[Cites]
Dev Biol. 2004 Dec 15;276(2):431-40
[
15581876.001
]
[Cites]
Blood. 2004 Jul 1;104(1):51-7
[
14996702.001
]
[Cites]
Nature. 1999 Feb 4;397(6718):405-9
[
9989404.001
]
[Cites]
Development. 2000 Aug;127(16):3619-29
[
10903185.001
]
[Cites]
Cancer Res. 2003 Jul 1;63(13):3735-42
[
12839967.001
]
[Cites]
Biol Reprod. 2005 Dec;73(6):1135-46
[
16093361.001
]
[Cites]
BMC Dev Biol. 2006 Oct 03;6:44
[
17014734.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10356-61
[
11526241.001
]
[Cites]
J Biol Chem. 2007 Oct 19;282(42):30938-48
[
17720811.001
]
[Cites]
Mech Dev. 1999 Dec;89(1-2):173-7
[
10559494.001
]
[Cites]
Clin Cancer Res. 2008 Jan 1;14 (1):55-61
[
18172252.001
]
(PMID = 19034702.001).
[ISSN]
1046-3976
[Journal-full-title]
Endocrine pathology
[ISO-abbreviation]
Endocr. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / FZD6 protein, human; 0 / Frizzled Receptors; 0 / Receptors, G-Protein-Coupled; 0 / WNT4 protein, human; 0 / Wnt Proteins; 0 / Wnt4 Protein; 0 / Wnt4 protein, mouse; 0 / beta Catenin
92.
Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, Richmond A, Strieter R, Dey SK, DuBois RN:
CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer.
J Exp Med
; 2006 Apr 17;203(4):941-51
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Proinflammatory mediators such as prostaglandin E2 (PGE2) promote colorectal
tumor
growth by stimulating angiogenesis,
cell
invasion, and
cell
growth, and inhibiting apoptosis.
Molecules that regulate
tumor
-associated angiogenesis provide promising therapeutic targets for treatment of colorectal cancer (CRC) as indicated by the recent development of the novel anti-angiogenic agent bevacizumab (Avastin).
However, use of this drug only prolongs survival by several months, highlighting the importance
of finding
more effective treatment regimens.
We report here that PGE2 induces expression of CXCL1 (growth-regulated oncogene
alpha
), a pro-angiogenic chemokine, in human CRC
cells
.
More importantly, CXCL1 released from carcinoma
cells
induces microvascular endothelial
cell
migration and tube formation in vitro.
Furthermore, PGE2 promotes
tumor
growth in vivo by induction of CXCL1 expression, which results in increased
tumor
microvessel formation.
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
COS Scholar Universe.
author profiles
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
The Lens.
Cited by Patents in
.
antibodies-online.
View related products from antibodies-online.com
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Gastroenterology. 2002 Jun;122(7):1800-7
[
12055587.001
]
[Cites]
Nat Med. 2001 Sep;7(9):1041-7
[
11533708.001
]
[Cites]
J Biol Chem. 2002 Nov 15;277(46):44147-54
[
12215436.001
]
[Cites]
J Leukoc Biol. 2002 Nov;72(5):847-55
[
12429706.001
]
[Cites]
J Biol Chem. 2002 Nov 29;277(48):45838-46
[
12237321.001
]
[Cites]
J Biol Chem. 2003 Mar 7;278(10):8508-15
[
12496258.001
]
[Cites]
Cancer Res. 2003 Aug 15;63(16):5136-42
[
12941845.001
]
[Cites]
J Biol Chem. 2003 Sep 12;278(37):35451-7
[
12824187.001
]
[Cites]
J Leukoc Biol. 2003 Nov;74(5):868-79
[
12960284.001
]
[Cites]
Clin Exp Immunol. 2003 Dec;134(3):431-41
[
14632748.001
]
[Cites]
Gastroenterology. 2004 Feb;126(2):425-31
[
14762779.001
]
[Cites]
Cancer Res. 2004 Mar 1;64(5):1853-60
[
14996749.001
]
[Cites]
N Engl J Med. 2004 Jun 3;350(23):2335-42
[
15175435.001
]
[Cites]
Nat Rev Cancer. 2004 Jul;4(7):540-50
[
15229479.001
]
[Cites]
Mol Endocrinol. 2001 Nov;15(11):1983-92
[
11682628.001
]
[Cites]
Annu Rev Pharmacol Toxicol. 2002;42:55-80
[
11807164.001
]
[Cites]
Cancer Res. 2002 Feb 1;62(3):632-5
[
11830510.001
]
[Cites]
Nat Rev Cancer. 2001 Oct;1(1):11-21
[
11900248.001
]
[Cites]
Biochemistry. 2002 Jun 4;41(22):7100-7
[
12033944.001
]
[Cites]
Cancer Res. 1985 Dec;45(12 Pt 1):6390-4
[
3864531.001
]
[Cites]
J Cell Physiol. 1986 Dec;129(3):375-84
[
3465735.001
]
[Cites]
Proc Natl Acad Sci U S A. 1987 Oct;84(20):7188-92
[
2890161.001
]
[Cites]
J Exp Med. 1990 Sep 1;172(3):911-9
[
2201751.001
]
[Cites]
J Immunol. 1991 Jul 15;147(2):520-7
[
1906501.001
]
[Cites]
Oncogene. 1991 Jul;6(7):1115-24
[
1861861.001
]
[Cites]
J Lab Clin Med. 1993 Nov;122(5):518-23
[
8228569.001
]
[Cites]
J Clin Invest. 1994 Feb;93(2):493-8
[
8113389.001
]
[Cites]
Gut. 1994 May;35(5):675-8
[
8200564.001
]
[Cites]
Gastroenterology. 1994 Oct;107(4):1183-8
[
7926468.001
]
[Cites]
Nat Med. 1995 Jan;1(1):27-31
[
7584949.001
]
[Cites]
J Biol Chem. 1996 Apr 5;271(14):8228-35
[
8626516.001
]
[Cites]
J Clin Invest. 1996 Jun 15;97(12):2792-802
[
8675690.001
]
[Cites]
Cell. 1996 Aug 9;86(3):353-64
[
8756718.001
]
[Cites]
Cell. 1996 Nov 29;87(5):803-9
[
8945508.001
]
[Cites]
Nature. 1997 Apr 17;386(6626):671-4
[
9109485.001
]
[Cites]
J Leukoc Biol. 1997 Nov;62(5):554-62
[
9365108.001
]
[Cites]
J Leukoc Biol. 1997 Nov;62(5):588-97
[
9365113.001
]
[Cites]
Annu Rev Med. 1998;49:407-24
[
9509272.001
]
[Cites]
Curr Opin Cell Biol. 1998 Apr;10(2):159-64
[
9561839.001
]
[Cites]
Cell. 1998 May 29;93(5):705-16
[
9630216.001
]
[Cites]
FASEB J. 1998 Sep;12(12):1063-73
[
9737710.001
]
[Cites]
FASEB J. 1999 Jan;13(1):9-22
[
9872925.001
]
[Cites]
Carcinogenesis. 1999 Feb;20(2):299-303
[
10069468.001
]
[Cites]
JAMA. 1999 Oct 6;282(13):1254-7
[
10517428.001
]
[Cites]
J Biol Chem. 2004 Dec 31;279(53):55176-86
[
15498767.001
]
[Cites]
Clin J Oncol Nurs. 2005 Feb;9(1):55-60
[
15751499.001
]
[Cites]
J Biol Chem. 1995 Nov 10;270(45):27348-57
[
7592998.001
]
[Cites]
Semin Cancer Biol. 2004 Jun;14(3):171-9
[
15246052.001
]
[Cites]
Am J Obstet Gynecol. 2004 Jun;190(6):1788-95; discussion 1795-6
[
15284801.001
]
[Cites]
Cancer Cell. 2004 Sep;6(3):285-95
[
15380519.001
]
[Cites]
N Engl J Med. 1971 Nov 18;285(21):1182-6
[
4938153.001
]
[Cites]
Science. 1983 Apr 8;220(4593):210-2
[
6828888.001
]
[Cites]
Cell. 1983 Jul;33(3):939-47
[
6872001.001
]
[Cites]
Nat Med. 1999 Dec;5(12):1418-23
[
10581086.001
]
[Cites]
J Clin Invest. 2000 Jun;105(11):1589-94
[
10841517.001
]
[Cites]
J Intern Med. 2000 Sep;248(3):171-83
[
10971784.001
]
[Cites]
Cancer Res. 2000 Sep 1;60(17):4705-8
[
10987272.001
]
[Cites]
Lancet. 2001 Feb 17;357(9255):539-45
[
11229684.001
]
[Cites]
J Biol Chem. 2001 Mar 23;276(12):9366-74
[
11112786.001
]
[Cites]
J Exp Med. 2001 Mar 19;193(6):727-40
[
11257139.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2001 Apr 1;49(5):1213-7
[
11286825.001
]
[Cites]
Clin Cancer Res. 2001 Apr;7(4):861-7
[